publicationId,doi,pmid,publicationTitle,abstract,journal,publicationDate,authors
PUB12057013,10.1186/1471-2164-3-13,PMID:12057013,Complex splicing pattern generates great diversity in human NF1 transcripts.,"BACKGROUND: Mutation analysis of the neurofibromatosis type 1 (NF1) gene has shown that about 30% of NF1 patients carry a splice mutation resulting in the production of one or several shortened transcripts. Some of these transcripts were also found in fresh lymphocytes of healthy individuals, albeit typically at a very low level. Starting from this initial observation, we were interested to gain further insight into the complex nature of NF1 mRNA processing. RESULTS: We have used a RT-PCR plasmid library based method to identify novel NF1 splice variants. Several transcripts were observed with specific insertions/deletions and a survey was made. This large group of variants detected in one single gene allows to perform a comparative analysis of the factors involved in splice regulation. Exons that are prone to skipping were systematically analysed for 5' and 3' splice site strength, branch point strength and secondary structure. CONCLUSION: Our study revealed a complex splicing pattern, generating a great diversity in NF1 transcripts. We found that, on average, exons that are spliced out in part of the mRNA have significantly weaker acceptor sites. Some variants identified in this study could have distinct roles and might expand our knowledge of neurofibromin.",BMC genomics,2002-05-24,Ina Vandenbroucke; Tom Callens; Anne De Paepe; Ludwine Messiaen
PUB15240917,10.1155/S1110724304308107,PMID:15240917,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,"Neurofibromatosis type I is a common tumor predisposing disease in humans. Surgical therapy can be applied only in selected patients with resectable masses. Hence, development of new therapies for this disease is urgent. We used human neurofibroma implants in mice with severe combined immunodeficiency (SCID) as a model to test the toxicity and potential efficacy of pirfenidone, a new therapeutic agent. Two hundred twelve human neurofibromas were transplanted into various locations in 59 experimental animals, and 30 mice with implants received oral pirfenidone for up to six weeks. Survival of neurofibromas in animals treated with pirfenidone was lower than in the control group $(P=.02)$. Tumors did not change histologic appearance or vascularization in response to pirfenidone. Treatment with pirfenidone, a new antifibrotic agent, inhibits survival of some tumors without causing toxicity in animals.",Journal of biomedicine & biotechnology,2004,Dusica Babovic-Vuksanovic; Lydia Petrovic; Bruce E. Knudsen; Timothy B. Plummer; Joseph E. Parisi; Srdan Babovic; Jeffrey L. Platt
PUB16835260,10.1093/hmg/ddl165,PMID:16835260,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,"Neurofibromas are common tumors found in neurofibromatosis type 1 (NF1) patients. These complex tumors are composed of Schwann cells, mast cells, fibroblasts and perineurial cells embedded in collagen that provide a lattice for tumor invasion. Genetic studies demonstrate that in neurofibromas, nullizygous loss of Nf1 in Schwann cells and haploinsufficiency of Nf1 in non-neuronal cells are required for tumorigenesis. Fibroblasts are a major cellular constituent in neurofibromas and are a source of collagen that constitutes approximately 50% of the dry weight of the tumor. Here, we show that two of the prevalent heterozygous cells found in neurofibromas, mast cells and fibroblasts interact directly to contribute to tumor phenotype. Nf1+/- mast cells secrete elevated concentrations of the profibrotic transforming growth factor-beta (TGF-beta). In response to TGF-beta, both murine Nf1+/- fibroblasts and fibroblasts from human neurofibromas proliferate and synthesize excessive collagen, a hallmark of neurofibromas. We also establish that the TGF-beta response occurs via hyperactivation of a novel Ras-c-abl signaling pathway. Genetic or pharmacological inhibition of c-abl reverses fibroblast proliferation and collagen synthesis to wild-type levels. These studies identify a novel molecular target to inhibit neurofibroma formation.",Human molecular genetics,2006-08-15,Feng-Chun Yang; Shi Chen; Travis Clegg; Xiaohong Li; Trent Morgan; Selina A Estwick; Jin Yuan; Waleed Khalaf; Sarah Burgin; Jeff Travers; Luis F Parada; David A Ingram; D Wade Clapp
PUB17924978,10.1111/j.1750-3639.2007.00105.x,PMID:17924978,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,"Meningiomas account for approximately 30% of all primary central nervous system tumors and are found in half of neurofibromatosis type 2 patients often causing significant morbidity. Although most meningiomas are benign, 10% are classified as atypical or anaplastic, displaying aggressive clinical behavior. Biallelic inactivation of the neurofibromatosis 2 (NF2) tumor suppressor is associated with meningioma formation in all NF2 patients and 60% of sporadic meningiomas. Deletion of the p16(INK4a)/p14(ARF) locus is found in both benign and malignant meningiomas, while mutation of the p53 tumor suppressor gene is uncommon. Previously, we inactivated Nf2 in homozygous conditional knockout mice by adenoviral Cre delivery and showed that Nf2 loss in arachnoid cells is rate-limiting for meningioma formation. Here, we report that additional nullizygosity for p16(Ink4a) increases the frequency of meningioma and meningothelial proliferation in these mice without modifying the tumor grade. In addition, by using magnetic resonance imaging (MRI) to screen a large cohort of mutant mice, we were able to detect meningothelial proliferation and meningioma development opening the way to future studies in which therapeutic interventions can be tested as preclinical assessment of their potential clinical application.","Brain pathology (Zurich, Switzerland)",2008-01,Michel Kalamarides; Anat O Stemmer-Rachamimov; Masaya Takahashi; Zhi-Yan Han; Fabrice Chareyre; Michiko Niwa-Kawakita; Peter M Black; Rona S Carroll; Marco Giovannini
PUB18242513,10.1016/j.ccr.2008.01.003,PMID:18242513,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,"Neurofibromatosis is caused by the loss of neurofibromin (Nf1), leading to peripheral nervous system (PNS) tumors, including neurofibromas and malignant peripheral nerve sheath tumors (MPNSTs). A long-standing question has been whether these tumors arise from neural crest stem cells (NCSCs) or differentiated glia. Germline or conditional Nf1 deficiency caused a transient increase in NCSC frequency and self-renewal in most regions of the fetal PNS. However, Nf1-deficient NCSCs did not persist postnatally in regions of the PNS that developed tumors and could not form tumors upon transplantation into adult nerves. Adult P0a-Cre+Nf1(fl/-) mice developed neurofibromas, and Nf1(+/-)Ink4a/Arf(-/-) and Nf1/p53(+/-) mice developed MPNSTs, but NCSCs did not persist postnatally in affected locations in these mice. Tumors appeared to arise from differentiated glia, not NCSCs.",Cancer cell,2008-02,Nancy M Joseph; Jack T Mosher; Johanna Buchstaller; Paige Snider; Paul E McKeever; Megan Lim; Simon J Conway; Luis F Parada; Yuan Zhu; Sean J Morrison
PUB18367665,10.1124/jpet.107.135830,PMID:18367665,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,"Neurofibromatosis type 1 (NF1) is a genetic disorder that is driven by the loss of neurofibromin (Nf) protein function. Nf contains a Ras-GTPase-activating protein domain, which directly regulates Ras signaling. Numerous clinical manifestations are associated with the loss of Nf and increased Ras activity. Ras proteins must be prenylated to traffic and functionally localize with target membranes. Hence, Ras is a potential therapeutic target for treating NF1. We have tested the efficacy of two novel farnesyl transferase inhibitors (FTIs), 1 and 2, alone or in combination with lovastatin, on two NF1 malignant peripheral nerve sheath tumor (MPNST) cell lines, NF90-8 and ST88-14. Single treatments of 1, 2, or lovastatin had no effect on Ras prenylation or MPNST cell proliferation. However, low micromolar combinations of 1 or 2 with lovastatin (FTI/lovastatin) reduced Ras prenylation in both MPNST cell lines. Furthermore, this FTI/lovastatin combination treatment reduced cell proliferation and induced an apoptotic response as shown by morphological analysis, procaspase-3/-7 activation, loss of mitochondrial membrane potential, and accumulation of cells with sub-G(1) DNA content. Little to no detectable toxicity was observed in normal rat Schwann cells following FTI/lovastatin combination treatment. These data support the hypothesis that combination FTI plus lovastatin therapy may be a potential treatment for NF1 MPNSTs.",The Journal of pharmacology and experimental therapeutics,2008-07,Jonathan W Wojtkowiak; Farid Fouad; Daniel T LaLonde; Miriam D Kleinman; Richard A Gibbs; John J Reiners; Richard F Borch; Raymond R Mattingly
PUBf8e8a007,10.1124/jpet.107.135830 | 10.1038/s41416-021-01270-8 | 10.1158/0008-5472.CAN-20-1365,PMID:18367665 | PMID:33658640 | PMID:33032988,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,,,
PUB18413802,10.1158/1535-7163.MCT-07-0518,PMID:18413802,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,"Malignant peripheral nerve sheath tumors (MPNST) are soft-tissue tumors with a very poor prognosis and largely resistant to chemotherapy. MPNSTs are characterized by activation of the Ras pathway by loss of tumor suppressor neurofibromatosis type 1. In view of this, MPNST may be susceptible to inhibition of the activated Ras/Raf/mitogen-activated protein kinase pathway by the B-Raf inhibitor sorafenib. MPNST (MPNST and ST8814) and dedifferentiated liposarcoma (LS141 and DDLS) human tumor cell lines were characterized for Ras activation and B-Raf expression. Tumor cells were treated with sorafenib and examined for growth inhibition, inhibition of phospho-MEK, phospho-ERK, cell cycle arrest, and changes in cyclin D1 and pRb expression. MPNSTs were sensitive to sorafenib at nanomolar concentrations. This appeared to be due to inhibition of phospho-MEK, phospho-ERK, suppression of cyclin D1, and hypophosphorylation of pRb at the CDK4-specific sites, resulting in a G(1) cell cycle arrest. These effects were not seen in the liposarcoma cells, which either did not express B-Raf or showed decreased Ras activation. Small interfering RNA-mediated depletion of B-Raf in MPNSTs also induced a G(1) cell cycle arrest in these cells, with a marked inhibition of cyclin D1 expression and Rb phosphorylation, whereas depletion of C-Raf did not affect either. With growth inhibition at the low nanomolar range, sorafenib, by inhibiting the mitogen-activated protein kinase pathway, may prove to be a novel therapy for patients with MPNST.",Molecular cancer therapeutics,2008-04,Grazia Ambrosini; Haider S Cheema; Sharon Seelman; Allison Teed; Elliot B Sambol; Samuel Singer; Gary K Schwartz
PUB18483311,10.1158/1535-7163.MCT-07-2335,PMID:18483311,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,"Malignant peripheral nerve sheath tumors (MPNST) are chemoresistant sarcomas with poor 5-year survival that arise in patients with neurofibromatosis type 1 (NF1) or sporadically. We tested three drugs for single and combinatorial effects on collected MPNST cell lines and in MPNST xenografts. The mammalian target of rapamycin complex 1 inhibitor RAD001 (Everolimus) decreased growth 19% to 60% after 4 days of treatment in NF1 and sporadic-derived MPNST cell lines. Treatment of subcutaneous sporadic MPNST cell xenografts with RAD001 significantly, but transiently, delayed tumor growth, and decreased vessel permeability within xenografts. RAD001 combined with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib caused additional inhibitory effects on growth and apoptosis in vitro, and a small but significant additional inhibitory effect on MPNST growth in vivo that were larger than the effects of RAD001 with doxorubicin. RAD001 plus erlotinib, in vitro and in vivo, reduced phosphorylation of AKT and total AKT levels, possibly accounting for their additive effect. The results support the consideration of RAD001 therapy in NF1 patient and sporadic MPNST. The preclinical tests described allow rapid screening strata for drugs that block MPNST growth, prior to tests in more complex models, and should be useful to identify drugs that synergize with RAD001.",Molecular cancer therapeutics,2008-05,Gunnar Johansson; Yonatan Y Mahller; Margaret H Collins; Mi-Ok Kim; Takahiro Nobukuni; John Perentesis; Timothy P Cripe; Heidi A Lane; Sara C Kozma; George Thomas; Nancy Ratner
PUB18636037,10.1097/MAO.0b013e31817f7398,PMID:18636037,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,"OBJECTIVE: To analyze the ability of ErbB inhibitors to reduce the growth of vestibular schwannoma (VS) xenografts. METHODS: Vestibular schwannoma xenografts were established in the interscapular fat pad in nude mice for 4 weeks. Initially, a small cohort of animals was treated with the ErbB2 inhibitor trastuzumab or saline for 2 weeks. Animals also received bromodeoxyuridine injections to label proliferating cells. In a longer-term experiment, animals were randomized to receive trastuzumab, erlotinib (an ErbB kinase inhibitor), or placebo for 12 weeks. Tumor growth was monitored by magnetic resonance imaging during the treatment period. Cell death was analyzed by terminal deoxynucleotidyl transferase-mediated dUTP-biotin end labeling of fragmented DNA. RESULTS: Tumors can be distinguished with T2-weighted magnetic resonance imaging sequences. Trastuzumab significantly reduced the proliferation of VS cells compared with control (p < 0.01) as analyzed by bromodeoxyuridine uptake. Control tumors demonstrated slight growth during the 12-week treatment period. Both trastuzumab and erlotinib significantly reduced the growth of VS xenografts (p < 0.05). Erlotinib, but not trastuzumab, resulted in a significant increase in the percentage of terminal deoxynucleotidyl transferase-mediated dUTP-biotin end labeling of fragmented DNA-positive VS cells (p < 0.01). CONCLUSION: In this preliminary study, the ErbB inhibitors trastuzumab and erlotinib decreased growth of VS xenografts in nude mice, raising the possibility of using ErbB inhibitors in the management of patients with schwannomas, particularly those with neurofibromatosis Type 2.","Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology",2008-09,J Jason Clark; Matthew Provenzano; Henry R Diggelmann; Ningyong Xu; Skylar S Hansen; Marlan R Hansen
PUB18974932,10.1007/s11060-008-9721-3,PMID:18974932,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,"The neurofibromatosis 2 locus (NF2) is inactivated through mutation and loss of heterozygosity (LOH) in 40-65% of all sporadic meningiomas, while the role of the p53 tumor suppression pathway in meningioma initiation and progression is still unclear. This study aims to determine if a p53 codon 72 arginine-to-proline polymorphism, found to be correlated with cancer development and cancer patient survival in other tumors, is associated with sporadic meningioma initiation or progression. We investigated Pro72 incidence in a cohort of 92 sporadic meningiomas and analyzed its association with histological grade (WHO classification) and with NF2 LOH (determined using polymorphic microsatellite markers on 22q). The Pro72 allele was not found to be selected for in the cohort. However, in the subgroup of meningiomas with NF2 LOH and carrying Pro72, 50.0% had high grade tumors (WHO grades II and III) compared to only 14.3% of those without NF2 LOH (OR = 6.0, CI = 1.56-23.11, P = 0.012). The significant association occurred only when considering subgroups of meningiomas with or without NF2 LOH, suggesting that not including NF2 status when analyzing study cohorts may explain the variability seen in the literature where all meningiomas were grouped together. Our data suggests a role for the p53 pathway in the progression of meningiomas in which NF2 is inactivated, and highlights the importance of accounting for NF2 LOH in future studies of meningiomas and the p53 pathway.",Journal of neuro-oncology,2009-02,ZeNan Chang; Chin-Lin Guo; Iris Ahronowitz; Anat O Stemmer-Rachamimov; Mia MacCollin; Fabio P Nunes
PUB19144871,10.3181/0809-RM-275,PMID:19144871,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,"Neurofibromatosis type 2 is an inherited disorder characterized by the development of benign and malignant tumors on the auditory nerves and central nervous system with symptoms including hearing loss, poor balance, skin lesions, and cataracts. Here, we report a novel protein-protein interaction between NF2 protein (merlin or schwannomin) and erythrocyte p55, also designated as MPP1. The p55 is a conserved scaffolding protein with postulated functions in cell shape, hair cell development, and neural patterning of the retina. The FERM domain of NF2 protein binds directly to p55, and surface plasmon resonance analysis indicates a specific interaction with a kD value of 3.7 nM. We developed a specific monoclonal antibody against human erythrocyte p55, and found that both p55 and NF2 proteins are colocalized in the non-myelin-forming Schwann cells. This finding suggests that the p55-NF2 protein interaction may play a functional role in the regulation of apico-basal polarity and tumor suppression pathways in non-erythroid cells.","Experimental biology and medicine (Maywood, N.J.)",2009-03,Pil-Soo Seo; Brendan J Quinn; Anwar A Khan; Lixiao Zeng; Christos G Takoudis; Toshihiko Hanada; Annalisa Bolis; Alessandra Bolino; Athar H Chishti
PUB19191334,10.1002/glia.20845,PMID:19191334,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,"Numerous studies have suggested that astrocytes in the central nervous system (CNS) exhibit molecular and functional heterogeneity. In this regard, astroglia from different CNS locations express distinct immune system, and neurotransmitter proteins, have varying levels of gap junction coupling and respond differently to injury. However, the relevance of these differences to human disease is unclear. As brain tumors in children arise in specific CNS locations, we hypothesized that regional astroglial cell heterogeneity might partly underlie the propensity for gliomas to arise in these areas. In this study, we performed high-density RNA microarray profiling on astrocytes from postnatal day 1 optic nerve, cerebellum, brainstem, and neocortex. We showed that astroglia from each region are molecularly distinct, and we were able to develop gene expression patterns that distinguish astroglia, but not neural stem cells, from these different brain regions. We next used these microarray data to determine whether brain tumor suppressor genes were differentially expressed in these distinct populations of astroglia. Interestingly, neurofibromatosis type 1 (NF1) gene expression was decreased at both the RNA and protein levels in neocortical astroglia relative to astroglia from the other brain regions. To determine the functional significance of this finding, we found increased astroglial cell proliferation in optic nerve, brainstem, and cerebellum, but not neocortex, following Nf1 inactivation in vitro and in vivo. These findings provide molecular evidence for CNS astroglial cell heterogeneity, and suggest that differences in tumor suppressor gene expression might contribute to the regional localization of human brain tumors.",Glia,2009-08-15,Tu-Hsueh Yeh; Da Yong Lee; Scott M Gianino; David H Gutmann
PUB20049725,10.1002/emmm.200900027,PMID:20049725,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,"Understanding the biological pathways critical for common neurofibromatosis type 1 (NF1) peripheral nerve tumours is essential, as there is a lack of tumour biomarkers, prognostic factors and therapeutics. We used gene expression profiling to define transcriptional changes between primary normal Schwann cells (n = 10), NF1-derived primary benign neurofibroma Schwann cells (NFSCs) (n = 22), malignant peripheral nerve sheath tumour (MPNST) cell lines (n = 13), benign neurofibromas (NF) (n = 26) and MPNST (n = 6). Dermal and plexiform NFs were indistinguishable. A prominent theme in the analysis was aberrant differentiation. NFs repressed gene programs normally active in Schwann cell precursors and immature Schwann cells. MPNST signatures strongly differed; genes up-regulated in sarcomas were significantly enriched for genes activated in neural crest cells. We validated the differential expression of 82 genes including the neural crest transcription factor SOX9 and SOX9 predicted targets. SOX9 immunoreactivity was robust in NF and MPSNT tissue sections and targeting SOX9 - strongly expressed in NF1-related tumours - caused MPNST cell death. SOX9 is a biomarker of NF and MPNST, and possibly a therapeutic target in NF1.",EMBO molecular medicine,2009-07,Shyra J Miller; Walter J Jessen; Tapan Mehta; Atira Hardiman; Emily Sites; Sergio Kaiser; Anil G Jegga; Hua Li; Meena Upadhyaya; Marco Giovannini; David Muir; Margaret R Wallace; Eva Lopez; Eduard Serra; G Petur Nielsen; Conxi Lazaro; Anat Stemmer-Rachamimov; Grier Page; Bruce J Aronow; Nancy Ratner
PUBbd46e5f9,10.1002/emmm.200900027 | 10.1158/1535-7163.MCT-07-2335,PMID:20049725 | PMID:18483311,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,,,
PUB20195187,10.1097/MAO.0b013e3181d2777f,PMID:20195187,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,"HYPOTHESIS: To investigate the early events in molecular progression toward schwannoma tumorigenesis, we developed an in vitro model of human Schwann cell tumorigenesis by merlin knockdown. BACKGROUND: Neurofibromatosis 2 (NF2)-related and sporadic vestibular schwannoma (VS) exhibit loss of functional merlin (schwannomin). After loss of merlin expression in the Schwann cell, the initial steps toward VS tumorigenesis are unknown. Merlin, a putative tumor suppressor protein, interacts with many cellular proteins, regulating their function. Among these are receptor tyrosine kinases, including the epidermal growth factor receptor family B (ErbB) family receptors epidermal growth factor receptor and ErbB2. Functional merlin interacts with and internalizes these growth factor receptors, silencing their proliferation and survival signaling. Deregulation of CD44, the cell adhesion/signaling molecule and cancer stem cell marker, has also been implicated in VS tumorigenesis. METHODS: Merlin knockdown was performed using small interfering RNA transfection into human Schwann cell primary cultures. Knockdown was confirmed by real-time quantitative PCR, immunofluorescence, and Western analysis. Expression profiles of ErbB, merlin, and the stem cell markers nestin and CD44 were examined in knockdowns. Proliferation rate was assessed with bromodeoxyuridine incorporation, and radiation sensitivity was assessed using the Annexin assay in knockdowns versus controls. RESULTS: Merlin knockdowns demonstrated increased proliferation rate, upregulation of epidermal growth factor receptor, ErbB2, and ErbB3, CD44, and nestin. Short-term merlin depletion had no effect on gamma irradiation sensitivity compared with controls. CONCLUSION: Merlin depletion results in deregulation of ErbB receptor signaling, promotes a dedifferentiated state, and increases Schwann cell proliferation, suggesting critical steps toward schwannoma tumorigenesis.","Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology",2010-04,Zana Ahmad; Carrie Maiorana Brown; Andrew K Patel; Allen F Ryan; Rutherford Ongkeko; Joni K Doherty
PUB20200958,10.1002/jbmr.42,PMID:20200958,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,"Postfracture tibial nonunion (pseudoarthrosis) leads to lifelong disability in patients with neurofibromatosis type I (NF1), a disorder caused by mutations in the NF1 gene. To determine the contribution of NF1 in bone healing, we assessed bone healing in the Nf1(ob) (-/-) conditional mouse model lacking Nf1 specifically in osteoblasts. A closed distal tibia fracture protocol and a longitudinal study design were used. During the 21- to 28-day postfracture period, callus volume, as expected, decreased in wild-type but not in Nf1(ob) (-/-) mice, suggesting delayed healing. At these two time points, bone volume (BV/TV) and volumetric bone mineral density (vBMD) measured by 3D micro-computed tomography were decreased in Nf1(ob) (-/-) callus-bridging cortices and trabecular compartments compared with wild-type controls. Histomorphometric analyses revealed the presence of cartilaginous remnants, a high amount of osteoid, and increased osteoclast surfaces in Nf1(ob) (-/-) calluses 21 days after fracture, which was accompanied by increased expression of osteopontin, Rankl, and Tgfbeta. Callus strength measured by three-point bending 28 days after fracture was reduced in Nf1(ob) (-/-) versus wild-type calluses. Importantly, from a clinical point of view, this defect of callus maturation and strength could be ameliorated by local delivery of low-dose lovastatin microparticles, which successfully decreased osteoid volume and cartilaginous remnant number and increased callus BV/TV and strength in mutant mice. These results thus indicate that the dysfunctions caused by loss of Nf1 in osteoblasts impair callus maturation and weaken callus mechanical properties and suggest that local delivery of low-dose lovastatin may improve bone healing in NF1 patients.",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,2010-07,Weixi Wang; Jeffry S Nyman; Heather E Moss; Gloria Gutierrez; Gregory R Mundy; Xiangli Yang; Florent Elefteriou
PUB20551058,10.1158/0008-5472.CAN-09-3769,PMID:20551058,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,"Current models of oncogenesis incorporate the contributions of chronic inflammation and aging to the patterns of tumor formation. These oncogenic pathways, involving leukocytes and fibroblasts, are not readily applicable to brain tumors (glioma), and other mechanisms must account for microenvironmental influences on central nervous system tumorigenesis. Previous studies from our laboratories have used neurofibromatosis-1 (NF1) genetically engineered mouse (GEM) models to understand the spatial restriction of glioma formation to the optic pathway of young children. Based on our initial findings, we hypothesize that brain region-specific differences in cAMP levels account for the pattern of NF1 gliomagenesis. To provide evidence that low levels of cAMP promote glioma formation in NF1, we generated foci of decreased cAMP in brain regions where gliomas rarely form in children with NF1. Focal cAMP reduction was achieved by forced expression of phosphodiesterase 4A1 (PDE4A1) in the cortex of Nf1 GEM strains. Ectopic PDE4A1 expression produced hypercellular lesions with features of human NF1-associated glioma. Conversely, pharmacologic elevation of cAMP with the PDE4 inhibitor rolipram dramatically inhibited optic glioma growth and tumor size in Nf1 GEM in vivo. Together, these results indicate that low levels of cAMP in a susceptible Nf1 mouse strain are sufficient to promote gliomagenesis, and justify the implementation of cAMP-based stroma-targeted therapies for glioma.",Cancer research,2010-07-15,Nicole M Warrington; Scott M Gianino; Erin Jackson; Patricia Goldhoff; Joel R Garbow; David Piwnica-Worms; David H Gutmann; Joshua B Rubin
PUB20554030,10.1016/j.jneuroim.2010.05.002,PMID:20554030,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,"Tumorigenesis requires interactions between tumor progenitors and their microenvironment. We found that low cAMP levels were sufficient for tumorigenesis in a mouse model of Neurofibromatosis-1 (NF1)-associated optic pathway glioma (OPG). We hypothesized that the distinct pattern of glioma in NF1 reflected spatiotemporal differences in CXCL12 effects on cAMP levels. Thus, we sought to alter the pattern of gliomagenesis through manipulation of CXCL12-CXCR4 pathway activation in Nf1 OPG mice. Forced CXCL12 expression induced glioma at a low frequency. Further, treatment of Nf1 OPG mice with AMD3100, a CXCR4 antagonist, did not attenuate glioma growth. Thus, it appears, CXCL12 alone cannot promote gliomagenesis in NF1 mice.",Journal of neuroimmunology,2010-07-27,Tao Sun; Scott M Gianino; Erin Jackson; David Piwnica-Worms; David H Gutmann; Joshua B Rubin
PUB21072183,10.1371/journal.pone.0013791,PMID:21072183,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,"BACKGROUND: NF2 is an autosomal dominant disease characterized by development of bilateral vestibular schwannomas and other benign tumors in central nervous system. Loss of the NF2 gene product, Merlin, leads to aberrant Schwann cell proliferation, motility, and survival, but the mechanisms by which this tumor suppressor functions remain unclear. One well-defined target of Merlin is the group I family of p21-activated kinases, which are allosterically inhibited by Merlin and which, when activated, stimulate cell cycle progression, motility, and increased survival. Here, we examine the effect of Pak inhibition on cells with diminished Merlin function. METHODOLOGY/PRINCIPAL FINDINGS: Using a specific peptide inhibitor of group I Paks, we show that loss of Pak activity restores normal cell movement in cells lacking Merlin function. In addition, xenografts of such cells form fewer and smaller tumors than do cells without Pak inhibition. However, in tumors, loss of Pak activity does not reduce Erk or Akt activity, two signaling proteins that are thought to mediate Pak function in growth factor pathways. CONCLUSIONS/SIGNIFICANCE: These results suggest that Pak functions in novel signaling pathways in NF2, and may serve as a useful therapeutic target in this disease.",PloS one,2010-11-02,Hoi Yee Chow; Dina Stepanova; Jennifer Koch; Jonathan Chernoff
PUBe7e07743,10.1016/j.jneumeth.2010.10.021 | 10.1038/s41467-023-40408-5 | 10.1038/s41596-018-0105-7 | 10.1016/j.ebiom.2018.09.042,PMID:21111000 | PMID:38216587 | PMID:30617350 | PMID:30274821,"A novel imaging-compatible sciatic nerve schwannoma model. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.",,,,
PUB21199799,10.1158/0008-5472.CAN-10-2732,PMID:21199799,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,"Secondary malignant neoplasms (SMN) are increasingly common complications of cancer therapy that have proven difficult to model in mice. Clinical observations suggest that the development of SMN correlates with radiation dose; however, this relationship has not been investigated systematically. We developed a novel procedure for administering fractionated cranial irradiation (CI) and investigated the incidence and spectrum of cancer in control and heterozygous Nf1 mutant mice irradiated to a moderate (15 Gy) or high dose (30 Gy). Heterozygous Nf1 inactivation cooperated with CI to induce solid tumors and myeloid malignancies, with mice developing many of the most common SMNs found in human patients. CI-induced malignancies segregated according to radiation dose as Nf1(+/-) mice developed predominately hematologic abnormalities after 15 Gy, whereas solid tumors predominated at 30 Gy, suggesting that radiation dose thresholds exist for hematologic and nonhematologic cancers. Genetic and biochemical studies revealed discrete patterns of somatic Nf1 and Trp53 inactivation and we observed hyperactive Ras signaling in many radiation-induced solid tumors. This technique for administering focal fractionated irradiation will facilitate mechanistic and translational studies of SMNs.",Cancer research,2011-01-01,Jean L Nakamura; Connie Phong; Emile Pinarbasi; Scott C Kogan; Scott Vandenberg; Andrew E Horvai; Bruce A Faddegon; Dorothea Fiedler; Kevan Shokat; Benjamin T Houseman; Richard Chao; Russell O Pieper; Kevin Shannon
PUB21216928,10.1158/1535-7163.MCT-10-0654,PMID:21216928,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,"The identification of mammalian target of rapamycin (mTOR) as a major mediator of neurofibromatosis-1 (NF1) tumor growth has led to the initiation of clinical trials using rapamycin analogs. Previous studies from our laboratory have shown that durable responses to rapamycin treatment in a genetically engineered mouse model of Nf1 optic glioma require 20 mg/kg/day, whereas only transient tumor growth suppression was observed with 5 mg/kg/day rapamycin despite complete silencing of ribosomal S6 activity. To gain clinically relevant insights into the mechanism underlying this dose-dependent effect, we used Nf1-deficient glial cells in vitro and in vivo. First, there was an exponential relationship between blood and brain rapamycin levels. Second, we show that currently used biomarkers of mTOR pathway inhibition (phospho-S6, phospho-4EBP1, phospho-STAT3, and Jagged-1 levels) and tumor proliferation (Ki67) do not accurately reflect mTOR target inhibition or Nf1-deficient glial growth suppression. Third, the incomplete suppression of Nf1-deficient glial cell proliferation in vivo following 5 mg/kg/day rapamycin treatment reflects mTOR-mediated AKT activation, such that combined 5 mg/kg/day rapamycin and PI3-kinase (PI3K) inhibition or dual PI3K/mTOR inhibition recapitulates the growth suppressive effects of 20 mg/kg/day rapamycin. These new findings argue for the identification of more accurate biomarkers for rapamycin treatment response and provide reference preclinical data for comparing human rapamycin levels with target effects in the brain.",Molecular cancer therapeutics,2011-02,Sutapa Banerjee; Scott M Gianino; Feng Gao; Uwe Christians; David H Gutmann
PUBff6e5d17,10.1158/1535-7163.MCT-10-0654 | 10.1016/j.jprot.2016.02.004 | 10.1158/0008-5472.CAN-09-3769,PMID:21216928 | PMID:26883872 | PMID:20551058,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. | 3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,,,
PUB21439418,10.1016/j.bone.2011.03.760,PMID:21439418,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,"Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder caused by mutation of the NF1 tumor suppressor gene. Spinal deformities are common skeletal manifestations in patients with NF1. To date, the mechanism of vertebral abnormalities remains unclear because of the lack of appropriate animal models for the skeletal manifestations of NF1. In the present study, we report a novel murine NF1 model, Nf1(flox/-);Col2.3Cre(+) mice. These mice display short vertebral segments. In addition, a significant reduction in cortical and trabecular bone mass of the vertebrae was observed in Nf1(flox/-);Col2.3Cre(+) mice as measured by dual-energy X-ray absorptiometry (DEXA) and peripheral quantitative computed tomography (pQCT). Peak stress and peak load were also significantly reduced in Nf1(flox/-);Col2.3Cre(+) mice as compared to controls. Furthermore, the lumbar vertebrae showed enlargement of the inter-vertebral canal, a characteristic feature of lumbar vertebrae in NF1 patients. Finally, histologic analysis demonstrated increased numbers of osteoclasts and decreased numbers of osteoblasts in the vertebrae of Nf1(flox/-);Col2.3Cre(+) mice in comparison to controls. In summary, Nf1(flox/-);Col2.3Cre(+) mice demonstrate multiple structural and functional abnormalities in the lumbar vertebrae which recapitulate the dystrophic vertebral changes in NF1 patients. This novel murine model provides a platform to understand the cellular and molecular mechanisms underlying the pathogenesis of spinal deficits in NF1 patients.",Bone,2011-06-01,Wei Zhang; Steven D Rhodes; Liming Zhao; Yongzheng He; Yingze Zhang; Yong Shen; Dalong Yang; Xiaohua Wu; Xiaohong Li; Xianlin Yang; Su-Jung Park; Shi Chen; Charles Turner; Feng-Chun Yang
PUB21681782,10.1002/ajh.22035,PMID:21681782,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,"Juvenile Myelomonocytic Leukemia (JMML) is a relentlessly progressive myeloproliferative/myelodysplastic (MPD/MDS) hematopoietic disorder more common in patients with any one of at least three distinct genetic lesions, specifically NF1 gene loss and PTPN11 and NRAS mutations. NF1 and PTPN11 are molecular lesions associated with Neurofibromatosis Syndrome Type I (NF1 Syndrome) and Noonan's Syndrome, respectively. The occurrence of JMML is rare; even among those predisposed with these syndromes to development of disease, and secondary genetic events likely contribute to the development and progression of disease. In NF1 syndrome, loss of p53 function is a common event in solid tumors, but uncommon in JMML, suggesting that the p53 pathway may be modified by other events in this hematopoietic disorder. The work presented here investigates the possible role of the p19(Arf) (p19) tumor suppressor in development of MPD associated with Nf1 gene loss in mice. We find that Nf1 mutant hematopoietic cells with loss of p19 develop accelerated hematopoietic disease similar to acute leukemia with a variable phenotype. This suggests that p19 may play a role in development of JMML and evaluation of the human p19 homolog (p14(ARF)) in JMML may be informative.",American journal of hematology,2011-07,Stephen M Wiesner; Jennifer L Geurts; Miechaleen D Diers; Rachel J Bergerson; Diane E Hasz; Kelly J Morgan; David A Largaespada
PUBa1435977,10.1016/j.expneurol.2011.09.005 | 10.1002/glia.20845 | 10.1002/ana.23793 | 10.1016/j.celrep.2015.02.041,PMID:21963652 | PMID:19191334 | PMID:23225063 | PMID:25772366,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,,,
PUB22901811,10.1016/j.cell.2012.06.034,PMID:22901811,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,"Germline mutations in the RAS/ERK signaling pathway underlie several related developmental disorders collectively termed neuro-cardio-facial-cutaneous (NCFC) syndromes. NCFC patients manifest varying degrees of cognitive impairment, but the developmental basis of their brain abnormalities remains largely unknown. Neurofibromatosis type 1 (NF1), an NCFC syndrome, is caused by loss-of-function heterozygous mutations in the NF1 gene, which encodes neurofibromin, a RAS GTPase-activating protein. Here, we show that biallelic Nf1 inactivation promotes Erk-dependent, ectopic Olig2 expression specifically in transit-amplifying progenitors, leading to increased gliogenesis at the expense of neurogenesis in neonatal and adult subventricular zone (SVZ). Nf1-deficient brains exhibit enlarged corpus callosum, a structural defect linked to severe learning deficits in NF1 patients. Strikingly, these NF1-associated developmental defects are rescued by transient treatment with an MEK/ERK inhibitor during neonatal stages. This study reveals a critical role for Nf1 in maintaining postnatal SVZ-derived neurogenesis and identifies a potential therapeutic window for treating NF1-associated brain abnormalities.",Cell,2012-08-17,Yuan Wang; Edward Kim; Xiaojing Wang; Bennett G Novitch; Kazuaki Yoshikawa; Long-Sheng Chang; Yuan Zhu
PUB23328114,10.18632/oncotarget.793,PMID:23328114,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,"Malignant peripheral nerve sheath tumours (MPNST) are rare, hereditary cancers associated with neurofibromatosis type I. MPNSTs lack effective treatment options as they often resist chemotherapies and have high rates of disease recurrence. Aurora kinase A (AURKA) is an emerging target in cancer and an aurora kinase inhibitor (AKI), termed MLN8237, shows promise against MPNST cell lines in vitro and in vivo. Here, we test MLN8237 against two primary human MPNST grown in vivo as xenotransplants and find that treatment results in tumour cells exiting the cell cycle and undergoing endoreduplication, which cumulates in stabilized disease. Targeted therapies can often fail in the clinic due to insufficient knowledge about factors that determine tumour susceptibilities, so we turned to three MPNST cell-lines to further study and modulate the cellular responses to AKI. We find that the sensitivity of cell-lines with amplification of AURKA depends upon the activity of the kinase, which correlates with the expression of the regulatory gene products TPX2 and HMMR/RHAMM. Silencing of HMMR/RHAMM, but not TPX2, augments AURKA activity and sensitizes MPNST cells to AKI. Furthermore, we find that AURKA activity is critical to the propagation and self-renewal of sphere-enriched MPNST cancer stem-like cells. AKI treatment significantly reduces the formation of spheroids, attenuates the self-renewal of spheroid forming cells, and promotes their differentiation. Moreover, silencing of HMMR/RHAMM is sufficient to endow MPNST cells with an ability to form and maintain sphere culture. Collectively, our data indicate that AURKA is a rationale therapeutic target for MPNST and tumour cell responses to AKI, which include differentiation, are modulated by the abundance of HMMR/RHAMM.",Oncotarget,2013-01,Pooja Mohan; Joan Castellsague; Jihong Jiang; Kristi Allen; Helen Chen; Oksana Nemirovsky; Melanie Spyra; Kaiji Hu; Lan Kluwe; Miguel Angel Pujana; Alberto Villanueva; Victor F Mautner; Jonathan J Keats; Sandra E Dunn; Conxi Lazaro; Christopher A Maxwell
PUB62b99413,10.1038/ng.2641 | 10.1186/s40478-025-01965-6,PMID:23685747 | PMID:40025578,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,,,
PUB2c295693,10.1038/ng.2641 | 10.1158/1535-7163.MCT-24-1053,PMID:23685747 | PMID:41036607,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,,,
PUB24040940,10.1186/1479-5876-11-213,PMID:24040940,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,"BACKGROUND: Malignant peripheral nerve sheath tumors (MPNST) are rare highly aggressive sarcomas that affect 8-13% of people with neurofibromatosis type 1. The prognosis for patients with MPNST is very poor. Despite TOP2A overexpression in these tumors, doxorubicin resistance is common, and the mechanisms of chemotherapy resistance in MPNST are poorly understood. Molecular-guided therapy prediction is an emerging strategy for treatment refractory sarcomas that involves identification of therapy response and resistance mechanisms in individual tumors. Here, we report the results from a personalized, molecular-guided therapy analysis of MPNST samples. METHODS: Established molecular-guided therapy prediction software algorithms were used to analyze published microarray data from human MPNST samples and cell lines, with benign neurofibroma tissue controls. MPNST and benign neurofibroma-derived cell lines were used for confirmatory in vitro experimentation using quantitative real-time PCR and growth inhibition assays. Microarray data was analyzed using Affymetrix expression console MAS 5.0 method. Significance was calculated with Welch's t-test with non-corrected p-value < 0.05 and validated using permutation testing across samples. Paired Student's t-tests were used to compare relative EC50 values from independent growth inhibition experiments. RESULTS: Molecular guided therapy predictions highlight substantial variability amongst human MPNST samples in expression of drug target and drug resistance pathways, as well as some similarities amongst samples, including common up-regulation of DNA repair mechanisms. In a subset of MPNSTs, high expression of ABCC1 is observed, serving as a predicted contra-indication for doxorubicin and related therapeutics in these patients. These microarray-based results are confirmed with quantitative, real-time PCR and immunofluorescence. The functional effect of drug efflux in MPNST-derived cells is confirmed using in vitro growth inhibition assays. Alternative therapeutics supported by the molecular-guided therapy predictions are reported and tested in MPNST-derived cells. CONCLUSIONS: These results confirm the substantial molecular heterogeneity of MPNSTs and validate molecular-guided therapy predictions in vitro. The observed molecular heterogeneity in MPNSTs influences therapy prediction. Also, mechanisms involving drug transport and DNA damage repair are primary mediators of MPNST chemotherapy resistance. Together, these findings support the utility of individualized therapy in MPNST as in other sarcomas, and provide initial proof-of concept that individualized therapy prediction can be accomplished.",Journal of translational medicine,2013-09-17,Jacqueline D Peacock; David Cherba; Kevin Kampfschulte; Mallory K Smith; Noel R Monks; Craig P Webb; Matthew Steensma
PUB11a16d05,10.1186/1479-5876-11-213 | 10.1158/0008-5472.CAN-20-1365,PMID:24040940 | PMID:33032988,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,,,
PUB24371224,10.1158/0008-5472.CAN-13-2062,PMID:24371224,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,"Malignant mesothelioma is a highly aggressive, asbestos-related cancer frequently marked by mutations of both NF2 and CDKN2A. We demonstrate that germline knockout of one allele of each of these genes causes accelerated onset and progression of asbestos-induced malignant mesothelioma compared with asbestos-exposed Nf2(+/-) or wild-type mice. Ascites from some Nf2(+/-);Cdkn2a(+/-) mice exhibited large tumor spheroids, and tail vein injections of malignant mesothelioma cells established from these mice, but not from Nf2(+/-) or wild-type mice, produced numerous tumors in the lung, suggesting increased metastatic potential of tumor cells from Nf2(+/-);Cdkn2a(+/-) mice. Intraperitoneal injections of malignant mesothelioma cells derived from Nf2(+/-);Cdkn2a(+/-) mice into severe combined immunodeficient mice produced tumors that penetrated the diaphragm and pleural cavity and harbored increased cancer stem cells (CSC). Malignant mesothelioma cells from Nf2(+/-);Cdkn2a(+/-) mice stained positively for CSC markers and formed CSC spheroids in vitro more efficiently than counterparts from wild-type mice. Moreover, tumor cells from Nf2(+/-);Cdkn2a(+/-) mice showed elevated c-Met expression/activation, which was partly dependent on p53-mediated regulation of miR-34a and required for tumor migration/invasiveness and maintenance of the CSC population. Collectively, these studies demonstrate in vivo that inactivation of Nf2 and Cdkn2a cooperate to drive the development of highly aggressive malignant mesotheliomas characterized by enhanced tumor spreading capability and the presence of a CSC population associated with p53/miR-34a-dependent activation of c-Met. These findings suggest that cooperativity between losses of Nf2 and Cdkn2a plays a fundamental role in driving the highly aggressive tumorigenic phenotype considered to be a hallmark of malignant mesothelioma.",Cancer research,2014-02-15,Craig W Menges; Yuwaraj Kadariya; Deborah Altomare; Jacqueline Talarchek; Erin Neumann-Domer; Yue Wu; Guang-Hui Xiao; Irina M Shapiro; Vihren N Kolev; Jonathan A Pachter; Andres J Klein-Szanto; Joseph R Testa
PUB8087f428,10.1002/ana.24093 | 10.1158/0008-5472.CAN-09-3769 | 10.18632/oncotarget.17589,PMID:24375753 | PMID:20551058 | PMID:28525381,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,,,
PUB24465906,10.1371/journal.pone.0086115,PMID:24465906,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.","Bone fragility due to osteopenia, osteoporosis or debilitating focal skeletal dysplasias is a frequent observation in the Mendelian disease Neurofibromatosis type 1 (NF1). To determine the mechanisms underlying bone fragility in NF1 we analyzed two conditional mouse models, Nf1Prx1 (limb knock-out) and Nf1Col1 (osteoblast specific knock-out), as well as cortical bone samples from individuals with NF1. We examined mouse bone tissue with micro-computed tomography, qualitative and quantitative histology, mechanical tensile analysis, small-angle X-ray scattering (SAXS), energy dispersive X-ray spectroscopy (EDX), and scanning acoustic microscopy (SAM). In cortical bone of Nf1Prx1 mice we detected ectopic blood vessels that were associated with diaphyseal mineralization defects. Defective mineral binding in the proximity of blood vessels was most likely due to impaired bone collagen formation, as these areas were completely devoid of acidic matrix proteins and contained thin collagen fibers. Additionally, we found significantly reduced mechanical strength of the bone material, which was partially caused by increased osteocyte volume. Consistent with these observations, bone samples from individuals with NF1 and tibial dysplasia showed increased osteocyte lacuna volume. Reduced mechanical properties were associated with diminished matrix stiffness, as determined by SAM. In line with these observations, bone tissue from individuals with NF1 and tibial dysplasia showed heterogeneous mineralization and reduced collagen fiber thickness and packaging. Collectively, the data indicate that bone fragility in NF1 tibial dysplasia is partly due to an increased osteocyte-related micro-porosity, hypomineralization, a generalized defect of organic matrix formation, exacerbated in the regions of tensional and bending force integration, and finally persistence of ectopic blood vessels associated with localized macro-porotic bone lesions.",PloS one,2014,Jirko Khnisch; Jong Seto; Claudia Lange; Susanne Schrof; Sabine Stumpp; Karolina Kobus; Julia Grohmann; Nadine Kossler; Peter Varga; Monika Osswald; Denise Emmerich; Sigrid Tinschert; Falk Thielemann; Georg Duda; Wenke Seifert; Thaqif El Khassawna; David A Stevenson; Florent Elefteriou; Uwe Kornak; Kay Raum; Peter Fratzl; Stefan Mundlos; Mateusz Kolanczyk
PUB24509877,10.1038/onc.2013.506,PMID:24509877,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,"Mutations in the neurofibromatosis type 1 (NF1) tumor suppressor gene are common in cancer and can cause resistance to therapy. Using transcriptome analysis we identified MAF as an NF1- regulated transcription factor and verified MAF regulation through RAS/MAPK/AP-1 signaling in malignant peripheral nerve sheath tumor (MPNST) cell lines. MAF was also downregulated in human MPNST. Acute re-expression of MAF promoted expression of glial differentiation markers in MPNST cells in vitro, decreased self-renewal of embryonic precursors and transiently affected tumor cell phenotypes in vitro by increasing MPNST cell death and reducing metabolic activity and anchorage-independent growth. Paradoxically, chronic MAF overexpression enhanced MPNST cell tumor growth in vivo, correlating with elevated pS6 in vitro and in vivo. RAD001 blocked MAF-mediated tumor growth, and MAF regulated the mTOR pathway through DEPTOR. MAPK inhibition with NF1 loss of function is predicted to show limited efficacy due to reactivation of mTOR signaling via MAF.",Oncogene,2014-12-04,M E Brundage; P Tandon; D W Eaves; J P Williams; S J Miller; R H Hennigan; A Jegga; T P Cripe; N Ratner
PUB0329016d,10.1038/onc.2013.506 | 10.1158/1535-7163.MCT-07-0518,PMID:24509877 | PMID:18413802,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,,,
PUB5de229dd,10.1038/onc.2013.506 | 10.1038/s41418-022-00991-4 | 10.1093/hmg/ddl165 | 10.1126/sciadv.adg8876,PMID:24509877 | PMID:35393510 | PMID:16835260 | PMID:38000020,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD | Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,,,
PUB24595234,10.1371/journal.pone.0090853,PMID:24595234,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,"The proper control of tissue growth is essential during normal development and an important problem in human disease. Merlin, the product of the Neurofibromatosis 2 tumor suppressor gene, has been extensively studied to understand its functions in growth control. Here we describe experiments in which we used Drosophila as an in vivo system to test the functions of the normal human NF2 gene products and patient-derived mutant alleles. Although the predominant NF2 gene isoform, isoform 1, could functionally replace the Drosophila Merlin gene, a second isoform with a distinct C-terminal tail could not. Immunofluorescence studies show that the two isoforms have distinct subcellular localizations when expressed in the polarized imaginal epithelium, and function in genetic rescue assays correlates with apical localization of the NF2 protein. Interestingly, we found that a patient-derived missense allele, NF2L64P, appears to be temperature sensitive. These studies highlight the utility of Drosophila for in vivo functional analysis of highly conserved human disease genes.",PloS one,2014,Heather S Gavilan; Rima M Kulikauskas; David H Gutmann; Richard G Fehon
PUB24817309,10.1371/journal.pone.0097320,PMID:24817309,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,"OBJECTIVE: Individuals with the neurofibromatosis type 2 (NF2) cancer predisposition syndrome develop spinal cord glial tumors (ependymomas) that likely originate from neural progenitor cells. Whereas many spinal ependymomas exhibit indolent behavior, the only treatment option for clinically symptomatic tumors is surgery. In this regard, medical therapies are unfortunately lacking due to an incomplete understanding of the critical growth control pathways that govern the function of spinal cord (SC) neural progenitor cells (NPCs). METHODS: To identify potential therapeutic targets for these tumors, we leveraged primary mouse Nf2-deficient spinal cord neural progenitor cells. RESULTS: We demonstrate that the Nf2 protein, merlin, negatively regulates spinal neural progenitor cell survival and glial differentiation in an ErbB2-dependent manner, and that NF2-associated spinal ependymomas exhibit increased ErbB2 activation. Moreover, we show that Nf2-deficient SC NPC ErbB2 activation results from Rac1-mediated ErbB2 retention at the plasma membrane. SIGNIFICANCE: Collectively, these findings establish ErbB2 as a potential rational therapeutic target for NF2-associated spinal ependymoma.",PloS one,2014,Cynthia Garcia; David H Gutmann
PUB24824755,10.1371/journal.pone.0096733,PMID:24824755,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,"Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive Schwann cell-derived sarcomas and are the leading cause of mortality in patients with neurofibromatosis type 1 (NF1). Current treatment modalities have been largely ineffective, resulting in a high rate of MPNST recurrence and poor five-year patient survival. This necessitates the exploration of alternative chemotherapeutic options for MPNST patients. This study sought to assess the cytotoxic effect of the BH3-mimetic AT101 [(-)-gossypol] on MPNST cells in vitro and to identify key regulators of AT101-induced MPNST cell death. We found that AT101 caused caspase-independent, non-apoptotic MPNST cell death, which was accompanied by autophagy and was mediated through HIF-1 induced expression of the atypical BH3-only protein BNIP3. These effects were mediated by intracellular iron chelation, a previously unreported mechanism of AT101 cytotoxicity.",PloS one,2014,Niroop Kaza; Latika Kohli; Christopher D Graham; Barbara J Klocke; Steven L Carroll; Kevin A Roth
PUB168d0863,10.1371/journal.pone.0096733 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335,PMID:24824755 | PMID:20049725 | PMID:32642733 | PMID:18483311,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,,,
PUB24882693,10.1016/j.jmb.2014.05.011,PMID:24882693,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,"The tumor suppressor protein Merlin inhibits cell proliferation upon establishing cell-cell contacts. Because Merlin has high level of sequence similarity to the Ezrin-Radixin-Moesin family of proteins, the structural model of Ezrin-Radixin-Moesin protein autoinhibition and cycling between closed/resting and open/active conformational states is often employed to explain Merlin function. However, recent biochemical studies suggest alternative molecular models of Merlin function. Here, we have determined the low-resolution molecular structure and binding activity of Merlin and a Merlin(S518D) mutant that mimics the inactivating phosphorylation at S518 using small-angle neutron scattering and binding experiments. Small-angle neutron scattering shows that, in solution, both Merlin and Merlin(S518D) adopt a closed conformation, but binding experiments indicate that a significant fraction of either Merlin or Merlin(S518D) is capable of binding to the target protein NHERF1. Upon binding to the phosphatidylinositol 4,5-bisphosphate lipid, the wild-type Merlin adopts a more open conformation than in solution, but Merlin(S518D) remains in a closed conformation. This study supports a rheostat model of Merlin in NHERF1 binding and contributes to resolving a controversy about the molecular conformation and binding activity of Merlin.",Journal of molecular biology,2014-07-29,Jahan Ali Khajeh; Jeong Ho Ju; Moussoubaou Atchiba; Marc Allaire; Christopher Stanley; William T Heller; David J E Callaway; Zimei Bu
PUB25026211,10.1016/j.ccr.2014.05.001,PMID:25026211,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,"It is currently unclear whether Merlin/NF2 suppresses tumorigenesis by activating upstream components of the Hippo pathway at the plasma membrane or by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. We found that derepressed CRL4(DCAF1) promotes YAP- and TEAD-dependent transcription by ubiquitylating and, thereby, inhibiting Lats1 and 2 in the nucleus. Genetic epistasis experiments and analysis of tumor-derived missense mutations indicate that this signaling connection sustains the oncogenicity of Merlin-deficient tumor cells. Analysis of clinical samples confirms that this pathway operates in NF2-mutant tumors. We conclude that derepressed CRL4(DCAF1) promotes activation of YAP by inhibiting Lats1 and 2 in the nucleus.",Cancer cell,2014-07-14,Wei Li; Jonathan Cooper; Lu Zhou; Chenyi Yang; Hediye Erdjument-Bromage; David Zagzag; Matija Snuderl; Marc Ladanyi; C Oliver Hanemann; Pengbo Zhou; Matthias A Karajannis; Filippo G Giancotti
PUB25043298,10.1038/onc.2014.185,PMID:25043298,Oncogenic role of Merlin/NF2 in glioblastoma.,"Glioblastoma is the most common and aggressive primary brain tumor in adults, with a poor prognosis because of its resistance to radiotherapy and chemotherapy. Merlin/NF2 (moesin-ezrin-radixin-like protein/neurofibromatosis type 2) is a tumor suppressor found to be mutated in most nervous system tumors; however, it is not mutated in glioblastomas. Merlin associates with several transmembrane receptors and intracellular proteins serving as an anchoring molecule. Additionally, it acts as a key component of cell motility. By selecting sub-populations of U251 glioblastoma cells, we observed that high expression of phosphorylated Merlin at serine 518 (S518-Merlin), NOTCH1 and epidermal growth factor receptor (EGFR) correlated with increased cell proliferation and tumorigenesis. These cells were defective in cell-contact inhibition with changes in Merlin phosphorylation directly affecting NOTCH1 and EGFR expression, as well as downstream targets HES1 (hairy and enhancer of split-1) and CCND1 (cyclin D1). Of note, we identified a function for S518-Merlin, which is distinct from what has been reported when the expression of Merlin is diminished in relation to EGFR and NOTCH1 expression, providing first-time evidence that demonstrates that the phosphorylation of S518-Merlin in glioblastoma promotes oncogenic properties that are not only the result of inactivation of the tumor suppressor role of Merlin but also an independent process implicating a Merlin-driven regulation of NOTCH1 and EGFR.",Oncogene,2015-05-14,P A Guerrero; W Yin; L Camacho; D Marchetti
PUB25043591,10.1002/jbmr.2316,PMID:25043591,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,"Neurofibromatosis type I (NF1) is an autosomal dominant disease with an incidence of 1/3000, caused by mutations in the NF1 gene, which encodes the RAS/GTPase-activating protein neurofibromin. Non-bone union after fracture (pseudarthrosis) in children with NF1 remains a challenging orthopedic condition to treat. Recent progress in understanding the biology of neurofibromin suggested that NF1 pseudarthrosis stems primarily from defects in the bone mesenchymal lineage and hypersensitivity of hematopoietic cells to TGF. However, clinically relevant pharmacological approaches to augment bone union in these patients remain limited. In this study, we report the generation of a novel conditional mutant mouse line used to model NF1 pseudoarthrosis, in which Nf1 can be ablated in an inducible fashion in osteoprogenitors of postnatal mice, thus circumventing the dwarfism associated with previous mouse models where Nf1 is ablated in embryonic mesenchymal cell lineages. An ex vivo-based cell culture approach based on the use of Nf1(flox/flox) bone marrow stromal cells showed that loss of Nf1 impairs osteoprogenitor cell differentiation in a cell-autonomous manner, independent of developmental growth plate-derived or paracrine/hormonal influences. In addition, in vitro gene expression and differentiation assays indicated that chronic ERK activation in Nf1-deficient osteoprogenitors blunts the pro-osteogenic property of BMP2, based on the observation that only combination treatment with BMP2 and MEK inhibition promoted the differentiation of Nf1-deficient osteoprogenitors. The in vivo preclinical relevance of these findings was confirmed by the improved bone healing and callus strength observed in Nf1osx (-/-) mice receiving Trametinib (a MEK inhibitor) and BMP2 released locally at the fracture site via a novel nanoparticle and polyglycidol-based delivery method. Collectively, these results provide novel evidence for a cell-autonomous role of neurofibromin in osteoprogenitor cells and insights about a novel targeted approach for the treatment of NF1 pseudoarthrosis.",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,2015-01,Jean de la Croix Ndong; David M Stevens; Guillaume Vignaux; Sasidhar Uppuganti; Daniel S Perrien; Xiangli Yang; Jeffry S Nyman; Eva Harth; Florent Elefteriou
PUB25329635,10.1371/journal.pgen.1004575,PMID:25329635,Genetic modifiers of neurofibromatosis type 1-associated caf-au-lait macule count identified using multi-platform analysis.,"Neurofibromatosis type 1 (NF1) is an autosomal dominant, monogenic disorder of dysregulated neurocutaneous tissue growth. Pleiotropy, variable expressivity and few NF1 genotype-phenotype correlates limit clinical prognostication in NF1. Phenotype complexity in NF1 is hypothesized to derive in part from genetic modifiers unlinked to the NF1 locus. In this study, we hypothesized that normal variation in germline gene expression confers risk for certain phenotypes in NF1. In a set of 79 individuals with NF1, we examined the association between gene expression in lymphoblastoid cell lines with NF1-associated phenotypes and sequenced select genes with significant phenotype/expression correlations. In a discovery cohort of 89 self-reported European-Americans with NF1 we examined the association between germline sequence variants of these genes with caf-au-lait macule (CALM) count, a tractable, tumor-like phenotype in NF1. Two correlated, common SNPs (rs4660761 and rs7161) between DPH2 and ATP6V0B were significantly associated with the CALM count. Analysis with tiled regression also identified SNP rs4660761 as significantly associated with CALM count. SNP rs1800934 and 12 rare variants in the mismatch repair gene MSH6 were also associated with CALM count. Both SNPs rs7161 and rs4660761 (DPH2 and ATP6V0B) were highly significant in a mega-analysis in a combined cohort of 180 self-reported European-Americans; SNP rs1800934 (MSH6) was near-significant in a meta-analysis assuming dominant effect of the minor allele. SNP rs4660761 is predicted to regulate ATP6V0B, a gene associated with melanosome biology. Individuals with homozygous mutations in MSH6 can develop an NF1-like phenotype, including multiple CALMs. Through a multi-platform approach, we identified variants that influence NF1 CALM count.",PLoS genetics,2014-10,Alexander Pemov; Heejong Sung; Paula L Hyland; Jennifer L Sloan; Sarah L Ruppert; Andrea M Baldwin; Joseph F Boland; Sara E Bass; Hyo Jung Lee; Kristine M Jones; Xijun Zhang; James C Mullikin; Brigitte C Widemann; Alexander F Wilson; Douglas R Stewart
PUB25340526,10.1371/journal.pone.0107760,PMID:25340526,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,"Plexiform neurofibromas (PNFs) are benign nerve sheath tumors mostly associated with neurofibromatosis type 1. They often extend through multiple layers of tissue and therefore cannot be treated satisfactorily by surgery. Nilotinib is a tyrosine kinase inhibitor used to treat leukemia, with advantages over the prototype imatinib in terms of potency and selectivity towards BCR-ABL, and the DDR, PDGFR, and KIT receptor kinases. In this study, we compared efficacies of the two drugs on cultured cells of PNF in vitro and on xenografted tumor fragments on sciatic nerve of athymic nude mice. Xenografts were monitored weekly using a high resolution ultrasound measurement. Treatment with nilotinib at a daily dose of 100 mg/kg for four weeks led to a reduction of the graft sizesstd by 687% in the 8 treated mice, significantly more than the 338% reduction in the 8 untreated mice (P<0.05) and the 4715% in the 7 mice treated with imatinib (P<0.05). The peak plasma nilotinib concentration 6.61.1 M is within the pharmacological range of clinical application. Imatinib, but not nilotinib significantly hindered body weight increase of the mice and elevated cytotoxicity of mouse spleen cells (P<0.05). Our results suggest that nilotinib may be more potent than imatinib for treating PNFs and may also be better tolerated. Imatinib seems to have some off-target effect in elevating immunity.",PloS one,2014,Jiang Wei; Marcus Freytag; Yvonne Schober; Wolfgang A Nockher; Victor F Mautner; Reinhard E Friedrich; Paul W Manley; Lan Kluwe; Andreas Kurtz
PUB25535838,10.7554/eLife.05151,PMID:25535838,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,"Individuals with neurofibromatosis type 1 (NF1) frequently exhibit cognitive and motor impairments and characteristics of autism. The cerebellum plays a critical role in motor control, cognition, and social interaction, suggesting that cerebellar defects likely contribute to NF1-associated neurodevelopmental disorders. Here we show that Nf1 inactivation during early, but not late stages of cerebellar development, disrupts neuronal lamination, which is partially caused by overproduction of glia and subsequent disruption of the Bergmann glia (BG) scaffold. Specific Nf1 inactivation in glutamatergic neuronal precursors causes premature differentiation of granule cell (GC) precursors and ectopic production of unipolar brush cells (UBCs), indirectly disrupting neuronal migration. Transient MEK inhibition during a neonatal window prevents cerebellar developmental defects and improves long-term motor performance of Nf1-deficient mice. This study reveals essential roles of Nf1 in GC/UBC migration by generating correct numbers of glia and controlling GC/UBC fate-specification/differentiation, identifying a therapeutic prevention strategy for multiple NF1-associcated developmental abnormalities.",eLife,2014-12-23,Edward Kim; Yuan Wang; Sun-Jung Kim; Miriam Bornhorst; Emmanuelle S Jecrois; Todd E Anthony; Chenran Wang; Yi E Li; Jun-Lin Guan; Geoffrey G Murphy; Yuan Zhu
PUB25917366,10.1038/mp.2015.48,PMID:25917366,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,"Cognitive impairments are a major clinical feature of the common neurogenetic disease neurofibromatosis type 1 (NF1). Previous studies have demonstrated that increased neuronal inhibition underlies the learning deficits in NF1, however, the molecular mechanism underlying this cell-type specificity has remained unknown. Here, we identify an interneuron-specific attenuation of hyperpolarization-activated cyclic nucleotide-gated (HCN) current as the cause for increased inhibition in Nf1 mutants. Mechanistically, we demonstrate that HCN1 is a novel NF1-interacting protein for which loss of NF1 results in a concomitant increase of interneuron excitability. Furthermore, the HCN channel agonist lamotrigine rescued the electrophysiological and cognitive deficits in two independent Nf1 mouse models, thereby establishing the importance of HCN channel dysfunction in NF1. Together, our results provide detailed mechanistic insights into the pathophysiology of NF1-associated cognitive defects, and identify a novel target for clinical drug development.",Molecular psychiatry,2015-11,A Omrani; T van der Vaart; E Mientjes; G M van Woerden; M R Hojjati; K W Li; D H Gutmann; C N Levelt; A B Smit; A J Silva; S A Kushner; Y Elgersma
PUB26219339,10.18632/oncotarget.4858,PMID:26219339,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,"Meningiomas are the most common primary intracranial adult tumor. All Neurofibromatosis 2 (NF2)-associated meningiomas and ~60% of sporadic meningiomas show loss of NF2 tumor suppressor protein. There are no effective medical therapies for progressive and recurrent meningiomas. Our previous work demonstrated aberrant activation of mTORC1 signaling that led to ongoing clinical trials with rapamycin analogs for NF2 and sporadic meningioma patients. Here we performed a high-throughput kinome screen to identify kinases responsible for mTORC1 pathway activation in NF2-deficient meningioma cells. Among the emerging top candidates were the mTORC2-specific target serum/glucocorticoid-regulated kinase 1 (SGK1) and p21-activated kinase 1 (PAK1). In NF2-deficient meningioma cells, inhibition of SGK1 rescues mTORC1 activation, and SGK1 activation is sensitive to dual mTORC1/2 inhibitor AZD2014, but not to rapamycin. PAK1 inhibition also leads to attenuated mTORC1 but not mTORC2 signaling, suggesting that mTORC2/SGK1 and Rac1/PAK1 pathways are independently responsible for mTORC1 activation in NF2-deficient meningiomas. Using CRISPR-Cas9 genome editing, we generated isogenic human arachnoidal cell lines (ACs), the origin cell type for meningiomas, expressing or lacking NF2. NF2-null CRISPR ACs recapitulate the signaling of NF2-deficient meningioma cells. Interestingly, we observe increased SGK1 transcription and protein expression in NF2-CRISPR ACs and in primary NF2-negative meningioma lines. Moreover, we demonstrate that the dual mTORC1/mTORC2 inhibitor, AZD2014 is superior to rapamycin and PAK inhibitor FRAX597 in blocking proliferation of meningioma cells. Importantly, AZD2014 is currently in use in several clinical trials of cancer. Therefore, we believe that AZD2014 may provide therapeutic advantage over rapalogs for recurrent and progressive meningiomas.",Oncotarget,2015-07-10,Roberta L Beauchamp; Marianne F James; Patrick A DeSouza; Vilas Wagh; Wen-Ning Zhao; Justin T Jordan; Anat Stemmer-Rachamimov; Scott R Plotkin; James F Gusella; Stephen J Haggarty; Vijaya Ramesh
PUB26904939,10.1016/j.celrep.2016.01.074,PMID:26904939,Insertional Mutagenesis Identifies a STAT3/Arid1b/-catenin Pathway Driving Neurofibroma Initiation.,"To identify genes and signaling pathways that initiate Neurofibromatosis type 1 (NF1) neurofibromas, we used unbiased insertional mutagenesis screening, mouse models, and molecular analyses. We mapped an Nf1-Stat3-Arid1b/-catenin pathway that becomes active in the context of Nf1 loss. Genetic deletion of Stat3 in Schwann cell progenitors (SCPs) and Schwann cells (SCs) prevents neurofibroma formation, decreasing SCP self-renewal and -catenin activity. -catenin expression rescues effects of Stat3 loss in SCPs. Importantly, P-STAT3 and -catenin expression correlate in human neurofibromas. Mechanistically, P-Stat3 represses Gsk3 and the SWI/SNF gene Arid1b to increase -catenin. Knockdown of Arid1b or Gsk3 in Stat3(fl/fl);Nf1(fl/fl);DhhCre SCPs rescues neurofibroma formation after in vivo transplantation. Stat3 represses Arid1b through histone modification in a Brg1-dependent manner, indicating that epigenetic modification plays a role in early tumorigenesis. Our data map a neural tumorigenesis pathway and support testing JAK/STAT and Wnt/-catenin pathway inhibitors in neurofibroma therapeutic trials.",Cell reports,2016-03-01,Jianqiang Wu; Vincent W Keng; Deanna M Patmore; Jed J Kendall; Ami V Patel; Edwin Jousma; Walter J Jessen; Kwangmin Choi; Barbara R Tschida; Kevin A T Silverstein; Danhua Fan; Eric B Schwartz; James R Fuchs; Yuanshu Zou; Mi-Ok Kim; Eva Dombi; David E Levy; Gang Huang; Jose A Cancelas; Anat O Stemmer-Rachamimov; Robert J Spinner; David A Largaespada; Nancy Ratner
PUB27999334,10.3390/genes7120133,PMID:27999334,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,Neurofibromatosis 1 (NF1) is one of the most common genetic disorders and is caused by mutations in the ,Genes,2016-12-17,Karin Soares Cunha; Nathalia Silva Oliveira; Anna Karoline Fausto; Carolina Cruz de Souza; Audrey Gros; Thomas Bandres; Yamina Idrissi; Jean-Philippe Merlio; Rodrigo Soares de Moura Neto; Rosane Silva; Mauro Geller; David Cappellen
PUB28029918,10.1056/NEJMoa1605943,PMID:28029918,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,"BACKGROUND: Effective medical therapies are lacking for the treatment of neurofibromatosis type 1-related plexiform neurofibromas, which are characterized by elevated RAS-mitogen-activated protein kinase (MAPK) signaling. METHODS: We conducted a phase 1 trial of selumetinib (AZD6244 or ARRY-142886), an oral selective inhibitor of MAPK kinase (MEK) 1 and 2, in children who had neurofibromatosis type 1 and inoperable plexiform neurofibromas to determine the maximum tolerated dose and to evaluate plasma pharmacokinetics. Selumetinib was administered twice daily at a dose of 20 to 30 mg per square meter of body-surface area on a continuous dosing schedule (in 28-day cycles). We also tested selumetinib using a mouse model of neurofibromatosis type 1-related neurofibroma. Response to treatment (i.e., an increase or decrease from baseline in the volume of plexiform neurofibromas) was monitored by using volumetric magnetic resonance imaging analysis to measure the change in size of the plexiform neurofibroma. RESULTS: A total of 24 children (median age, 10.9 years; range, 3.0 to 18.5) with a median tumor volume of 1205 ml (range, 29 to 8744) received selumetinib. Patients were able to receive selumetinib on a long-term basis; the median number of cycles was 30 (range, 6 to 56). The maximum tolerated dose was 25 mg per square meter (approximately 60% of the recommended adult dose). The most common toxic effects associated with selumetinib included acneiform rash, gastrointestinal effects, and asymptomatic creatine kinase elevation. The results of pharmacokinetic evaluations of selumetinib among the children in this trial were similar to those published for adults. Treatment with selumetinib resulted in confirmed partial responses (tumor volume decreases from baseline of 20%) in 17 of the 24 children (71%) and decreases from baseline in neurofibroma volume in 12 of 18 mice (67%). Disease progression (tumor volume increase from baseline of 20%) has not been observed to date. Anecdotal evidence of decreases in tumor-related pain, disfigurement, and functional impairment was observed. CONCLUSIONS: Our early-phase data suggested that children with neurofibromatosis type 1 and inoperable plexiform neurofibromas benefited from long-term dose-adjusted treatment with selumetinib without having excess toxic effects. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01362803 .).",The New England journal of medicine,2016-12-29,Eva Dombi; Andrea Baldwin; Leigh J Marcus; Michael J Fisher; Brian Weiss; AeRang Kim; Patricia Whitcomb; Staci Martin; Lindsey E Aschbacher-Smith; Tilat A Rizvi; Jianqiang Wu; Rachel Ershler; Pamela Wolters; Janet Therrien; John Glod; Jean B Belasco; Elizabeth Schorry; Alessandra Brofferio; Amy J Starosta; Andrea Gillespie; Austin L Doyle; Nancy Ratner; Brigitte C Widemann
PUB28126595,10.1016/j.ebiom.2017.01.020,PMID:28126595,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,"Loss or mutation of the tumour suppressor Merlin predisposes individuals to develop multiple nervous system tumours, including schwannomas and meningiomas, sporadically or as part of the autosomal dominant inherited condition Neurofibromatosis 2 (NF2). These tumours display largely low grade features but their presence can lead to significant morbidity. Surgery and radiotherapy remain the only treatment options despite years of research, therefore an effective therapeutic is required. Unbiased omics studies have become pivotal in the identification of differentially expressed genes and proteins that may act as drug targets or biomarkers. Here we analysed the proteome and phospho-proteome of these genetically defined tumours using primary human tumour cells to identify upregulated/activated proteins and/or pathways. We identified over 2000 proteins in comparative experiments between Merlin-deficient schwannoma and meningioma compared to human Schwann and meningeal cells respectively. Using functional enrichment analysis we highlighted several dysregulated pathways and Gene Ontology terms. We identified several proteins and phospho-proteins that are more highly expressed in tumours compared to controls. Among proteins jointly dysregulated in both tumours we focused in particular on PDZ and LIM domain protein 2 (PDLIM2) and validated its overexpression in several tumour samples, while not detecting it in normal cells. We showed that shRNA mediated knockdown of PDLIM2 in both primary meningioma and schwannoma leads to significant reductions in cellular proliferation. To our knowledge, this is the first comprehensive assessment of the NF2-related meningioma and schwannoma proteome and phospho-proteome. Taken together, our data highlight several commonly deregulated factors, and indicate that PDLIM2 may represent a novel, common target for meningioma and schwannoma.",EBioMedicine,2017-02,Kayleigh Bassiri; Sara Ferluga; Vikram Sharma; Nelofer Syed; Claire L Adams; Edwin Lasonder; C Oliver Hanemann
PUB28166733,10.1186/s12864-017-3519-7,PMID:28166733,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,"BACKGROUND: We have identified molecules that exhibit synthetic lethality in cells with loss of the neurofibromin 1 (NF1) tumor suppressor gene. However, recognizing tumors that have inactivation of the NF1 tumor suppressor function is challenging because the loss may occur via mechanisms that do not involve mutation of the genomic locus. Degradation of the NF1 protein, independent of NF1 mutation status, phenocopies inactivating mutations to drive tumors in human glioma cell lines. NF1 inactivation may alter the transcriptional landscape of a tumor and allow a machine learning classifier to detect which tumors will benefit from synthetic lethal molecules. RESULTS: We developed a strategy to predict tumors with low NF1 activity and hence tumors that may respond to treatments that target cells lacking NF1. Using RNAseq data from The Cancer Genome Atlas (TCGA), we trained an ensemble of 500 logistic regression classifiers that integrates mutation status with whole transcriptomes to predict NF1 inactivation in glioblastoma (GBM). On TCGA data, the classifier detected NF1 mutated tumors (test set area under the receiver operating characteristic curve (AUROC) mean=0.77, 95% quantile=0.53 - 0.95) over 50 random initializations. On RNA-Seq data transformed into the space of gene expression microarrays, this method produced a classifier with similar performance (test set AUROC mean=0.77, 95% quantile=0.53 - 0.96). We applied our ensemble classifier trained on the transformed TCGA data to a microarray validation set of 12 samples with matched RNA and NF1 protein-level measurements. The classifier's NF1 score was associated with NF1 protein concentration in these samples. CONCLUSIONS: We demonstrate that TCGA can be used to train accurate predictors of NF1 inactivation in GBM. The ensemble classifier performed well for samples with very high or very low NF1 protein concentrations but had mixed performance in samples with intermediate NF1 concentrations. Nevertheless, high-performing and validated predictors have the potential to be paired with targeted therapies and personalized medicine.",BMC genomics,2017-02-06,Gregory P Way; Robert J Allaway; Stephanie J Bouley; Camilo E Fadul; Yolanda Sanchez; Casey S Greene
PUB28193237,10.1186/s12955-017-0607-y,PMID:28193237,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,"BACKGROUND: Neurofibromatosis 1 (NF1) is an inherited, multi-system, tumour suppressor disorder with variable complications that cause psychological distress and social isolation. The study aim was to develop and validate a disease-specific questionnaire to measure quality of life (QOL) in NF1 that is suitable both as an assessment tool in clinical practice and in clinical trials of novel therapy. METHODS: The Impact of NF1 on Quality of Life (INF1-QOL) questionnaire was developed by a literature search for common terms, focus group (n=6), semi-structured interviews (n=21), initial drafts (n =50) and final 14 item questionnaire (n=50). Bivariate correlations between items, exploratory factor analysis, correlations with severity and EuroQol were employed. RESULTS: INF1-QOL showed good internal reliability (Cronbach's alpha 0.87), mean total INF1-QOL score was 8.64 (SD 6.3), median 7.00, range 0-30 (possible range 0-42); no significant correlations with age or gender. The mean total EuroQol score was 7.38 (SD 2.87), median 6.5, mean global EuroQol score was 76.34 (SD 16.56), median 80. Total INF1-QOL score correlated with total EuroQol r=0.82, p<0.0001. The highest impact on QOL was moderate or severe problems with anxiety and depression (32%) and negative effects of NF1 on role and outlook on life (42%). The mean inter-relater reliability for grading of clinical severity scores was 0.71 (range 0.65-0.79), and intra-class correlation was 0.92. The mean clinical severity score was 1.95 (SD 0.65) correlating r=0.34 with total INF1-QOL score p<0.05 and correlated 0.37 with total EuroQol score p<0.01. The clinical severity score was mild in 17 (34%), moderate in 16 (32%) and 17 (34%) individuals had severe disease. CONCLUSIONS: INF1-QOL is a validated, reliable disease specific questionnaire that is easy and quick to complete. Role and outlook on life and anxiety and depression have the highest impact on QOL indicating the variability, severity and unpredictability of NF1. INFI-QOL correlates moderately with clinical severity. The moderate relationship between INF1-QOL and physician rated severity emphasizes the difference between clinical and patient perception. INFI-QOL will be useful in individual patient assessment and as an outcome measure for clinical trials.",Health and quality of life outcomes,2017-02-14,Rosalie E Ferner; Mary Thomas; Gemma Mercer; Victoria Williams; Guy D Leschziner; Shazia K Afridi; John F Golding
PUB8758ff08,10.1038/srep43315 | 10.1016/j.celrep.2016.01.074,PMID:28256556 | PMID:26904939,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. | Insertional Mutagenesis Identifies a STAT3/Arid1b/-catenin Pathway Driving Neurofibroma Initiation.,,,,
PUB28392281,10.1016/j.expneurol.2017.04.001,PMID:28392281,Human stem cell modeling in neurofibromatosis type 1 (NF1).,"The future of precision medicine is heavily reliant on the use of human tissues to identify the key determinants that account for differences between individuals with the same disorder. This need is exemplified by the neurofibromatosis type 1 (NF1) neurogenetic condition. As such, individuals with NF1 are born with a germline mutation in the NF1 gene, but may develop numerous distinct neurological problems, ranging from autism and attention deficit to brain and peripheral nerve sheath tumors. Coupled with accurate preclinical mouse models, the availability of NF1 patient-derived induced pluripotent stem cells (iPSCs) provides new opportunities to define the critical factors that underlie NF1-associated nervous system disease pathogenesis and progression. In this review, we discuss the generation and potential applications of iPSC technology to the study of NF1.",Experimental neurology,2018-01,Michelle L Wegscheid; Corina Anastasaki; David H Gutmann
PUB46ecf57f,10.1016/j.expneurol.2017.04.001 | 10.3390/ijms22105367,PMID:28392281 | PMID:34065204,Human stem cell modeling in neurofibromatosis type 1 (NF1). | RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,,,
PUB28525381,10.18632/oncotarget.17589,PMID:28525381,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,"Low-grade gliomas are one of the most common brain tumors in children, where they frequently form within the optic pathway (optic pathway gliomas; OPGs). Since many OPGs occur in the context of the Neurofibromatosis Type 1 (NF1) cancer predisposition syndrome, we have previously employed Nf1 genetically-engineered mouse (GEM) strains to study the pathogenesis of these low-grade glial neoplasms. In the light of the finding that human and mouse low-grade gliomas are composed of Olig2+ cells and that Olig2+ oligodendrocyte precursor cells (OPCs) give rise to murine high-grade gliomas, we sought to determine whether Olig2+ OPCs could be tumor-initiating cells for Nf1 optic glioma. Similar to the GFAP-Cre transgenic strain previously employed to generate Nf1 optic gliomas, Olig2+ cells also give rise to astrocytes in the murine optic nerve in vivo. However, in contrast to the GFAP-Cre strain where somatic Nf1 inactivation in embryonic neural progenitor/stem cells (Nf1flox/mut; GFAP-Cre mice) results in optic gliomas by 3 months of age in vivo, mice with Nf1 gene inactivation in Olig2+ OPCs (Nf1flox/mut; Olig2-Cre mice) do not form optic gliomas until 6 months of age. These distinct patterns of glioma latency do not reflect differences in the timing or brain location of somatic Nf1 loss. Instead, they most likely reflect the cell of origin, as somatic Nf1 loss in CD133+ neural progenitor/stem cells during late embryogenesis results in optic gliomas at 3 months of age. Collectively, these data demonstrate that the cell of origin dictates the time to tumorigenesis in murine optic glioma.",Oncotarget,2017-07-18,Anne C Solga; Joseph A Toonen; Yuan Pan; Patrick J Cimino; Yu Ma; Guillaume A Castillon; Scott M Gianino; Mark H Ellisman; Da Yong Lee; David H Gutmann
PUB28831766,10.1007/s12104-017-9768-1,PMID:28831766,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,"Neurofibromin and Sprouty-related EVH1 domain-containing protein 1 (Spred1) both act as negative regulators of the mitogen-activated protein kinase pathway and are associated with the rare diseases Neurofibromatosis type 1 and Legius syndrome, respectively. Spred1 recruits the major GTPase activating protein (GAP) neurofibromin from the cytosol to the membrane in order to inactivate the small G protein Ras. These functions are dependent on the N-terminal EVH1 domain and the C-terminal Sprouty domain of Spred1 whereas the former specifically recognizes the GAP related domain of neurofibromin and the latter is responsible for membrane targeting. Within the GAP domain, Spred1 binding depends on the GAPex portion which is dispensable for Ras inactivation. In a first step towards the characterization of the Neurofibromin Spred1 interface in solution we assigned backbone and side chain ",Biomolecular NMR assignments,2017-10,Sebastian Fhrer; Linda Ahammer; Angela Ausserbichler; Klaus Scheffzek; Theresia Dunzendorfer-Matt; Martin Tollinger
PUB29408605,10.1016/j.neuroscience.2018.01.054,PMID:29408605,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,"Merlin is the protein product of the NF2 tumor suppressor gene. Germline NF2 mutation leads to neurofibromatosis type 2 (NF2), characterized by multiple intracranial and spinal schwannomas. Patients with NF2 also frequently develop peripheral neuropathies. While the role of merlin in SC neoplasia is well established, its role in SC homeostasis is less defined. Here we explore the role of merlin in SC responses to nerve injury and their ability to support axon regeneration. We performed sciatic nerve crush in wild-type (WT) and in P0Sch39-121 transgenic mice that express a dominant negative Nf2 isoform in SCs. Recovery of nerve function was assessed by measuring mean contact paw area on a pressure pad 7, 21, 60, and 90days following nerve injury and by nerve conduction assays at 90days following injury. After 90days, the nerves were harvested and axon regeneration was quantified stereologically. Myelin ultrastructure was analyzed by electron microscopy. Functional studies showed delayed nerve regeneration in Nf2 mutant mice compared to the WT mice. Delayed neural recovery correlated with a reduced density of regenerated axons and increased endoneurial space in mutants compared to WT mice. Nevertheless, functional and nerve conduction measures ultimately recovered to similar levels in WT and Nf2 mutant mice, while there was a small (17%) reduction in the percent of regenerated axons in the Nf2 mutant mice. The data suggest that merlin function in SCs regulates neural ultrastructure and facilitates neural regeneration, in addition to its role in SC neoplasia.",Neuroscience,2018-03-15,Kristy Truong; Iram Ahmad; J Jason Clark; Alison Seline; Tyler Bertroche; Brian Mostaert; Douglas J Van Daele; Marlan R Hansen
PUB61b2d569,10.1016/j.ccell.2018.01.005 | 10.1038/s41467-024-44755-9,PMID:29438698 | PMID:38216572,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,,,
PUB29715273,10.1371/journal.pone.0196726,PMID:29715273,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,"The neurofibromatosis type 2 (NF2) tumor suppressor protein Merlin functions as a negative regulator of cell growth and actin dynamics in different cell types amongst which Schwann cells have been extensively studied. In contrast, the presence and the role of Merlin in oligodendrocytes, the myelin forming cells within the CNS, have not been elucidated. In this work, we demonstrate that Merlin immunoreactivity was broadly distributed in the white matter throughout the central nervous system. Following Merlin expression during development in the cerebellum, Merlin could be detected in the cerebellar white matter tract at early postnatal stages as shown by its co-localization with Olig2-positive cells as well as in adult brain sections where it was aligned with myelin basic protein containing fibers. This suggests that Merlin is expressed in immature and mature oligodendrocytes. Expression levels of Merlin were low in oligodendrocytes as compared to astrocytes and neurons throughout development. Expression of Merlin in oligodendroglia was further supported by its identification in either immortalized cell lines of oligodendroglial origin or in primary oligodendrocyte cultures. In these cultures, the two main splice variants of Nf2 could be detected. Merlin was localized in clusters within the nuclei and in the cytoplasm. Overexpressing Merlin in oligodendrocyte cell lines strengthened reduced impedance in XCELLigence measurements and Ki67 stainings in cultures over time. In addition, the initiation and elongation of cellular projections were reduced by Merlin overexpression. Consistently, cell migration was retarded in scratch assays done on Nf2-transfected oligodendrocyte cell lines. These data suggest that Merlin actively modulates process outgrowth and migration in oligodendrocytes.",PloS one,2018,Andrea Toledo; Elena Grieger; Khalad Karram; Helen Morrison; Stephan L Baader
PUB50430a7b,10.1371/journal.pone.0196726 | 10.18632/oncotarget.4858,PMID:29715273 | PMID:26219339,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,,,
PUB29941005,10.1186/s13023-018-0843-1,PMID:29941005,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,"BACKGROUND: Neurofibromatosis 1 (NF1) presents a wide range of clinical manifestations, including bone alterations. Studies that seek to understand cellular and molecular mechanisms underlying NF1 orthopedic problems are of great importance to better understand the pathogenesis and the development of new therapies. Dental pulp stem cells (DPSCs) are being used as an in vitro model for several diseases and appear as a suitable model for NF1. The aim of this study was to evaluate in vitro chondrogenic differentiation of DPSCs from individuals with NF1 using two-dimensional (2D) and three-dimensional (3D) cultures. RESULTS: To fulfill the criteria of the International Society for Cellular Therapy, DPSCs were characterized by surface antigen expression and by their multipotentiality, being induced to differentiate towards adipogenic, osteogenic, and chondrogenic lineages in 2D cultures. Both DPSCs from individuals with NF1 (NF1 DPSCs) and control cultures were positive for CD90, CD105, CD146 and negative for CD13, CD14, CD45 and CD271, and successfully differentiated after the protocols. Chondrogenic differentiation was evaluated in 2D and in 3D (pellet) cultures, which were further evaluated by optical microscopy and transmission electron microscopy (TEM). 2D cultures showed greater extracellular matrix deposition in NF1 DPSCs comparing with controls during chondrogenic differentiation. In semithin sections, control pellets hadhomogenous-sized intra and extracelullar matrix vesicles, whereas NF1 cultures had matrix vesicles of different sizes. TEM analysis showed higher amount of collagen fibers in NF1 cultures compared with control cultures. CONCLUSION: NF1 DPSCs presented increased extracellular matrix deposition during chondrogenic differentiation, which could be related to skeletal changes in individuals with NF1.",Orphanet journal of rare diseases,2018-06-25,Paula Nascimento Almeida; Deuilton do Nascimento Barboza; Elo Borges Luna; Maria Clara de Macena Correia; Rhayra Braga Dias; Ana Caroline Siquara de Sousa; Maria Eugenia Leite Duarte; Maria Isabel Doria Rossi; Karin Soares Cunha
PUB30274821,10.1016/j.ebiom.2018.09.042,PMID:30274821,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,"BACKGROUND: The great majority of sporadic vestibular schwannomas (VSs) are due to the mutations of the NF2 gene encoding merlin. Sporadic VSs exhibit variable growth patterns and only a small fraction of the tumours are fast-growing; however, the underlying mechanisms remain undefined. METHODS: DNA sequencing and dosage analysis were used to identify the NF2 mutation status in sporadic schwannomas. The expression and sub-cellular localization of merlin and p53-MDM2 were assessed by immunoblotting, qRT-PCR and immunofluorescence. In vitro and in vivo studies were performed to reveal the effects of Nutlin-3 (a MDM2 inhibitor) and/or MG-132(a proteasome inhibitor) on schwannomas. The proliferation of schwannoma cells was assessed by CCK-8 assay, EdU staining and Flow cytometry analysis. FINDINGS: Double genetic hits of NF2 tended to occur in fast-growing tumours, characterized by the absence of merlin. The deregulation of p53-MDM2 was demonstrated to mediate merlin-deficient tumour growth, characterized by a nuclear accumulation of stabilized MDM2, contributing to a nuclear export of p53 for degradation. Nutlin-3 blocked the proliferation of schwannoma cells via a cooperative recovery of merlin and p53, accompanied by the shuttling of both proteins from the cytoplasm to the nucleus. We further demonstrated a difference in the sensitivity to Nutlin-3 between schwannoma cells with and without merlin expression. Nutlin-3 combined with MG-132 narrowed this between-group difference and triggered stronger inhibitory effects on the growth of schwannomas through coordinated reactivation of p53. INTERPRETATION: These findings present treatment strategies directed on the pathogenesis of sporadic schwannomas. FUND: National Natural Science Foundation of China.",EBioMedicine,2018-10,Hongsai Chen; Lu Xue; He Huang; Hantao Wang; Xiaoman Zhang; Weidong Zhu; Zhigang Wang; Zhaoyan Wang; Hao Wu
PUB30479396,10.1038/s41467-018-07452-y,PMID:30479396,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,"Neurofibromatosis type 1 (NF1) is an autosomal genetic disorder. Patients with NF1 are associated with mono-allelic loss of the tumor suppressor gene NF1 in their germline, which predisposes them to develop a wide array of benign lesions. Intriguingly, recent sequencing efforts revealed that the NF1 gene is frequently mutated in multiple malignant tumors not typically associated with NF1 patients, suggesting that NF1 heterozygosity is refractory to at least some cancer types. In two orthogonal mouse models representing NF1- and non-NF1-related tumors, we discover that an Nf1",Nature communications,2018-11-27,Jean-Philippe Brosseau; Chung-Ping Liao; Yong Wang; Vijay Ramani; Travis Vandergriff; Michelle Lee; Amisha Patel; Kiyoshi Ariizumi; Lu Q Le
PUB30531922,10.1038/s41591-018-0263-8,PMID:30531922,The molecular landscape of glioma in patients with Neurofibromatosis 1.,"Neurofibromatosis type 1 (NF1) is a common tumor predisposition syndrome in which glioma is one of the prevalent tumors. Gliomagenesis in NF1 results in a heterogeneous spectrum of low- to high-grade neoplasms occurring during the entire lifespan of patients. The pattern of genetic and epigenetic alterations of glioma that develops in NF1 patients and the similarities with sporadic glioma remain unknown. Here, we present the molecular landscape of low- and high-grade gliomas in patients affected by NF1 (NF1-glioma). We found that the predisposing germline mutation of the NF1 gene was frequently converted to homozygosity and the somatic mutational load of NF1-glioma was influenced by age and grade. High-grade tumors harbored genetic alterations of TP53 and CDKN2A, frequent mutations of ATRX associated with Alternative Lengthening of Telomere, and were enriched in genetic alterations of transcription/chromatin regulation and PI3 kinase pathways. Low-grade tumors exhibited fewer mutations that were over-represented in genes of the MAP kinase pathway. Approximately 50% of low-grade NF1-gliomas displayed an immune signature, T lymphocyte infiltrates, and increased neo-antigen load. DNA methylation assigned NF1-glioma to LGm6, a poorly defined Isocitrate Dehydrogenase 1 wild-type subgroup enriched with ATRX mutations. Thus, the profiling of NF1-glioma defined a distinct landscape that recapitulates a subset of sporadic tumors.",Nature medicine,2019-01,Fulvio D'Angelo; Michele Ceccarelli; Tala; Luciano Garofano; Jing Zhang; Vronique Frattini; Francesca P Caruso; Genevieve Lewis; Kristin D Alfaro; Luc Bauchet; Giulia Berzero; David Cachia; Mario Cangiano; Laurent Capelle; John de Groot; Francesco DiMeco; Franois Ducray; Walid Farah; Gaetano Finocchiaro; Stphane Goutagny; Carlos Kamiya-Matsuoka; Cinzia Lavarino; Hugues Loiseau; Vronique Lorgis; Carlo E Marras; Ian McCutcheon; Do-Hyun Nam; Susanna Ronchi; Veronica Saletti; Romuald Seizeur; John Slopis; Mariona Suol; Fanny Vandenbos; Pascale Varlet; Dominique Vidaud; Colin Watts; Viviane Tabar; David E Reuss; Seung-Ki Kim; David Meyronet; Karima Mokhtari; Hector Salvador; Krishna P Bhat; Marica Eoli; Marc Sanson; Anna Lasorella; Antonio Iavarone
PUB30571760,10.1371/journal.pone.0208835,PMID:30571760,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,"The fertility of men with neurofibromatosis 1 (NF1) is reduced. Despite this observation, gonadal function has not been examined in patients with NF1. In order to assess the role of reduced neurofibromin in the testes, we examined testicular morphology and function in an Nf1+/- mouse model. We found that although Nf1+/- male mice are able to reproduce, they have significantly fewer pups per litter than Nf1+/+ control males. Reduced fertility in Nf1+/- male mice is associated with disorganization of the seminiferous epithelium, with exfoliation of germ cells and immature spermatids into the tubule lumen. Morphometric analysis shows that these alterations are associated with decreased Leydig cell numbers and increased spermatid cell numbers. We hypothesized that hyper-activation of Ras in Nf1+/- males affects ectoplasmic specialization, a Sertoli-spermatid adherens junction involved in spermiation. Consistent with this idea, we found increased expression of phosphorylated ERK, a downstream effector of Ras that has been shown to alter ectoplasmic specialization, in Nf1+/- males in comparison to control Nf1+/+ littermates. These data demonstrate that neurofibromin haploinsufficiency impairs spermatogenesis and fertility in a mouse model of NF1.",PloS one,2018,Harleen Chohan; Mitra Esfandiarei; Darian Arman; Catherine D Van Raamsdonk; Cornelis van Breemen; Jan M Friedman; Kimberly A Jett
PUB30617350,10.1038/s41596-018-0105-7,PMID:30617350,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.","Neurofibromatosis type II (NF2) is a disease that lacks effective therapies. NF2 is characterized by bilateral vestibular schwannomas (VSs) that cause progressive and debilitating hearing loss, leading to social isolation and increased rates of depression. A major limitation in NF2 basic and translational research is the lack of animal models that allow the full spectrum of research into the biology and molecular mechanisms of NF2 tumor progression, as well as the effects on neurological function. In this protocol, we describe how to inject schwannoma cells into the mouse brain cerebellopontine angle (CPA) region. We also describe how to apply state-of-the-art intravital imaging and hearing assessment techniques to study tumor growth and hearing loss. In addition, ataxia, angiogenesis, and tumor-stroma interaction assays can be applied, and the model can be used to test the efficacy of novel therapeutic approaches. By studying the disease from every angle, this model offers the potential to unravel the basic biological underpinnings of NF2 and to develop novel therapeutics to control this devastating disease. Our protocol can be adapted to study other diseases within the CPA, including meningiomas, lipomas, vascular malformations, hemangiomas, epidermoid cysts, cerebellar astrocytomas, and metastatic lesions. The entire surgical procedure takes ~45 min per mouse and allows for subsequent longitudinal imaging, as well as neurological and hearing assessment, for up to 2 months.",Nature protocols,2019-02,Jie Chen; Lukas D Landegger; Yao Sun; Jun Ren; Nir Maimon; Limeng Wu; Mei R Ng; John W Chen; Na Zhang; Yingchao Zhao; Xing Gao; Takeshi Fujita; Sylvie Roberge; Peigen Huang; Rakesh K Jain; Scott R Plotkin; Konstantina M Stankovic; Lei Xu
PUB31053133,10.1186/s13023-019-1067-8,PMID:31053133,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,"BACKGROUND: Neurofibromatosis Type 1 (NF1) is a common genetic neurocutaneous disease, with an autosomal dominant inheritance mode. Quality of life has been shown impaired in NF1, due to severe complications, cosmetic features, and uncertainty about the disorder. METHODS: This study sought to develop a self-administered questionnaire in French to assess the burden of NF1 (BoN), then translate and linguistically and cross-culturally validate it into American English, standardized methodology applied, as outlined in the report. RESULTS: Based on several discussions with NF1 patients, a 17-item conceptual questionnaire was first produced. Of the 91 NF1 adult patients who responded to the conceptual questionnaire, 65 (64.6% females) were accessible. Subsequent confirmatory analyses generated a 15-item questionnaire grouped into four domains, demonstrating internal consistency (Cronbach's alpha: 091), discriminant validity, and high reliability. The BoN was likewise shown to significantly correlate with other validated questionnaires, such as Dermatology Life Quality Index, Perceived Stress Scale, and SF12 mental score, indicating good external validity. CONCLUSIONS: BoN is a specific tool for assessing the burden that NF1 generates on many practical aspects of the patient daily activities, beyond the notion of quality of life"". Given the increasing relevance that regulatory authorities attribute to patient-reported outcomes, the BoN questionnaire provides such supplementary information while accounting for the burden of NF1 patients in the broadest sense.",Orphanet journal of rare diseases,2019-05-03,Marie-Laure Armand; Charles Taieb; Aline Bourgeois; Mireille Bourlier; Mohammed Bennani; Christine Bodemer; Pierre Wolkenstein
PUB31545171,10.7554/eLife.48983,PMID:31545171,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type1.,"Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder whose neurodevelopmental symptoms include impaired executive function, attention, and spatial learning and could be due to perturbed mesolimbic dopaminergic circuitry. However, these circuits have never been directly assayed in vivo. We employed the genetically encoded optical dopamine sensor dLight1 to monitor dopaminergic neurotransmission in the ventral striatum of NF1 mice during motivated behavior. Additionally, we developed novel systemic AAV vectors to facilitate morphological reconstruction of dopaminergic populations in cleared tissue. We found that NF1 mice exhibit reduced spontaneous dopaminergic neurotransmission that was associated with excitation/inhibition imbalance in the ventral tegmental area and abnormal neuronal morphology. NF1 mice also had more robust dopaminergic and behavioral responses to salient visual stimuli, which were independent of learning, and rescued by optogenetic inhibition of non-dopaminergic neurons in the VTA. Overall, these studies provide a first in vivo characterization of dopaminergic circuit function in the context of NF1 and reveal novel pathophysiological mechanisms.",eLife,2019-09-23,J Elliott Robinson; Gerard M Coughlin; Acacia M Hori; Jounhong Ryan Cho; Elisha D Mackey; Zeynep Turan; Tommaso Patriarchi; Lin Tian; Viviana Gradinaru
PUB31836666,10.1074/jbc.RA119.010934,PMID:31836666,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,Neurofibromin is a tumor suppressor encoded by the ,The Journal of biological chemistry,2020-01-24,Mukul Sherekar; Sae-Won Han; Rodolfo Ghirlando; Simon Messing; Matthew Drew; Dana Rabara; Timothy Waybright; Puneet Juneja; Hugh O'Neill; Christopher B Stanley; Debsindhu Bhowmik; Arvind Ramanathan; Sriram Subramaniam; Dwight V Nissley; William Gillette; Frank McCormick; Dominic Esposito
PUB021451f7,10.1074/jbc.RA119.010934 | 10.1073/pnas.2208960120,PMID:31836666 | PMID:36689660,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,,,
PUB4be6d563,10.15252/embr.201949117 | 10.3390/molecules28135128,PMID:32383545 | PMID:37446790,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,,,
PUB396b63ee,10.1177/1533033820919759 | 10.1038/s41419-021-03716-6 | 10.1038/onc.2014.185,PMID:32419643 | PMID:33934112 | PMID:25043298,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma. | HIF1-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Oncogenic role of Merlin/NF2 in glioblastoma.,,,,
PUB32438526,10.1002/lary.28671,PMID:32438526,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,"OBJECTIVES: The objective was to explore the effect of the proneuronal transcription factor neurogenic differentiation 1 (Neurod1, ND1) on Schwann cells (SC) and schwannoma cell proliferation. METHODS: Using a variety of transgenic mouse lines, we investigated how expression of Neurod1 effects medulloblastoma (MB) growth, schwannoma tumor progression, vestibular function, and SC cell proliferation. Primary human vestibular schwannoma (VS) cell cultures were transduced with adenoviral vectors expressing Neurod1. Cell proliferation was assessed by 5-ethynyl-2'-deoxyuridine (EdU) uptake. STUDY DESIGN: Basic science investigation. RESULTS: Expression of Neurod1 reduced the growth of slow-growing but not fast-growing MB models. Gene transfer of Neurod1 in human schwannoma cultures significantly reduced cell proliferation in dose-dependent way. Deletion of the neurofibromatosis type 2 (Nf2) tumor-suppressor gene via Cre expression in SCs led to increased intraganglionic SC proliferation and mildly reduced vestibular sensory-evoked potentials (VsEP) responses compared to age-matched wild-type littermates. The effect of Neurod1-induced expression on intraganglionic SC proliferation in animals lacking Nf2 was mild and highly variable. Sciatic nerve axotomy significantly increased SC proliferation in wild-type and Nf2-null animals, and expression of Neurod1 reduced the proliferative capacity of both wild-type and Nf2-null SCs following nerve injury. CONCLUSION: Expression of Neurod1 reduces slow-growing MB progression and reduces human SC proliferation in primary VS cultures. In a genetic mouse model of schwannomas, we find some effects of Neurod1 expression; however, the high variability indicates that more tightly regulated Neurod1 expression levels that mimic our in vitro data are needed to fully validate Neurod1 effects on schwannoma progression. LEVEL OF EVIDENCE: NA Laryngoscope, 131:E259-E270, 2021.",The Laryngoscope,2021-01,Jennifer Kersigo; Lintao Gu; Linjing Xu; Ning Pan; Sarath Vijayakuma; Timothy Jones; Seiji B Shibata; Bernd Fritzsch; Marlan R Hansen
PUB32457840,10.3389/fonc.2020.00687,PMID:32457840,"TGF Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.","Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer-related death, with a 5-year survival of <10% and severely limited treatment options. PDAC hallmarks include profound metabolic acid production and aggressive local proliferation and invasiveness. This phenotype is supported by upregulated net acid extrusion and epithelial-to-mesenchymal transition (EMT), the latter typically induced by aberrant transforming growth factor- (TGF) signaling. It is, however, unknown whether TGF-induced EMT and upregulation of acid extrusion are causally related. Here, we show that mRNA and protein expression of the net acid extruding transporters Na",Frontiers in oncology,2020,Raj R Malinda; Katrine Zeeberg; Patricia C Sharku; Mette Q Ludwig; Lotte B Pedersen; Sren T Christensen; Stine F Pedersen
PUB935bfae1,10.3389/fonc.2020.00687 | 10.1097/MAO.0b013e3181d2777f | 10.1371/journal.pone.0013791 | 10.1126/scisignal.aau8749 | 10.1016/j.ebiom.2017.01.020 | 10.1371/journal.pone.0196726 | 10.1016/j.ebiom.2018.09.042 | 10.1242/dmm.050862 | 10.1016/j.redox.2024.103249 | 10.1371/journal.pone.0090853,PMID:32457840 | PMID:20195187 | PMID:21072183 | PMID:31015291 | PMID:28126595 | PMID:29715273 | PMID:30274821 | PMID:39415595 | PMID:38945076 | PMID:24595234,"TGF Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling. | Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.",,,,
PUB01669d95,10.1038/s41467-020-16432-0 | 10.3389/fcell.2024.1359561 | 10.1038/s41598-024-84493-y | 10.1155/2021/9386823 | 10.3390/molecules28135128 | 10.1038/s41419-021-03802-9 | 10.1038/s41598-018-24310-5 | 10.1172/JCI168227 | 10.1038/s12276-022-00850-9,PMID:32461556 | PMID:38481529 | PMID:39890807 | PMID:34646065 | PMID:37446790 | PMID:34011935 | PMID:29670214 | PMID:37140985 | PMID:36241865,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1. | Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism. | Survival and | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Restoring functional neurofibromin by protein transduction. | Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,,,
PUB32642733,10.1093/noajnl/vdz061,PMID:32642733,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,"BACKGROUND: Malignant peripheral nerve sheath tumor (MPNST) constitutes the leading cause of neurofibromatosis type 1-related mortality. MPNSTs contain highly rearranged hyperploid genomes and exhibit a high division rate and aggressiveness. We have studied in vitro whether the mitotic kinesins KIF11, KIF15, and KIF23 have a functional role in maintaining MPNST cell survival and can represent potential therapeutic vulnerabilities. METHODS: We studied the expression of kinesin mRNAs and proteins in tumors and cell lines and used several in vitro functional assays to analyze the impact of kinesin genetic suppression (KIF15, KIF23) and drug inhibition (KIF11) in MPNST cells. We also performed in vitro combined treatments targeting KIF11 together with other described MPNST targets. RESULTS: The studied kinesins were overexpressed in MPNST samples. KIF15 and KIF23 were required for the survival of MPNST cell lines, which were also more sensitive than benign control fibroblasts to the KIF11 inhibitors ispinesib and ARRY-520. Co-targeting KIF11 and BRD4 with ARRY-520 and JQ1 reduced MPNST cell viability, synergistically killing a much higher proportion of MPNST cells than control fibroblasts. In addition, genetic suppression of  CONCLUSIONS: The mitotic spindle kinesins KIF11 and KIF15 and the cytokinetic kinesin KIF23 play a clear role in maintaining MPNST cell survival and may represent potential therapeutic vulnerabilities. Although further in vivo evidences are still mandatory, we propose a simultaneous suppression of KIF11, KIF15, and BRD4 as a potential therapy for MPNSTs.",Neuro-oncology advances,2020-07,Ernest Terribas; Marco Fernndez; Helena Mazuelas; Juana Fernndez-Rodrguez; Josep Biayna; Ignacio Blanco; Gabriela Bernal; Irma Ramos-Oliver; Craig Thomas; Rajiv Guha; Xiaohu Zhang; Bernat Gel; Cleof Romagosa; Marc Ferrer; Conxi Lzaro; Eduard Serra
PUBbaf4f291,10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-21-0947,PMID:32642733 | PMID:35511749,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,,,
PUB32642734,10.1093/noajnl/vdz026,PMID:32642734,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,"BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas with high metastatic rates and poor overall patient survival. There are currently no effective therapies, underscoring the pressing need to define the molecular etiologies that underlie MPNST progression. The aim of this study was to examine clonal progression and identify the molecular events critical for MPNST spread. METHODS: In two patients with temporally and spatially distinct metastatic lesions, we employed whole exome sequencing (WES) to elucidate the genetic events of clonal progression, thus identifying the molecular events critical for MPNST spread. RESULTS: First, we demonstrated shared clonal origins for the metastatic lesions relative to the primary tumors, which were maintained throughout the course of MPNST progression, supporting the conclusion that cancer cells with metastatic potential already exist in the primary neoplasm. Second, we discovered TRIM23, a member of the Tripartite Motif family of proteins, as a regulator of MPNST lung metastatic spread in vivo. CONCLUSIONS: The ability to track the genomic evolution from primary to metastatic MPNST offers new insights into the sequence of genetic events required for tumor progression and has identified TRIM23 as a novel target for future study in this rare cancer.",Neuro-oncology advances,2020-07,Abigail Godec; Reyka Jayasinghe; John S A Chrisinger; Bethany Prudner; Tyler Ball; Yuxi Wang; Divya Srihari; Madhurima Kaushal; Hilary Dietz; Xiaochun Zhang; Melike Pekmezci; Sonika Dahiya; Yu Tao; Jinqin Luo; Brian A Van Tine; Li Ding; David H Gutmann; Angela C Hirbe
PUB51363032,10.1016/j.trsl.2020.08.001 | 10.1158/0008-5472.CAN-10-2732 | 10.1242/dev.121.11.3583 | 10.2478/v10134-010-0025-8 | 10.1172/JCI188932 | 10.1186/s40478-023-01525-w | 10.1186/s40478-025-02075-z | 10.1158/0008-5472.CAN-12-1728 | 10.3389/fncel.2015.00234 | 10.1016/j.bone.2011.03.760 | 10.1016/j.celrep.2015.02.041 | 10.1167/iovs.17-22588 | 10.1016/j.ccr.2008.01.003 | 10.18632/oncotarget.17589 | 10.1093/hmg/ddl165 | 10.1001/jama.300.3.287,PMID:32781282 | PMID:21199799 | PMID:8582272 | PMID:21949590 | PMID:40590220 | PMID:36890585 | PMID:40684195 | PMID:23071067 | PMID:26190969 | PMID:21439418 | PMID:25772366 | PMID:29847659 | PMID:18242513 | PMID:28525381 | PMID:16835260 | PMID:18632543,"Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1. | Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. | Neurofibromin-deficient fibroblasts fail to form perineurium in vitro. | ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE. | A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Neurofibromatosistype 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms. | In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome. | Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. | Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. | Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.",,,,
PUB32948135,10.1186/s12885-020-07397-w,PMID:32948135,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,"BACKGROUND: Anticancer compound 3-bromopyruvate (3-BrPA) suppresses cancer cell growth via targeting glycolytic and mitochondrial metabolism. The malignant peripheral nerve sheath tumor (MPNST), a very aggressive, therapy resistant, and Neurofibromatosis type 1 associated neoplasia, shows a high metabolic activity and affected patients may therefore benefit from 3-BrPA treatment. To elucidate the specific mode of action, we used a controlled cell model overexpressing proteasome activator (PA) 28, subsequently leading to p53 inactivation and oncogenic transformation and therefore reproducing an important pathway in MPNST and overall tumor pathogenesis. METHODS: Viability of MPNST cell lines S462, NSF1, and T265 in response to increasing doses (0-120M) of 3-BrPA was analyzed by CellTiter-Blue assay. Additionally, we investigated viability, reactive oxygen species (ROS) production (dihydroethidium assay), nicotinamide adenine dinucleotide dehydrogenase activity (NADH-TR assay) and lactate production (lactate assay) in mouse B8 fibroblasts overexpressing PA28 in response to 3-BrPA application. For all experiments normal and nutrient deficient conditions were tested. MPNST cell lines were furthermore characterized immunohistochemically for Ki67, p53, bcl2, bcl6, cyclin D1, and p21. RESULTS: MPNST significantly responded dose dependent to 3-BrPA application, whereby S462 cells were most responsive. Human control cells showed a reduced sensitivity. In PA28 overexpressing cancer cell model 3-BrPA application harmed mitochondrial NADH dehydrogenase activity mildly and significantly failed to inhibit lactate production. PA28 overexpression was associated with a functional glycolysis as well as a partial resistance to stress provoked by nutrient deprivation. 3-BrPA treatment was not associated with an increase of ROS. Starvation sensitized MPNST to treatment. CONCLUSIONS: Aggressive MPNST cells are sensitive to 3-BrPA therapy in-vitro with and without starvation. In a PA28 overexpression cancer cell model leading to p53 inactivation, thereby reflecting a key molecular feature in human NF1 associated MPNST, known functions of 3-BrPA to block mitochondrial activity and glycolysis were reproduced, however oncogenic cells displayed a partial resistance. To conclude, 3-BrPA was sufficient to reduce NF1 associated MPNST viability potentially due inhibition of glycolysis which should lead to the initiation of further studies and promises a potential benefit for NF1 patients.",BMC cancer,2020-09-18,Christian Linke; Markus Wsle; Anja Harder
PUB33032988,10.1158/0008-5472.CAN-20-1365,PMID:33032988,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,"Loss of the RAS GTPase-activating protein (RAS-GAP) NF1 drives aberrant activation of RAS/MEK/ERK signaling and other effector pathways in the majority of malignant peripheral nerve sheath tumors (MPNST). These dysregulated pathways represent potential targets for therapeutic intervention. However, studies of novel single agents including MEK inhibitors (MEKi) have demonstrated limited efficacy both preclinically and clinically, with little advancement in overall patient survival. By interrogation of kinome activity through an unbiased screen and targeted evaluation of the signaling response to MEK inhibition, we have identified global activation of upstream receptor tyrosine kinases (RTK) that converges on activation of RAS as a mechanism to limit sensitivity to MEK inhibition. As no direct inhibitors of pan-RAS were available, an inhibitor of the protein tyrosine phosphatase SHP2, a critical mediator of RAS signal transduction downstream of multiple RTK, represented an alternate strategy. The combination of MEKi plus SHP099 was superior to MEKi alone in models of NF1-MPNST, including those with acquired resistance to MEKi. Our findings have immediate translational implications and may inform future clinical trials for patients with MPNST harboring alterations in ",Cancer research,2020-12-01,Jiawan Wang; Kai Pollard; Amy N Allen; Tushar Tomar; Dirk Pijnenburg; Zhan Yao; Fausto J Rodriguez; Christine A Pratilas
PUB76829018,10.1002/jcsm.12632 | 10.1002/ajh.22035 | 10.1158/0008-5472.CAN-10-4577 | 10.1186/1741-7015-9-82 | 10.1073/pnas.2008391117 | 10.1016/j.ccr.2008.01.003,PMID:33078583 | PMID:21681782 | PMID:21551250 | PMID:21726432 | PMID:32839340 | PMID:18242513,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis. | Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype. | Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. | MIA is a potential biomarker for tumour load in neurofibromatosis type 1. | Brain-wide structural and functional disruption in mice with oligodendrocyte-specific | The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,,,
PUBc472289e,10.1002/mgg3.1530 | 10.1186/s41687-024-00714-y,PMID:33085177 | PMID:38499890,"The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas. | The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,,,
PUB33273014,10.1074/jbc.RA120.014960,PMID:33273014,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,"Meningiomas (MNs), arising from the arachnoid/meningeal layer, are nonresponsive to chemotherapies, with 50% showing loss of the Neurofibromatosis 2 (NF2) tumor suppressor gene. Previously, we established NF2 loss activates mechanistic target of rapamycin complex 1 (mTORC1) and mechanistic target of rapamycin complex 2 (mTORC2) signaling, leading to clinical trials for NF2 and MN. Recently our omics studies identified activated ephrin (EPH) receptor and Src family kinases upon NF2 loss. Here, we report increased expression of several ligands in NF2-null human arachnoidal cells (ACs) and the MNcell line Ben-Men-1, particularly neuregulin-1/heregulin (NRG1), and confirm increased NRG1 secretion and activation of V-ERB-B avian erythroblastic leukemia viral oncogene homolog 3 (ERBB3) receptor kinase. Conditioned-medium from NF2-null ACs or exogenous NRG1 stimulated ERBB3, EPHA2, and mTORC1/2 signaling, suggesting pathway crosstalk. NF2-null cells treated with an ERBB3-neutralizing antibody partially downregulated mTOR pathway activation but showed no effect on viability. mTORC1/2 inhibitor treatment decreased NRG1 expression and downregulated ERBB3 while re-activating pAkt T308, suggesting a mechanism independent of NRG1-ERBB3 but likely involving activation of another upstream receptor kinase. Transcriptomics after mTORC1/2 inhibition confirmed decreased ERBB3/ERBB4 while revealing increased expression of insulin-like growth factor receptor 1 (IGF1R). Drug treatment co-targeting mTORC1/2 and IGF1R/insulin receptor attenuated pAkt T308 and showed synergistic effects on viability. Our findings indicate potential autocrine signaling where NF2 loss leads to secretion/activation of NRG1-ERBB3 signaling. mTORC1/2 inhibition downregulates NRG1-ERBB3, while upregulating pAkt T308 through an adaptive response involving IGF1R/insulin receptor and co-targeting these pathways may prove effective for treatment of NF2-deficient MN.",The Journal of biological chemistry,2021,Roberta L Beauchamp; Serkan Erdin; Luke Witt; Justin T Jordan; Scott R Plotkin; James F Gusella; Vijaya Ramesh
PUBbfed82de,10.1074/jbc.RA120.014960 | 10.1016/j.ebiom.2017.01.020 | 10.18632/oncotarget.4858 | 10.1093/brain/awac342,PMID:33273014 | PMID:28126595 | PMID:26219339 | PMID:36148553,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,,,
PUB7332362a,10.1074/jbc.RA120.014960 | 10.1371/journal.pone.0196726 | 10.1016/j.ebiom.2018.09.042 | 10.18632/oncotarget.4858 | 10.1371/journal.pone.0090853,PMID:33273014 | PMID:29715273 | PMID:30274821 | PMID:26219339 | PMID:24595234,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,,,
PUB16e2956c,10.1074/jbc.RA120.014960 | 10.1038/s41467-024-44755-9 | 10.3181/0809-RM-275,PMID:33273014 | PMID:38216572 | PMID:19144871,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,,,
PUB69ba4f7d,10.1038/s41591-020-01193-6 | 10.1158/1535-7163.MCT-19-0123 | 10.1038/s41416-021-01270-8 | 10.1158/1078-0432.CCR-23-2548,PMID:33442015 | PMID:31527226 | PMID:33658640 | PMID:38127282,"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.",,,,
PUB33658640,10.1038/s41416-021-01270-8,PMID:33658640,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,"BACKGROUND: MPNST is a rare soft-tissue sarcoma that can arise from patients with NF1. Existing chemotherapeutic and targeted agents have been unsuccessful in MPNST treatment, and recent findings implicate STAT3 and HIF1- in driving MPNST. The DNA-binding and transcriptional activity of both STAT3 and HIF1- is regulated by Redox factor-1 (Ref-1) redox function. A first-generation Ref-1 inhibitor, APX3330, is being tested in cancer clinical trials and could be applied to MPNST. METHODS: We characterised Ref-1 and p-STAT3 expression in various MPNST models. Tumour growth, as well as biomarkers of apoptosis and signalling pathways, were measured by qPCR and western blot following treatment with inhibitors of Ref-1 or STAT3. RESULTS: MPNSTs from Nf1-Arf CONCLUSIONS: Our findings implicate a unique therapeutic approach to target important MPNST signalling nodes in sarcomas using new first-in-class small molecules for potential translation to the clinic.",British journal of cancer,2021-04,Silpa Gampala; Fenil Shah; Chi Zhang; Steven D Rhodes; Olivia Babb; Michelle Grimard; Randall S Wireman; Ellie Rad; Brian Calver; Ren-Yuan Bai; Verena Staedtke; Emily L Hulsey; M Reza Saadatzadeh; Karen E Pollok; Yan Tong; Abbi E Smith; D Wade Clapp; Andrew R Tee; Mark R Kelley; Melissa L Fishel
PUBbb685c75,10.3390/cancers13050999 | 10.1038/s41591-018-0263-8,PMID:33673681 | PMID:30531922,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of | The molecular landscape of glioma in patients with Neurofibromatosis 1.,,,,
PUBd038b8e3,10.1038/s41419-021-03716-6 | 10.3389/fonc.2020.00687,PMID:33934112 | PMID:32457840,"HIF1-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | TGF Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,,,
PUB33978635,10.1093/noajnl/vdab020,PMID:33978635,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,"BACKGROUND: The MEK1/2 inhibitor selumetinib was recently approved for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, but outcomes could be improved and its pharmacodynamic evaluation in other relevant tissues is limited. The aim of this study was to assess selumetinib tissue pharmacokinetics (PK) and pharmacodynamics (PD) using a minipig model of NF1. METHODS: WT ( RESULTS: Key selumetinib PK parameters aligned with those observed in human patients. Selumetinib concentrations were higher in CNS tissues from NF1 compared to WT animals. Inhibition of ERK phosphorylation was achieved in PBMCs (mean 60% reduction), skin (95%), and sciatic nerve (64%) from all minipigs, whereas inhibition of ERK phosphorylation in cerebral cortex was detected only in NF1 animals (71%). Basal p-ERK levels were significantly higher in NF1 minipig optic nerve compared to WT and were reduced to WT levels (60%) with selumetinib. Modulation of transcript biomarkers was observed in all tissues. CONCLUSIONS: Selumetinib reduces MAPK signaling in tissues clinically relevant to NF1, effectively normalizing p-ERK to WT levels in optic nerve but resulting in abnormally low levels of p-ERK in the skin. These results suggest that selumetinib exerts activity in NF1-associated CNS tumors by normalizing Ras/MAPK signaling and may explain common MEK inhibitor-associated dermatologic toxicities.",Neuro-oncology advances,2021,Sara H Osum; Alexander W Coutts; Dylan J Duerre; Barbara R Tschida; Mark N Kirstein; James Fisher; W Robert Bell; Oona Delpuech; Paul D Smith; Brigitte C Widemann; Christopher L Moertel; David A Largaespada; Adrienne L Watson
PUB34010628,10.1016/j.stem.2021.04.029,PMID:34010628,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,"NF1-associated malignant peripheral nerve sheath tumors (MPNSTs) are the major cause of mortality in neurofibromatosis. MPNSTs arise from benign peripheral nerve plexiform neurofibromas that originate in the embryonic neural crest cell lineage. Using reporter transgenes that label early neural crest lineage cells in multiple NF1 MPNST mouse models, we discover and characterize a rare MPNST cell population with stem-cell-like properties, including quiescence, that is essential for tumor initiation and relapse. Following isolation of these cells, we derive a cancer-stem-cell-specific gene expression signature that includes consensus embryonic neural crest genes and identify Nestin as a marker for the MPNST cell of origin. Combined targeting of cancer stem cells along with antimitotic chemotherapy yields effective tumor inhibition and prolongs survival. Enrichment of the cancer stem cell signature in cognate human tumors supports the generality and relevance of cancer stem cells to MPNST therapy development.",Cell stem cell,2021-08-05,Daochun Sun; Xuanhua P Xie; Xiyuan Zhang; Zilai Wang; Sameer Farouk Sait; Swathi V Iyer; Yu-Jung Chen; Rebecca Brown; Dan R Laks; Mollie E Chipman; Jack F Shern; Luis F Parada
PUB34011935,10.1038/s41419-021-03802-9,PMID:34011935,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,"Neurofibromatosis type 1 is an autosomal dominant genetic disorder caused by mutation in the neurofibromin 1 (NF1) gene. Its hallmarks are cutaneous findings including neurofibromas, benign peripheral nerve sheath tumors. We analyzed the collagen and matrix metalloproteinase 1 (MMP1) expression in Neurofibromatosis 1 cutaneous neurofibroma and found excessive expression of collagen and reduced expression of MMP1. To identify new therapeutic drugs for neurofibroma, we analyzed phosphorylation of components of the Ras pathway, which underlies NF1 regulation, and applied treatments to block this pathway (PD184352, U0126, and rapamycin) and lysosomal processes (chloroquine (CQ), hydroxychloroquine (HCQ), and bafilomycin A (BafA)) in cultured Neurofibromatosis 1 fibroblasts. We found that downregulation of the MMP1 protein was a key abnormal feature in the neurofibromatosis 1 fibroblasts and that the decreased MMP1 was restored by the lysosomal blockers CQ and HCQ, but not by the blockers of the Ras pathway. Moreover, the MMP1-upregulating activity of those lysosomal blockers was dependent on aryl hydrocarbon receptor (AHR) activation and ERK phosphorylation. Our findings suggest that lysosomal blockers are potential candidates for the treatment of Neurofibromatosis 1 neurofibroma.",Cell death & disease,2021-05-19,Gaku Tsuji; Ayako Takai-Yumine; Takahiro Kato; Masutaka Furue
PUB34040258,10.1038/s41586-021-03580-6,PMID:34040258,NF1 mutation drives neuronalactivity-dependent initiation of optic glioma.,"Neurons have recently emerged as essential cellular constituents of the tumour microenvironment, and their activity has been shown to increase the growth of a diverse number of solid tumours",Nature,2021-06,Yuan Pan; Jared D Hysinger; Tara Barron; Nicki F Schindler; Olivia Cobb; Xiaofan Guo; Belgin Yaln; Corina Anastasaki; Sara B Mulinyawe; Anitha Ponnuswami; Suzanne Scheaffer; Yu Ma; Kun-Che Chang; Xin Xia; Joseph A Toonen; James J Lennon; Erin M Gibson; John R Huguenard; Linda M Liau; Jeffrey L Goldberg; Michelle Monje; David H Gutmann
PUB34106871,10.1109/JBHI.2021.3087735,PMID:34106871,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,"Neurofibromatosis type 1 (NF1) is an autosomal dominant tumor predisposition syndrome that involves the central and peripheral nervous systems. Accurate detection and segmentation of neurofibromas are essential for assessing tumor burden and longitudinal tumor size changes. Automatic convolutional neural networks (CNNs) are sensitive and vulnerable as tumors' variable anatomical location and heterogeneous appearance on MRI. In this study, wepropose deep interactive networks (DINs) to address the above limitations. User interactions guide the model to recognize complicated tumors and quickly adapt to heterogeneous tumors. We introduce a simple but effective Exponential Distance Transform (ExpDT) that converts user interactions into guide maps regarded as the spatial and appearance prior. Comparing with popular Euclidean and geodesic distances, ExpDT is more robust to various image sizes, which reserves the distribution of interactive inputs. Furthermore, to enhance the tumor-related features, we design a deep interactive module to propagate the guides into deeper layers. We train and evaluate DINs on three MRI data sets from NF1 patients. The experiment results yield significant improvements of 44% and 14% in DSC comparing with automated and other interactive methods, respectively. We also experimentally demonstrate the efficiency of DINs in reducing user burden when comparing with conventional interactive methods.",IEEE journal of biomedical and health informatics,2022-02,Jian-Wei Zhang; Wei Chen; K Ina Ly; Xubin Zhang; Fan Yan; Justin Jordan; Gordon Harris; Scott Plotkin; Pengyi Hao; Wenli Cai
PUB34630515,10.3389/fgene.2021.721045,PMID:34630515,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and,"Genome editing in pigs has been made efficient, practical, and economically viable by the CRISPR/Cas9 platform, representing a promising new era in translational modeling of human disease for research and preclinical development of therapies and devices. Porcine embryo microinjection provides a universally available, efficient option over somatic-cell nuclear transfer, but requires that critical considerations be made in genotypic validation of the models that routinely go unaddressed. Accurate validation of genotypes is especially important when modeling genetic disorders, such as neurofibromatosis type 1 (NF1) that exhibits complex genotype-phenotypic relationships. NF1, an autosomal dominant disorder, is particularly hard to model as it manifests very differently across patients, and even within families, with over 3,000 disease-associated mutations of the neurofibromin 1 (",Frontiers in genetics,2021,Clifford Dustin Rubinstein; Dalton T McLean; Brent P Lehman; Jennifer J Meudt; Dominic T Schomberg; Kathy J Krentz; Jamie L Reichert; Mark B Meyer; Marie Adams; Charles M Konsitzke; Dhanansayan Shanmuganayagam
PUBad11fce9,10.1117/1.JBO.26.12.125001 | 10.1371/journal.pone.0086115 | 10.1186/1741-7015-9-82,PMID:34935315 | PMID:24465906 | PMID:21726432,"Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy. | Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1. | MIA is a potential biomarker for tumour load in neurofibromatosis type 1.",,,,
PUB35511749,10.1158/1535-7163.MCT-21-0947,PMID:35511749,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,"Malignant peripheral nerve sheath tumors (MPNST) are soft-tissue sarcomas that are the leading cause of mortality in patients with Neurofibromatosis type 1 (NF1). Single chemotherapeutic agents have shown response rates ranging from 18% to 44% in clinical trials, so there is still a high medical need to identify chemotherapeutic combination treatments that improve clinical prognosis and outcome. We screened a collection of compounds from the NCATS Mechanism Interrogation PlatE (MIPE) library in three MPNST cell lines, using cell viability and apoptosis assays. We then tested whether compounds that were active as single agents were synergistic when screened as pairwise combinations. Synergistic combinations in vitro were further evaluated in patient-derived orthotopic xenograft/orthoxenograft (PDOX) athymic models engrafted with primary MPNST matching with their paired primary-derived cell line where synergism was observed. The high-throughput screening identified 21 synergistic combinations, from which four exhibited potent synergies in a broad panel of MPNST cell lines. One of the combinations, MK-1775 with Doxorubicin, significantly reduced tumor growth in a sporadic PDOX model (MPNST-SP-01; sevenfold) and in an NF1-PDOX model (MPNST-NF1-09; fourfold) and presented greater effects in TP53 mutated MPNST cell lines. The other three combinations, all involving Panobinostat (combined with NVP-BGT226, Torin 2, or Carfilzomib), did not reduce the tumor volume in vivo at noncytotoxic doses. Our results support the utility of our screening platform of in vitro and in vivo models to explore new therapeutic approaches for MPNSTs and identified that combination MK-1775 with Doxorubicin could be a good pharmacologic option for the treatment of these tumors.",Molecular cancer therapeutics,2022-07-05,Juana Fernndez-Rodrguez; Edgar Creus-Bachiller; Xiaohu Zhang; Maria Martnez-Iniesta; Sara Ortega-Bertran; Rajarshi Guha; Craig J Thomas; Margaret R Wallace; Cleofe Romagosa; Lourdes Salazar-Huayna; Karlyne M Reilly; Jaishri O Blakely; Jordi Serra-Musach; Miguel Angel Pujana; Eduard Serra; Alberto Villanueva; Marc Ferrer; Conxi Lzaro
PUB35589737,10.1038/s41467-022-30466-6,PMID:35589737,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,"Neuronal activity is emerging as a driver of central and peripheral nervous system cancers. Here, we examined neuronal physiology in mouse models of the tumor predisposition syndrome Neurofibromatosis-1 (NF1), with different propensities to develop nervous system cancers. We show that central and peripheral nervous system neurons from mice with tumor-causing Nf1 gene mutations exhibit hyperexcitability and increased secretion of activity-dependent tumor-promoting paracrine factors. We discovered a neurofibroma mitogen (COL1A2) produced by peripheral neurons in an activity-regulated manner, which increases NF1-deficient Schwann cell proliferation, establishing that neurofibromas are regulated by neuronal activity. In contrast, mice with the Arg1809Cys Nf1 mutation, found in NF1 patients lacking neurofibromas or optic gliomas, do not exhibit neuronal hyperexcitability or develop these NF1-associated tumors. The hyperexcitability of tumor-prone Nf1-mutant neurons results from reduced NF1-regulated hyperpolarization-activated cyclic nucleotide-gated (HCN) channel function, such that neuronal excitability, activity-regulated paracrine factor production, and tumor progression are attenuated by HCN channel activation. Collectively, these findings reveal that NF1 mutations act at the level of neurons to modify tumor predisposition by increasing neuronal excitability and activity-regulated paracrine factor production.",Nature communications,2022-05-19,Corina Anastasaki; Juan Mo; Ji-Kang Chen; Jit Chatterjee; Yuan Pan; Suzanne M Scheaffer; Olivia Cobb; Michelle Monje; Lu Q Le; David H Gutmann
PUB35741605,10.3390/brainsci12060720,PMID:35741605,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,"Neurofibromatosis Type 1 (NF1) is one of the most common genetic tumor predisposition syndromes, affecting up to 1 in 2500 individuals. Up to half of patients with NF1 develop benign nerve sheath tumors called plexiform neurofibromas (PNs), characterized by biallelic NF1 loss. PNs can grow to immense sizes, cause extensive morbidity, and harbor a 15% lifetime risk of malignant transformation. Increasingly, molecular sequencing and drug screening data from various preclinical murine and human PN cell lines, murine models, and human PN tissues are available to help identify salient treatments for PNs. Despite this, Selumetinib, a MEK inhibitor, is the only currently FDA-approved pharmacotherapy for symptomatic and inoperable PNs in pediatric NF1 patients. The discovery of alternative and additional treatments has been hampered by the rarity of the disease, which makes prioritizing drugs to be tested in future clinical trials immensely important. Here, we propose a gene regulatory network-based integrated analysis to mine high-throughput cell line-based drug data combined with transcriptomes from resected human PN tumors. Conserved network modules were characterized and served as drug fingerprints reflecting the biological connections among drug effects and the inherent properties of PN cell lines and tissue. Drug candidates were ranked, and the therapeutic potential of drug combinations was evaluated via computational predication. Auspicious therapeutic agents and drug combinations were proposed for further investigation in preclinical and clinical trials.",Brain sciences,2022-05-31,Rebecca M Brown; Sameer Farouk Sait; Griffin Dunn; Alanna Sullivan; Benjamin Bruckert; Daochun Sun
PUB8c0a7b32,10.3390/brainsci12060720 | 10.1038/s41419-021-03716-6 | 10.1038/s41591-020-01193-6 | 10.3390/cancers15245811,PMID:35741605 | PMID:33934112 | PMID:33442015 | PMID:38136356,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | HIF1-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,,,
PUBad0fc128,10.3390/brainsci12060720 | 10.1002/1878-0261.13704 | 10.3390/cancers15245811 | 10.3390/cancers17142359,PMID:35741605 | PMID:39129390 | PMID:38136356 | PMID:40723243,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,,,
PUB2b259282,10.3390/brainsci12060720 | 10.1002/1878-0261.13704 | 10.3390/cells14161276 | 10.1073/pnas.2208960120 | 10.3390/cancers16142498 | 10.3390/cancers17142359,PMID:35741605 | PMID:39129390 | PMID:40862755 | PMID:36689660 | PMID:39061138 | PMID:40723243,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization. | A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,,,
PUBad2ac02e,10.3390/brainsci12060720 | 10.3390/cancers17142359,PMID:35741605 | PMID:40723243,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,,,
PUB36148553,10.1093/brain/awac342,PMID:36148553,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,"Schwannoma tumours typically arise on the eighth cranial nerve and are mostly caused by loss of the tumour suppressor Merlin (NF2). There are no approved chemotherapies for these tumours and the surgical removal of the tumour carries a high risk of damage to the eighth or other close cranial nerve tissue. New treatments for schwannoma and other NF2-null tumours such as meningioma are urgently required. Using a combination of human primary tumour cells and mouse models of schwannoma, we have examined the role of the Hippo signalling pathway in driving tumour cell growth. Using both genetic ablation of the Hippo effectors YAP and TAZ as well as novel TEAD palmitoylation inhibitors, we show that Hippo signalling may be successfully targeted in vitro and in vivo to both block and, remarkably, regress schwannoma tumour growth. In particular, successful use of TEAD palmitoylation inhibitors in a preclinical mouse model of schwannoma points to their potential future clinical use. We also identify the cancer stem cell marker aldehyde dehydrogenase 1A1 (ALDH1A1) as a Hippo signalling target, driven by the TAZ protein in human and mouse NF2-null schwannoma cells, as well as in NF2-null meningioma cells, and examine the potential future role of this new target in halting schwannoma and meningioma tumour growth.",Brain : a journal of neurology,2023-04-19,Liyam Laraba; Lily Hillson; Julio Grimm de Guibert; Amy Hewitt; Maisie R Jaques; Tracy T Tang; Leonard Post; Emanuela Ercolano; Ganesha Rai; Shyh-Ming Yang; Daniel J Jagger; Waldemar Woznica; Philip Edwards; Aditya G Shivane; C Oliver Hanemann; David B Parkinson
PUB36241865,10.1038/s12276-022-00850-9,PMID:36241865,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,"The poor survival and low efficiency of neuronal differentiation limits the therapeutic effects of transplanted neural stem cells in the treatment of spinal cord injury. Neurofibromatosis-1 (NF-1) is a tumor suppressor gene that restricts the rapid and abnormal growth and differentiation of neural cells. In the present study, lentiviral vectors were used to knock out NF-1, Ricotr (the core member of mTORC2) or NF-1+Ricotr in neural stem cells in vitro, and the NF-1, Ricotr or NF-1+Ricotr knockout neural stem cells were transplanted at the lesion site in a rat model of spinal cord injury (SCI). We first demonstrated that targeted knockout of NF-1 had an antiapoptotic effect and improved neuronal differentiation by enhancing the mTORC2/Rictor pathway of neural stem cells in vitro. Subsequently, transplanting NF-1 knockout neural stem cells into the injured site sufficiently promoted the tissue repair and functional recovery of rats with spinal cord injury by enhancing the survival and neuronal differentiation of grafted neural stem cells. Collectively, these findings reveal a prominent role of NF-1 in neural stem cell biology, which is an invaluable step forward in enhancing the benefit of neural stem cell-mediated regenerative cell therapy for spinal cord injury and identifies the transplantation of NF-1 knockout neural stem cells as a promising strategy for spinal cord injury.",Experimental & molecular medicine,2022-10,Guoliang Chen; Xianlong Li; Hongzhang Zhu; Huachuan Wu; Dacheng He; Liangyu Shi; Fuxin Wei; Xizhe Liu; Ningning Chen; Shaoyu Liu
PUB36322658,10.1126/sciadv.abo5442,PMID:36322658,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,"Malignant peripheral nerve sheath tumor (MPNST), a highly aggressive Schwann cell (SC)-derived soft tissue sarcoma, arises from benign neurofibroma (NF); however, the identity, heterogeneity and origins of tumor populations remain elusive. Nestin",Science advances,2022-11-04,Lai Man Natalie Wu; Feng Zhang; Rohit Rao; Mike Adam; Kai Pollard; Sara Szabo; Xuezhao Liu; Katie A Belcher; Zaili Luo; Sean Ogurek; Colleen Reilly; Xin Zhou; Li Zhang; Joshua Rubin; Long-Sheng Chang; Mei Xin; Jiyang Yu; Mario Suva; Christine A Pratilas; Steven Potter; Q Richard Lu
PUB3337a5d4,10.1126/sciadv.abo5442 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.3390/ijms25010277 | 10.1158/1078-0432.CCR-23-0749 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-21-0947 | 10.1158/0008-5472.CAN-20-1365,PMID:36322658 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38203448 | PMID:37410426 | PMID:23535903 | PMID:35511749 | PMID:33032988,"Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression. | Canonical Wnt/-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.",,,,
PUB556fe557,10.1126/sciadv.abo5442 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1186/s13104-018-3630-0 | 10.1080/23723556.2025.2561292 | 10.3390/ijms25010277 | 10.1186/s12885-020-07397-w | 10.1158/2159-8290.CD-13-0081,PMID:36322658 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:30055648 | PMID:41001593 | PMID:38203448 | PMID:32948135 | PMID:23535903,"Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Canonical Wnt/-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,,,
PUB36420221,10.1016/j.omtn.2022.10.026,PMID:36420221,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,NF2-related schwannomatosis (NF2-related SWN) is an autosomal dominant condition caused by loss of function variants in the ,Molecular therapy. Nucleic acids,2022-12-13,Nria Catass; Inma Rosas; Sandra Bonache; Alex Negro; Miguel Torres-Martin; Adri Plana-Pla; Hector Salvador; Eduard Serra; Ignacio Blanco; Elisabeth Castellanos
PUB36689660,10.1073/pnas.2208960120,PMID:36689660,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,The majority of pathogenic mutations in the neurofibromatosis type I (,Proceedings of the National Academy of Sciences of the United States of America,2023-01-31,Lucy C Young; Ruby Goldstein de Salazar; Sae-Won Han; Zi Yi Stephanie Huang; Alan Merk; Matthew Drew; Joseph Darling; Vanessa Wall; Reinhard Grisshammer; Alice Cheng; Madeline R Allison; Matthew J Sale; Dwight V Nissley; Dominic Esposito; Jana Ognjenovic; Frank McCormick
PUB36730269,10.1371/journal.pone.0277305,PMID:36730269,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,"Neurofibromatosis Type 1 (NF1) patients develop an array of benign and malignant tumors, of which Malignant Peripheral Nerve Sheath Tumors (MPNST) and High Grade Gliomas (HGG) have a dismal prognosis. About 15-20% of individuals with NF1 develop brain tumors and one third of these occur outside of the optic pathway. These non-optic pathway gliomas are more likely to progress to malignancy, especially in adults. Despite their low frequency, high grade gliomas have a disproportional effect on the morbidity of NF1 patients. In vitro drug combination screens have not been performed on NF1-associated HGG, hindering our ability to develop informed clinical trials. Here we present the first in vitro drug combination screen (21 compounds alone or in combination with MEK or PI3K inhibitors) on the only human NF1 patient derived HGG cell line available and on three mouse glioma cell lines derived from the NF1-P53 genetically engineered mouse model, which sporadically develop HGG. These mouse glioma cell lines were never exposed to serum, grow as spheres and express markers that are consistent with an Oligodendrocyte Precursor Cell (OPC) lineage origin. Importantly, even though the true cell of origin for HGG remains elusive, they are thought to arise from the OPC lineage. We evaluated drug sensitivities of the three murine glioma cell lines in a 3D spheroid growth assay, which more accurately reflects drug sensitivities in vivo. Excitingly, we identified six compounds targeting HDACs, BRD4, CHEK1, BMI-1, CDK1/2/5/9, and the proteasome that potently induced cell death in our NF1-associated HGG. Moreover, several of these inhibitors work synergistically with either MEK or PI3K inhibitors. This study forms the basis for further pre-clinical evaluation of promising targets, with an eventual hope to translate these to the clinic.",PloS one,2023,Jacquelyn Dougherty; Kyra Harvey; Angela Liou; Katherine Labella; Deborah Moran; Stephanie Brosius; Thomas De Raedt
PUB820f2963,10.1186/s40478-023-01525-w | 10.1186/s40478-025-02075-z | 10.1002/glia.20845 | 10.1016/j.bone.2011.03.760 | 10.1117/1.JBO.26.12.125001 | 10.1016/j.celrep.2015.02.041 | 10.1167/iovs.17-22588 | 10.1371/journal.pone.0190001 | 10.18632/oncotarget.17589 | 10.7554/eLife.05151 | 10.1002/jbmr.42,PMID:36890585 | PMID:40684195 | PMID:19191334 | PMID:21439418 | PMID:34935315 | PMID:25772366 | PMID:29847659 | PMID:29787563 | PMID:28525381 | PMID:25535838 | PMID:20200958,Neurofibromatosistype 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. | Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,,,
PUB37140985,10.1172/JCI168227,PMID:37140985,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,"Neurofibromatosis type 1 (NF1) is one of the most common tumor-predisposing genetic disorders. Neurofibromas are NF1-associated benign tumors. A hallmark feature of neurofibromas is an abundant collagen-rich extracellular matrix (ECM) that constitutes more than 50% of the tumor dry weight. However, little is known about the mechanism underlying ECM deposition during neurofibroma development and treatment response. We performed a systematic investigation of ECM enrichment during plexiform neurofibroma (pNF) development and identified basement membrane (BM) proteins, rather than major collagen isoforms, as the most upregulated ECM component. Following MEK inhibitor treatment, the ECM profile displayed an overall downregulation signature, suggesting ECM reduction as a therapeutic benefit of MEK inhibition. Through these proteomic studies, TGF-1 signaling was identified as playing a role in ECM dynamics. Indeed, TGF-1 overexpression promoted pNF progression in vivo. Furthermore, by integrating single-cell RNA sequencing, we found that immune cells including macrophages and T cells produce TGF-1 to induce Schwann cells to produce and deposit BM proteins for ECM remodeling. Following Nf1 loss, neoplastic Schwann cells further increased BM protein deposition in response to TGF-1. Our data delineate the regulation governing ECM dynamics in pNF and suggest that BM proteins could serve as biomarkers for disease diagnosis and treatment response.",The Journal of clinical investigation,2023-06-15,Chunhui Jiang; Ashwani Kumar; Ze Yu; Tracey Shipman; Yong Wang; Renee M McKay; Chao Xing; Lu Q Le
PUB5d46f60e,10.1172/JCI168227 | 10.1158/1078-0432.CCR-23-2548,PMID:37140985 | PMID:38127282,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,,,
PUB37164978,10.1038/s41467-023-38432-6,PMID:37164978,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,"Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive sarcoma, and a lethal neurofibromatosis type 1-related malignancy, with little progress made on treatment strategies. Here, we apply a multiplatform integrated molecular analysis on 108 tumors spanning the spectrum of peripheral nerve sheath tumors to identify candidate drivers of MPNST that can serve as therapeutic targets. Unsupervised analyses of methylome and transcriptome profiles identify two distinct subgroups of MPNSTs with unique targetable oncogenic programs. We establish two subgroups of MPNSTs: SHH pathway activation in MPNST-G1 and WNT/-catenin/CCND1 pathway activation in MPNST-G2. Single nuclei RNA sequencing characterizes the complex cellular architecture and demonstrate that malignant cells from MPNST-G1 and MPNST-G2 have neural crest-like and Schwann cell precursor-like cell characteristics, respectively. Further, in pre-clinical models of MPNST we confirm that inhibiting SHH pathway in MPNST-G1 prevent growth and malignant progression, providing the rational for investigating these treatments in clinical trials.",Nature communications,2023-05-10,Suganth Suppiah; Sheila Mansouri; Yasin Mamatjan; Jeffrey C Liu; Minu M Bhunia; Vikas Patil; Prisni Rath; Bharati Mehani; Pardeep Heir; Severa Bunda; German L Velez-Reyes; Olivia Singh; Nazanin Ijad; Neda Pirouzmand; Tatyana Dalcourt; Ying Meng; Shirin Karimi; Qingxia Wei; Farshad Nassiri; Trevor J Pugh; Gary D Bader; Kenneth D Aldape; David A Largaespada; Gelareh Zadeh
PUBc1ed5c82,10.1038/s41467-023-38432-6 | 10.3390/cancers15245811,PMID:37164978 | PMID:38136356,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,,,
PUB37410426,10.1158/1078-0432.CCR-23-0749,PMID:37410426,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.","PURPOSE: Malignant peripheral nerve sheath tumors (MPNST) are lethal, Ras-driven sarcomas that lack effective therapies. We investigated effects of targeting cyclin-dependent kinases 4 and 6 (CDK4/6), MEK, and/or programmed death-ligand 1 (PD-L1) in preclinical MPNST models. EXPERIMENTAL DESIGN: Patient-matched MPNSTs and precursor lesions were examined by FISH, RNA sequencing, IHC, and Connectivity-Map analyses. Antitumor activity of CDK4/6 and MEK inhibitors was measured in MPNST cell lines, patient-derived xenografts (PDX), and de novo mouse MPNSTs, with the latter used to determine anti-PD-L1 response. RESULTS: Patient tumor analyses identified CDK4/6 and MEK as actionable targets for MPNST therapy. Low-dose combinations of CDK4/6 and MEK inhibitors synergistically reactivated the retinoblastoma (RB1) tumor suppressor, induced cell death, and decreased clonogenic survival of MPNST cells. In immune-deficient mice, dual CDK4/6-MEK inhibition slowed tumor growth in 4 of 5 MPNST PDXs. In immunocompetent mice, combination therapy of de novo MPNSTs caused tumor regression, delayed resistant tumor outgrowth, and improved survival relative to monotherapies. Drug-sensitive tumors that regressed contained plasma cells and increased cytotoxic T cells, whereas drug-resistant tumors adopted an immunosuppressive microenvironment with elevated MHC II-low macrophages and increased tumor cell PD-L1 expression. Excitingly, CDK4/6-MEK inhibition sensitized MPNSTs to anti-PD-L1 immune checkpoint blockade (ICB) with some mice showing complete tumor regression. CONCLUSIONS: CDK4/6-MEK inhibition induces a novel plasma cell-associated immune response and extended antitumor activity in MPNSTs, which dramatically enhances anti-PD-L1 therapy. These preclinical findings provide strong rationale for clinical translation of CDK4/6-MEK-ICB targeted therapies in MPNST as they may yield sustained antitumor responses and improved patient outcomes.",Clinical cancer research : an official journal of the American Association for Cancer Research,2023-09-01,Jordan L Kohlmeyer; Joshua J Lingo; Courtney A Kaemmer; Amanda Scherer; Akshaya Warrier; Ellen Voigt; Juan A Raygoza Garay; Gavin R McGivney; Qierra R Brockman; Amy Tang; Ana Calizo; Kai Pollard; Xiaochun Zhang; Angela C Hirbe; Christine A Pratilas; Mariah Leidinger; Patrick Breheny; Michael S Chimenti; Jessica C Sieren; Varun Monga; Munir R Tanas; David K Meyerholz; Benjamin W Darbro; Rebecca D Dodd; Dawn E Quelle
PUB37520682,10.1016/j.omtn.2023.06.018,PMID:37520682,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,Neurofibromatosis type 1 (NF1) results from germline mutations in the tumor-suppressor gene ,Molecular therapy. Nucleic acids,2023-09-12,Sara H Osum; Eunice I Oribamise; Stanislas M A S Corbire; Mandy Taisto; Tyler Jubenville; Alex Coutts; Mark N Kirstein; James Fisher; Christopher Moertel; Ming Du; David Bedwell; David A Largaespada; Adrienne L Watson
PUB38000020,10.1126/sciadv.adg8876,PMID:38000020,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,"Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive soft tissue sarcomas with limited treatment options, and new effective therapeutic strategies are desperately needed. We observe antiproliferative potency of genetic depletion of ",Science advances,2023-11-24,Jiawan Wang; Ana Calizo; Lindy Zhang; James C Pino; Yang Lyu; Kai Pollard; Xiaochun Zhang; Alex T Larsson; Eric Conniff; Nicolas J Llosa; David K Wood; David A Largaespada; Susan E Moody; Sara J Gosline; Angela C Hirbe; Christine A Pratilas
PUBa15b955f,10.1126/sciadv.adg8876 | 10.1158/0008-5472.CAN-20-1365,PMID:38000020 | PMID:33032988,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,,,
PUBcb7cca4f,10.1126/sciadv.adg8876 | 10.1158/1078-0432.CCR-23-2548,PMID:38000020 | PMID:38127282,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,,,
PUBb9258046,10.1126/sciadv.adg8876 | 10.1158/1078-0432.CCR-23-2548 | 10.1158/0008-5472.CAN-20-1365,PMID:38000020 | PMID:38127282 | PMID:33032988,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,,,
PUB38127282,10.1158/1078-0432.CCR-23-2548,PMID:38127282,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,"PURPOSE: Plexiform neurofibromas (PNF) are benign peripheral nerve sheath tumors (PNST) associated with neurofibromatosis type 1 (NF1). Despite similar histologic appearance, these neoplasms exhibit diverse evolutionary trajectories, with a subset progressing to malignant peripheral nerve sheath tumor (MPNST), the leading cause of premature death in individuals with NF1. Malignant transformation of PNF often occurs through the development of atypical neurofibroma (ANF) precursor lesions characterized by distinct histopathologic features and CDKN2A copy-number loss. Although genomic studies have uncovered key driver events promoting tumor progression, the transcriptional changes preceding malignant transformation remain poorly defined. EXPERIMENTAL DESIGN: Here we resolve gene-expression profiles in PNST across the neurofibroma-to-MPNST continuum in NF1 patients and mouse models, revealing early molecular features associated with neurofibroma evolution and transformation. RESULTS: Our findings demonstrate that ANF exhibit enhanced signatures of antigen presentation and immune response, which are suppressed as malignant transformation ensues. MPNST further displayed deregulated survival and mitotic fidelity pathways, and targeting key mediators of these pathways, CENPF and BIRC5, disrupted the growth and viability of human MPNST cell lines and primary murine Nf1-Cdkn2a-mutant Schwann cell precursors. Finally, neurofibromas contiguous with MPNST manifested distinct alterations in core oncogenic and immune surveillance programs, suggesting that early molecular events driving disease progression may precede histopathologic evidence of malignancy. CONCLUSIONS: If validated prospectively in future studies, these signatures may serve as molecular diagnostic tools to augment conventional histopathologic diagnosis by identifying neurofibromas at high risk of undergoing malignant transformation, facilitating risk-adapted care.",Clinical cancer research : an official journal of the American Association for Cancer Research,2024-03-01,Dana K Mitchell; Breanne Burgess; Emily E White; Abbi E Smith; Elizabeth A Sierra Potchanant; Henry Mang; Brooke E Hickey; Qingbo Lu; Shaomin Qian; Waylan Bessler; Xiaohong Li; Li Jiang; Kylee Brewster; Constance Temm; Andrew Horvai; Eric A Albright; Melissa L Fishel; Christine A Pratilas; Steven P Angus; D Wade Clapp; Steven D Rhodes
PUB38136356,10.3390/cancers15245811,PMID:38136356,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,Cancers,2023-12-12,Paul O Zamora; Gabriel Altay; Ulisses Santamaria; Nathan Dwarshuis; Hari Donthi; Chang In Moon; Dana Bakalar; Matthew Zamora
PUB38175707,10.1172/jci.insight.168826,PMID:38175707,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,"Cutaneous neurofibromas (cNFs) are benign Schwann cell (SC) tumors arising from subepidermal glia. Individuals with neurofibromatosis type 1 (NF1) may develop thousands of cNFs, which greatly affect their quality of life. cNF growth is driven by the proliferation of NF1-/- SCs and their interaction with the NF1+/- microenvironment. We analyzed the crosstalk between human cNF-derived SCs and fibroblasts (FBs), identifying an expression signature specific to the SC-FB interaction. We validated the secretion of proteins involved in immune cell migration, suggesting a role of SC-FB crosstalk in immune cell recruitment. The signature also captured components of developmental signaling pathways, including the cAMP elevator G protein-coupled receptor 68 (GPR68). Activation of Gpr68 by ogerin in combination with the MEK inhibitor (MEKi) selumetinib reduced viability and induced differentiation and death of human cNF-derived primary SCs, a result corroborated using an induced pluripotent stem cell-derived 3D neurofibromasphere model. Similar results were obtained using other Gpr68 activators or cAMP analogs/adenylyl cyclase activators in combination with selumetinib. Interestingly, whereas primary SC cultures restarted their proliferation after treatment with selumetinib alone was stopped, the combination of ogerin-selumetinib elicited a permanent halt on SC expansion that persisted after drug removal. These results indicate that unbalancing the Ras and cAMP pathways by combining MEKi and cAMP elevators could be used as a potential treatment for cNFs.",JCI insight,2024-01-04,Helena Mazuelas; Miriam Magalln-Lorenz; Itziar Uriarte-Arrazola; Alejandro Negro; Inma Rosas; Ignacio Blanco; Elisabeth Castellanos; Conxi Lzaro; Bernat Gel; Meritxell Carri; Eduard Serra
PUB38201517,10.3390/cancers16010089,PMID:38201517,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,"Neurofibromatosis type 1 (NF1) is a disorder in which RAS is constitutively activated due to the loss of the Ras-GTPase-activating activity of neurofibromin. RAS must be prenylated (i.e., farnesylated or geranylgeranylated) to traffic and function properly. Previous studies showed that the anti-growth properties of farnesyl monophosphate prodrug farnesyltransferase inhibitors (FTIs) on human NF1 malignant peripheral nerve sheath tumor (MPNST) cells are potentiated by co-treatment with lovastatin. Unfortunately, such prodrug FTIs have poor aqueous solubility. In this study, we synthesized a series of prodrug FTI polyamidoamine generation 4 (PAMAM G4) dendrimers that compete with farnesyl pyrophosphate for farnesyltransferase (Ftase) and assessed their effects on human NF1 MPNST S462TY cells. The prodrug 3-tert-butylfarnesyl monophosphate FTI-dendrimer (i.e., ",Cancers,2023-12-23,John J Reiners; Patricia A Mathieu; Mary Gargano; Irene George; Yimin Shen; John F Callaghan; Richard F Borch; Raymond R Mattingly
PUB7b6d47c3,10.3390/cancers16010089 | 10.1124/jpet.107.135830,PMID:38201517 | PMID:18367665,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,,,
PUB4ea68a68,10.3390/cancers16010089 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1158/1535-7163.MCT-24-1053 | 10.3390/ijms25010277 | 10.1158/2159-8290.CD-13-0081,PMID:38201517 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:41036607 | PMID:38203448 | PMID:23535903,"Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Canonical Wnt/-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,,,
PUBe87ca157,10.3390/cancers16010089 | 10.1038/s41467-025-63619-4 | 10.1158/1078-0432.CCR-24-1750 | 10.1124/jpet.107.135830 | 10.1093/neuonc/noad097 | 10.1038/s41416-021-01270-8 | 10.1371/journal.pone.0096733 | 10.1002/1878-0261.13704 | 10.1158/1535-7163.MCT-07-0518 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.1158/1078-0432.CCR-23-2548 | 10.1038/s41467-024-44755-9 | 10.3390/ijms25010277 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-24-1053 | 10.1158/0008-5472.CAN-20-1365,PMID:38201517 | PMID:41022755 | PMID:39269317 | PMID:18367665 | PMID:37246765 | PMID:33658640 | PMID:24824755 | PMID:39129390 | PMID:18413802 | PMID:24681606 | PMID:23685747 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38127282 | PMID:38216572 | PMID:38203448 | PMID:23535903 | PMID:41036607 | PMID:33032988,"Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Canonical Wnt/-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.",,,,
PUB38203448,10.3390/ijms25010277,PMID:38203448,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,"Neurofibromatosis type 1 (NF1) stands as a prevalent neurocutaneous disorder. Approximately a quarter of NF1 patients experience the development of plexiform neurofibromas, potentially progressing into malignant peripheral nerve sheath tumors (MPNST). FT895, an HDAC11 inhibitor, exhibits potent anti-tumor effects on MPNST cells and enhances the cytotoxicity of cordycepin against MPNST. The study aims to investigate the molecular mechanism underlying FT895's efficacy against MPNST cells. Initially, our study unveiled that FT895 disrupts mitochondrial biogenesis and function. Post-FT895 treatment, reactive oxygen species (ROS) in MPNST notably increased, while mitochondrial DNA copy numbers decreased significantly. Seahorse analysis indicated a considerable decrease in basal, maximal, and ATP-production-coupled respiration following FT895 treatment. Immunostaining highlighted FT895's role in promoting mitochondrial aggregation without triggering mitophagy, possibly due to reduced levels of XBP1, Parkin, and PINK1 proteins. Moreover, the study using CHIP-qPCR analysis revealed a significant reduction in the copy numbers of promoters of the MPV17L2, POLG, TFAM, PINK1, and Parkin genes. The RNA-seq analysis underscored the prominent role of the HIF-1 signaling pathway post-FT895 treatment, aligning with the observed impairment in mitochondrial respiration. In summary, the study pioneers the revelation that FT895 induces mitochondrial respiratory damage in MPNST cells.",International journal of molecular sciences,2023-12-24,Po-Yuan Huang; I-An Shih; Ying-Chih Liao; Huey-Ling You; Ming-Jen Lee
PUB38216123,10.1016/j.molmet.2024.101876,PMID:38216123,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,"OBJECTIVE: NF1 is a tumor suppressor gene and its protein product, neurofibromin, is a negative regulator of the RAS pathway. NF1 is one of the top driver mutations in sporadic breast cancer such that 27% of breast cancers exhibit damaging NF1 alterations. NF1 loss-of-function is a frequent event in the genomic evolution of estrogen receptor (ER)+ breast cancer metastasis and endocrine resistance. Individuals with Neurofibromatosis type 1 (NF) - a disorder caused by germline NF1 mutations - have an increased risk of dying from breast cancer [1-4]. NF-related breast cancers are associated with decreased overall survival compared to sporadic breast cancer. Despite numerous studies interrogating the role of RAS mutations in tumor metabolism, no study has comprehensively profiled the NF1-deficient breast cancer metabolome to define patterns of energetic and metabolic reprogramming. The goals of this investigation were (1) to define the role of NF1 deficiency in estrogen receptor-positive (ER+) breast cancer metabolic reprogramming and (2) to identify potential targeted pathway and metabolic inhibitor combination therapies for NF1-deficient ER+breast cancer. METHODS: We employed two ER+ NF1-deficient breast cancer models: (1) an NF1-deficient MCF7 breast cancer cell line to model sporadic breast cancer, and (2) three distinct, Nf1-deficient rat models to model NF-related breast cancer [1]. IncuCyte proliferation analysis was used to measure the effect of NF1 deficiency on cell proliferation and drug response. Protein quantity was assessed by Western Blot analysis. We then used RNAseq to investigate the transcriptional effect of NF1 deficiency on global and metabolism-related transcription. We measured cellular energetics using Agilent Seahorse XF-96 Glyco Stress Test and Mito Stress Test assays. We performed stable isotope labeling and measured [U- RESULTS: Our results revealed that NF1 deficiency enhanced cell proliferation, altered neurofibromin expression, and increased RAS and PI3K/AKT pathway signaling while constraining oxidative ATP production and restricting energetic flexibility. Neurofibromin deficiency also increased glutamine influx into TCA intermediates and dramatically increased lipid pools, especially triglycerides (TG). Lastly, NF1 deficiency alters the synergy between metabolic inhibitors and traditional targeted inhibitors. This includes increased synergy with inhibitors targeting glycolysis, glutamine metabolism, mitochondrial fatty acid transport, and TG synthesis. CONCLUSIONS: NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. This reprogramming is characterized by oxidative ATP constraints, glutamine TCA influx, and lipid pool expansion, and these metabolic changes introduce novel metabolic-to-targeted inhibitor synergies.",Molecular metabolism,2024-02,Rachel Rae J House; Elizabeth A Tovar; Luke N Redlon; Curt J Essenburg; Patrick S Dischinger; Abigail E Ellis; Ian Beddows; Ryan D Sheldon; Evan C Lien; Carrie R Graveel; Matthew R Steensma
PUB25df4dd2,10.1016/j.molmet.2024.101876 | 10.3389/fcell.2024.1359561 | 10.3390/molecules28135128 | 10.1038/s41598-024-84493-y | 10.1016/j.ccell.2018.01.005 | 10.1167/iovs.17-22588 | 10.1038/s12276-022-00850-9,PMID:38216123 | PMID:38481529 | PMID:37446790 | PMID:39890807 | PMID:29438698 | PMID:29847659 | PMID:36241865,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1. | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway. | Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,,,
PUB75cf961f,10.1016/j.molmet.2024.101876 | 10.3390/cancers17111852,PMID:38216123 | PMID:40507334,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,,,
PUB38216572,10.1038/s41467-024-44755-9,PMID:38216572,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,"Schwann cell tumors are the most common cancers of the peripheral nervous system and can arise in patients with neurofibromatosis type-1 (NF-1) or neurofibromatosis type-2 (NF-2). Functional interactions between NF1 and NF2 and broader mechanisms underlying malignant transformation of the Schwann lineage are unclear. Here we integrate bulk and single-cell genomics, biochemistry, and pharmacology across human samples, cell lines, and mouse allografts to identify cellular de-differentiation mechanisms driving malignant transformation and treatment resistance. We find DNA methylation groups of Schwann cell tumors can be distinguished by differentiation programs that correlate with response to the MEK inhibitor selumetinib. Functional genomic screening in NF1-mutant tumor cells reveals NF2 loss and PAK activation underlie selumetinib resistance, and we find that concurrent MEK and PAK inhibition is effective in vivo. These data support a de-differentiation paradigm underlying malignant transformation and treatment resistance of Schwann cell tumors and elucidate a functional link between NF1 and NF2.",Nature communications,2024-01-12,Harish N Vasudevan; Emily Payne; Cyrille L Delley; S John Liu; Kanish Mirchia; Matthew J Sale; Sydney Lastella; Maria Sacconi Nunez; Calixto-Hope G Lucas; Charlotte D Eaton; Tim Casey-Clyde; Stephen T Magill; William C Chen; Steve E Braunstein; Arie Perry; Line Jacques; Alyssa T Reddy; Melike Pekmezci; Adam R Abate; Frank McCormick; David R Raleigh
PUB38216587,10.1038/s41467-023-40408-5,PMID:38216587,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,"Mechanisms specifying cancer cell states and response to therapy are incompletely understood. Here we show epigenetic reprogramming shapes the cellular landscape of schwannomas, the most common tumors of the peripheral nervous system. We find schwannomas are comprised of 2 molecular groups that are distinguished by activation of neural crest or nerve injury pathways that specify tumor cell states and the architecture of the tumor immune microenvironment. Moreover, we find radiotherapy is sufficient for interconversion of neural crest schwannomas to immune-enriched schwannomas through epigenetic and metabolic reprogramming. To define mechanisms underlying schwannoma groups, we develop a technique for simultaneous interrogation of chromatin accessibility and gene expression coupled with genetic and therapeutic perturbations in single-nuclei. Our results elucidate a framework for understanding epigenetic drivers of tumor evolution and establish a paradigm of epigenetic and metabolic reprograming of cancer cells that shapes the immune microenvironment in response to radiotherapy.",Nature communications,2024-01-12,S John Liu; Tim Casey-Clyde; Nam Woo Cho; Jason Swinderman; Melike Pekmezci; Mark C Dougherty; Kyla Foster; William C Chen; Javier E Villanueva-Meyer; Danielle L Swaney; Harish N Vasudevan; Abrar Choudhury; Joanna Pak; Jonathan D Breshears; Ursula E Lang; Charlotte D Eaton; Kamir J Hiam-Galvez; Erica Stevenson; Kuei-Ho Chen; Brian V Lien; David Wu; Steve E Braunstein; Penny K Sneed; Stephen T Magill; Daniel Lim; Michael W McDermott; Mitchel S Berger; Arie Perry; Nevan J Krogan; Marlan R Hansen; Matthew H Spitzer; Luke Gilbert; Philip V Theodosopoulos; David R Raleigh
PUB38481529,10.3389/fcell.2024.1359561,PMID:38481529,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,Neurofibromatosis type 1 (NF1) is one of the most common genetic disorders caused by heterozygous germline ,Frontiers in cell and developmental biology,2024,Annabelle Darle; Thibault Mahiet; Dborah Aubin; Manon Doyen; Lina El Kassar; Batrice Parfait; Gilles Lemaitre; Christine Baldeschi; Jennifer Allouche; Nathalie Holic
PUB38502231,10.1172/JCI176748,PMID:38502231,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,"Neurofibromatosis type 1 (NF1) is caused by mutations in the NF1 gene that encodes neurofibromin, a RAS GTPase-activating protein. Inactivating NF1 mutations cause hyperactivation of RAS-mediated signaling, resulting in the development of multiple neoplasms, including malignant peripheral nerve sheath tumors (MPNSTs). MPNSTs are an aggressive tumor and the main cause of mortality in patients with NF1. MPNSTs are difficult to resect and refractory to chemo- and radiotherapy, and no molecular therapies currently exist. Immune checkpoint blockade (ICB) is an approach to treat inoperable, undruggable cancers like MPNST, but successful outcomes require an immune cell-rich tumor microenvironment. While MPNSTs are noninflamed ""cold"" tumors, here, we converted MPNSTs into T cell-inflamed ""hot"" tumors by activating stimulator of IFN genes (STING) signaling. Mouse genetic and human xenograft MPNST models treated with a STING agonist plus ICB exhibited growth delay via increased apoptotic cell death. This strategy offers a potential treatment regimen for MPNSTs.",The Journal of clinical investigation,2024-03-19,Bandarigoda N Somatilaka; Laasya Madana; Ali Sadek; Zhiguo Chen; Sanjay Chandrasekaran; Renee M McKay; Lu Q Le
PUB7ceede6d,10.1172/JCI176748 | 10.1016/j.stem.2021.04.029,PMID:38502231 | PMID:34010628,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,,,
PUB323fc5a7,10.1172/JCI176748 | 10.1038/s41418-022-00991-4,PMID:38502231 | PMID:35393510,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,,,
PUB38714355,10.1158/1535-7163.MCT-23-0510,PMID:38714355,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,"Individuals with neurofibromatosis type 1, an autosomal dominant neurogenetic and tumor predisposition syndrome, are susceptible to developing low-grade glioma and less commonly high-grade glioma. These gliomas exhibit loss of the neurofibromin gene [neurofibromin type 1 (NF1)], and 10% to 15% of sporadic high-grade gliomas have somatic NF1 alterations. Loss of NF1 leads to hyperactive RAS signaling, creating opportunity given the established efficacy of MEK inhibitors in plexiform neurofibromas and some individuals with low-grade glioma. We observed that NF1-deficient glioblastoma neurospheres were sensitive to the combination of an MEK inhibitor (mirdametinib) with irradiation, as evidenced by synergistic inhibition of cell growth, colony formation, and increased cell death. In contrast, NF1-intact neurospheres were not sensitive to the combination, despite complete ERK pathway inhibition. No neurosphere lines exhibited enhanced sensitivity to temozolomide combined with mirdametinib. Mirdametinib decreased transcription of homologous recombination genes and RAD51 foci, associated with DNA damage repair, in sensitive models. Heterotopic xenograft models displayed synergistic growth inhibition to mirdametinib combined with irradiation in NF1-deficient glioma xenografts but not in those with intact NF1. In sensitive models, benefits were observed at least 3 weeks beyond the completion of treatment, including sustained phosphor-ERK inhibition on immunoblot and decreased Ki-67 expression. These observations demonstrate synergistic activity between mirdametinib and irradiation in NF1-deficient glioma models and may have clinical implications for patients with gliomas that harbor germline or somatic NF1 alterations.",Molecular cancer therapeutics,2024-09-04,Maria Ioannou; Kriti Lalwani; Abiola A Ayanlaja; Viveka Chinnasamy; Christine A Pratilas; Karisa C Schreck
PUB38744290,10.1016/j.crmeth.2024.100772,PMID:38744290,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,"Localized cutaneous neurofibromas (cNFs) are benign tumors that arise in the dermis of patients affected by neurofibromatosis type 1 syndrome. cNFs are benign lesions: they do not undergo malignant transformation or metastasize. Nevertheless, they can cover a significant proportion of the body, with some individuals developing hundreds to thousands of lesions. cNFs can cause pain, itching, and disfigurement resulting in substantial socio-emotional repercussions. Currently, surgery and laser desiccation are thesole treatment options but may result in scarring and potential regrowth from incomplete removal.To identify effective systemic therapies, we introduce an approach to establish and screen cNF organoids. We optimized conditions to support the exvivo growth of genomically diverse cNFs. Patient-derived cNF organoids closely recapitulate cellular and molecular features of parental tumors as measured by immunohistopathology, methylation, RNA sequencing, and flow cytometry. Our cNF organoid platform enables rapid screening of hundreds of compounds in a patient- and tumor-specific manner.",Cell reports methods,2024-05-20,Huyen Thi Lam Nguyen; Emily Kohl; Jessica Bade; Stefan E Eng; Anela Tosevska; Ahmad Al Shihabi; Peyton J Tebon; Jenny J Hong; Sarah Dry; Paul C Boutros; Andre Panossian; Sara J C Gosline; Alice Soragni
PUB38811427,10.1186/s41687-024-00732-w,PMID:38811427,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,"BACKGROUND: Almost all patients with Neurofibromatosis type 1 (NF1) develop cutaneous neurofibroma (cNF), benign dermal tumours that have a large impact on the patient's Quality of Life (QoL). The French cNF-Skindex is the first questionnaire to specifically assess cNF-related QoL in patients with NF1. We aimed to adapt and validate a Dutch version of the cNF-Skindex. METHODS: The questionnaire was translated using forward and backwards translation, and subsequently administered to a sample of 59 patients on two separate occasions. Feasibility was evaluated by the presence of floor/ceiling effects. Reliability was assessed by evaluating internal consistency and test-retest reliability, by calculating Cronbach's alpha and Spearman's rank correlation coefficients. The EQ-5D-5L and SF-36 were used to evaluate convergent validity, using Spearman's rank correlation coefficients. An exploratory factor analysis was performed to study the data's internal structure. Multivariable linear regression was used to model the relationship between patient characteristics and the cNF-Skindex. RESULTS: The Dutch cNF-Skindex demonstrated excellent feasibility and reliability (Cronbach's alpha 0.96, test-retest correlation coefficient 0.88). Convergent validity was confirmed for the EQ-5D-5L and relevant SF-36 scales. All items and subdomains from the original questionnaire were confirmed following exploratory factor analysis. The patient characteristics included in the multivariable linear regression were not significantly associated with the cNF-Skindex score. CONCLUSIONS: The Dutch cNF-Skindex displayed excellent psychometric properties, enabling use in the Netherlands.",Journal of patient-reported outcomes,2024-05-29,Britt A E Dhaenens; Sarah A van Dijk; Laura Fertitta; Walter Taal; Pierre Wolkenstein; Rianne Oostenbrink
PUB38931352,10.3390/ph17060685,PMID:38931352,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,"Neurofibromatosis type 1 (NF1) is a neurocutaneous disorder. Plexiform neurofibromas (PNFs) are benign tumors commonly formed in patients with NF1. PNFs have a high incidence of developing into malignant peripheral nerve sheath tumors (MPNSTs) with a 5-year survival rate of only 30%. Therefore, the accurate diagnosis and differentiation of MPNSTs from benign PNFs are critical to patient management. We studied a fluorine-18 labeled tryptophan positron emission tomography (PET) radiotracer, 1-(2-[","Pharmaceuticals (Basel, Switzerland)",2024-05-27,Xuyi Yue; Erik Stauff; Shriya Boyapati; Sigrid A Langhans; Wenqi Xu; Sokratis Makrogiannis; Uchenna J Okorie; Azubuike M Okorie; Vinay V R Kandula; Heidi H Kecskemethy; Rahul M Nikam; Lauren W Averill; Thomas H Shaffer
PUB38990917,10.1371/journal.pone.0305548,PMID:38990917,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,"BACKGROUND: Optic pathway glioma (OPG) is a feared complication to neurofibromatosis type 1 (NF1) since it can cause visual impairment in young children. The main goal of screening is to detect symptomatic OPGs that require treatment. Optical coherence tomography (OCT) has been suggested as a tool for detection of neuro-retinal damage. AIMS: To investigate whether the ganglion cell layer assessed by OCT is a reliable measure to identify and detect relapses of symptomatic OPGs in children with NF1. METHODS: Children (3-6 years) with NF1, with and without known OPG and children with sporadic OPG (S-OPG) resident in the Stockholm area, were invited and followed in a prospective study during a three-year period. Brain magnetic resonance tomography (MRI) had been performed in children with symptoms of OPG. Outcome measures were VA in logMAR, visual field index (VFI), average thicknesses of the ganglion cell-inner plexiform layer (GC-IPL), and peripapillary retinal nerve fiber layer (pRNFL). RESULTS: There were 25 children with MRI-verified OPG and 52 with NF1 without symptomatic OPG. Eyes from NF1 patients without symptoms of OPG showed significantly better results in all four analyzed parameters compared to eyes with NF1-associated OPG. Mean GC-IPL measurements seemed stable and reliable, significantly correlated to pRNFL (correlation coefficient (r) = 0.662, confidence interval (CI) = .507 to .773 p<0.001), VA (r = -0.661, CI = -7.45 to -.551, p<0.001) and VFI (r = 0.644, CI = .452 to .774, p<0.001). GC-IPL measurements were easy to obtain and acquired at considerably younger age than pRNFL (5.61.5 vs 6.81.3; p<0.001). CONCLUSIONS: The mean GC-IPL thickness could distinguish well between eyes with OPG and eyes without symptomatic OPG in children with NF1. As thinning of GC-IPL assessed with OCT could indicate underlying OPG, it should be included in the screening protocol of children with questionable VA measurements and in particular in children with NF1.",PloS one,2024,Urszula Arnljots; Maria Nilsson; Roberto Bolzani; Mariagrazia Benassi; Ulrika Sandvik; Daniel Martin Munoz; Klas Blomgren; Kerstin Hellgren
PUB39061138,10.3390/cancers16142498,PMID:39061138,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,Plexiform neurofibromas (PNs) occur in about a half of neurofibromatosis type 1 (NF1) patients and have garnered significant research attention due to their capacity for growth and potential for malignant transformation. NF1 plexiform neurofibroma (pNF1) is a complex tumor composed of Schwann cell-derived tumor cells (,Cancers,2024-07-09,Kyungmin Ji; George J Schwenkel; Raymond R Mattingly; Harini G Sundararaghavan; Zheng Gang Zhang; Michael Chopp
PUB39129390,10.1002/1878-0261.13704,PMID:39129390,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,"Neurofibromatosis type 1 (NF1) is a genetic disorder caused by mutation of the NF1 gene that is associated with various symptoms, including the formation of benign tumors, called neurofibromas, within nerves. Drug treatments are currently limited. The mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib is used for a subset of plexiform neurofibromas (PNs) but is not always effective and can cause side effects. Therefore, there is a clear need to discover new drugs to target NF1-deficient tumor cells. Using a Drosophila cell model of NF1, we performed synthetic lethal screens to identify novel drug targets. We identified 54 gene candidates, which were validated with variable dose analysis as a secondary screen. Pathways associated with five candidates could be targeted using existing drugs. Among these, chloroquine (CQ) and bafilomycin A1, known to target the autophagy pathway, showed the greatest potential for selectively killing NF1-deficient Drosophila cells. When further investigating autophagy-related genes, we found that 14 out of 30 genes tested had a synthetic lethal interaction with NF1. These 14 genes are involved in multiple aspects of the autophagy pathway and can be targeted with additional drugs that mediate the autophagy pathway, although CQ was the most effective. The lethal effect of autophagy inhibitors was conserved in a panel of human NF1-deficient Schwann cell lines, highlighting their translational potential. The effect of CQ was also conserved in a Drosophila NF1 in vivo model and in a xenografted NF1-deficient tumor cell line grown in mice, with CQ treatment resulting in a more significant reduction in tumor growth than selumetinib treatment. Furthermore, combined treatment with CQ and selumetinib resulted in a further reduction in NF1-deficient cell viability. In conclusion, NF1-deficient cells are vulnerable to disruption of the autophagy pathway. This pathway represents a promising target for the treatment of NF1-associated tumors, and we identified CQ as a candidate drug for the treatment of NF1 tumors.",Molecular oncology,2025-03,Megan Stevens; Yuanli Wang; Stephanie J Bouley; Torrey R Mandigo; Aditi Sharma; Sonali Sengupta; Amy Housden; Norbert Perrimon; James A Walker; Benjamin E Housden
PUB6189f9ee,10.1002/1878-0261.13704 | 10.3390/cells14161276 | 10.3390/cancers16142498 | 10.1038/s41416-021-01270-8,PMID:39129390 | PMID:40862755 | PMID:39061138 | PMID:33658640,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures. | A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,,,
PUB39269317,10.1158/1078-0432.CCR-24-1750,PMID:39269317,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,"PURPOSE: Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive subtype of soft-tissue sarcoma with a high propensity to metastasize and extremely limited treatment options. Loss of the RAS-GAP NF1 leads to sustained RAF/MEK/ERK signaling in MPNST. However, single-agent MEK inhibitors (MEKi) have failed to elicit a sustained inhibition of the MAPK signaling pathway in MPNST. EXPERIMENTAL DESIGN: We used pharmacological, biochemical, and genetic perturbations of the receptor tyrosine kinase and MAPK signaling pathway regulators to investigate the mechanisms of MEKi resistance and evaluated combination therapeutic strategies in various preclinical MPNST models in vitro and in vivo. RESULTS: Here, we report that MEKi treatment resistance in MPNST involves two adaptive pathways: direct transcriptional upregulation of the receptor tyrosine kinase PDGFR and MEKi-induced increase in RAF dimer formation and activation of downstream signaling. Although the pharmacologic combination of a MEKi with a PDGFR-specific inhibitor was more effective than treatment with the MEKi alone, the combination of the MEKi and RAF dimer inhibitors led to a robust inhibition of MAPK pathway signaling. This combination treatment was effective in vitro and in vivo, as demonstrated by the significant increase in drug synergism and its high effectiveness in decreasing MPNST viability. CONCLUSIONS: Our findings suggest that the combination of MEKis and PDGFR and/or RAF dimer inhibitors can overcome MEKi resistance and may serve as a novel targeted therapeutic strategy for patients with NF1-deficient MPNST, which in turn could impact future clinical investigations for this patient population.",Clinical cancer research : an official journal of the American Association for Cancer Research,2024-11-15,Miguel A Miranda-Romn; Cindy J Lee; Eve Fishinevich; Leili Ran; Amish J Patel; Juan Yan; Makhzuna N Khudoynazarova; Sarah Warda; Mohini R Pachai; Yu Chen; Ping Chi
PUBb5d6cacb,10.1158/1078-0432.CCR-24-1750 | 10.1038/bjc.2012.518 | 10.1016/j.ccell.2018.01.005 | 10.1186/s40478-025-01965-6 | 10.1126/sciadv.abo5442 | 10.1158/1535-7163.MCT-21-0947 | 10.1093/noajnl/vdz061 | 10.1038/s41467-024-44755-9,PMID:39269317 | PMID:23175151 | PMID:29438698 | PMID:40025578 | PMID:36322658 | PMID:35511749 | PMID:32642733 | PMID:38216572,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,,,
PUB2bd6c16e,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,PMID:39269317 | PMID:35789380,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,,,
PUB39415595,10.1242/dmm.050862,PMID:39415595,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,"Neurofibromatosis type 2 (NF-2) is a dominantly inherited genetic disorder that results from variants in the tumor suppressor gene, neurofibromin 2 (NF2). Here, we report the generation of a conditional zebrafish model of neurofibromatosis established by inducible genetic knockout of nf2a/b, the zebrafish homologs of human NF2. Analysis of nf2a and nf2b expression revealed ubiquitous expression of nf2b in the early embryo, with overlapping expression in the neural crest and its derivatives and in the cranial mesenchyme. In contrast, nf2a displayed lower expression levels. Induction of nf2a/b knockout at early stages increased the proliferation of larval Schwann cells and meningeal fibroblasts. Subsequently, in adult zebrafish, nf2a/b knockout triggered the development of a spectrum of tumors, including vestibular Schwannomas, spinal Schwannomas, meningiomas and retinal hamartomas, mirroring the tumor manifestations observed in patients with NF-2. Collectively, these findings highlight the generation of a novel zebrafish model that mimics the complexities of the human NF-2 disorder. Consequently, this model holds significant potential for facilitating therapeutic screening and elucidating key driver genes implicated in NF-2 onset.",Disease models & mechanisms,2024-12-01,Ayyappa Raja Desingu Rajan; Yuanyun Huang; Jan Stundl; Katelyn Chu; Anushka Irodi; Zihan Yang; Brian E Applegate; Marianne E Bronner
PUB39472976,10.1186/s40478-024-01875-z,PMID:39472976,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,"BACKGROUND: NF1 inactivation is associated with sensitivity to MEK inhibitor targeted therapy in low-grade and some high-grade gliomas. NF1 loss may also be a harbinger of exploitable vulnerabilities in IDH-wildtype glioblastoma (GBM). Accurate and consistent detection of NF1 loss, however, is fraught given the large gene size, challenges with complete coverage and variant calling upon sequencing, and mechanisms of mRNA and protein regulation that result in early degradation in the absence of genomic alterations. Here, we seek to perform a composite analysis for NF1 loss accounting for genomic alterations and protein expression via immunohistochemistry. We also characterize the landscape of NF1 alterations in GBM. METHODS: We assembled a single-institution, retrospective cohort of 542 IDH-wildtype GBM with somatic next generation sequencing to investigate the frequency and nature of detected NF1 alterations. We selected 69GBMs from which to build a tissue microarray (TMA) of 44 NF1-wildtype and 25 NF1-mutant cases. We performed NF1 immunohistochemistry using two different NF1 antibodies (NFC, Sigma-Aldrich; and iNF-07E, iNFixion Bioscience) and correlated results with clinical, genomic, and other immunohistochemical features. RESULTS: In our retrospective cohort, we identified 88 IDH-wildtype GBM with NF1 alterations (16%). NF1 alterations were mutually exclusive with EGFR and MDM2 alterations (p-adj<0.001, 0.05, respectively), but co-occurred with PIK3R1 alterations (Log CONCLUSION: NF1 immunostaining may serve as a sensitive surrogate marker of NF1 genomic inactivation and a valuable extension to next-generation sequencing for defining NF1 status. Minimal NF1 immunoreactivity is a poor prognostic marker, even in IDH-wildtype glioblastoma without apparent NF1 genomic alterations, but the underlying molecular mechanism requires further investigation.",Acta neuropathologica communications,2024-10-29,Michael Chang; Mohamed Sherief; Maria Ioannou; Viveka Chinnasamy; Lucy Chen; Michael Frost; Michelle Mattson-Hoss; Herb Sarnoff; David O Kamson; Matthias Holdhoff; Debraj Mukherjee; Chetan Bettegowda; Jordina Rincon-Torroella; Victoria Croog; Peng Huang; Fausto J Rodriguez; Calixto-Hope G Lucas; Karisa C Schreck
PUBcf268d95,10.1186/s40478-024-01875-z | 10.1158/1535-7163.MCT-23-0510,PMID:39472976 | PMID:38714355,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,,,
PUB39890807,10.1038/s41598-024-84493-y,PMID:39890807,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,"In efforts to evaluate potential biomarkers and drug targets for Neurofibromatosis Type I (NF1) we utilized affinity mass spectrometry and global proteomics to investigate how variation within and loss of NF1 affect immortalized human Schwann cells. We used Strep tagged mNf1 cDNAs (both wild type (WT) and variant) to affinity purity NF1 Protein-Protein interactors (PPIs) from the Schwann cells. We were able to identify 98 PPIs and show that some of these PPIs bind differentially to variant proteins. Next, we evaluated global proteomes. We identified over 1900 proteins in immortalized human Schwann cells both with and without NF1 expression. We identified 148 proteins with differential expression levels based on genotype. Following Ingenuity Pathway analysis (IPA) we found multiple pathways were altered including decreases in ""oxidative phosphorylation,"" increases in ""mitochondrial dysfunction"", and ""glycolysis"", as well as changes in ""Myelination Signaling Pathway."" When we evaluated the proteome of NF1 null cells stably transfected with tagged mNf1 cDNAs we again identified an overall trend of metabolic differences pertaining to ""oxidative phosphorylation"", ""mitochondria dysfunction"", and ""glycolysis"" in the variant cDNA expressing cells. We then validated differential expression of the following proteins: LAMC1, CYB5R3, and SOD2 that are observed in the altered pathways. Finally, consistent with our proteomics findings, we show that NF1 is required to maintain mitochondrial respiratory function in Schwann cells by stabilizing NADH-linked oxidative phosphorylation and electron transfer. Taken together, these data indicate that NF1 plays a significant role in mitochondrial metabolism that results in proteomic changes in Schwann cells and may serve as a future drug target.",Scientific reports,2025-01-31,Christian X Fay; Elizabeth R M Zunica; Elias Awad; William Bradley; Cameron Church; Jian Liu; Hui Liu; David K Crossman; James A Mobley; John P Kirwan; Christopher L Axelrod; Erik Westin; Robert A Kesterson; Deeann Wallis
PUB40025578,10.1186/s40478-025-01965-6,PMID:40025578,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,"Neurofibromatosis type 1 (NF1) and schwannomatosis (SWN) are rare genetic disorders with distinct genetic etiologies. Both syndromes are predominantly characterized by the development of multiple benign nerve sheath tumors, which typically arise from cranial/peripheral nerves. The management of NF1/SWN-associated benign nerve sheath tumors pose a substantial clinical challenge. In recent years, immunotherapy has demonstrated significant efficacy in treating various tumors, but its application to NF1/SWN has not been explored. In this study, we first evaluated the feasibility of chimeric antigen receptor (CAR)-T cell therapy for the treatment of benign NF1/SWN-related nerve sheath tumor by analyzing the expression of multiple antigens in 85 tumor samples. Our findings revealed that epidermal growth factor receptor (EGFR/HER1) was highly expressed in most samples, indicating its potential as an ideal target for CAR-T cell therapy. Additionally, TGF1 and PDL1, key inhibitory regulators of T cell function within solid tumor microenvironment (TME), were universally overexpressed in these samples, highlighting the immunosuppressive nature of NF1/SWN tumors. To target HER1, we constructed CARs using three distinct scFvs (806, E2 and NEC). All three types of CAR-T cells demonstrated significant tumor-eliminating capability against NF1/SWN tumor cell lines, with 806 CAR-T cells showing the highest efficacy. Considering the immunosuppressive TME, we knocked out TGFBR2 and/or PDCD1 in 806 CAR-T cells using CRISPR/Cas9. Their anti-tumor efficacy was further evaluated using a 3D tumor spheroid model, and the gene-edited 806 CAR-T cells exhibited superior anti-tumor efficacy. In conclusion, we identified HER1 as a target for CAR-T cell therapy in NF1/SWN-related nerve sheath tumors, and developed anti-HER1 CAR-T cells that effectively eliminated NF1/SWN tumor cells, providing a promising therapeutic strategy for patients with these conditions.",Acta neuropathologica communications,2025-03-01,Na Tang; Lei Cheng; Jiawei Hao; Beilei Xu; Xi Pan; Xiaofei Wei; Hao Wu; Haoyi Wang
PUBd9b452bd,10.1186/s40478-025-01965-6 | 10.1016/j.ccr.2014.05.001 | 10.18632/oncotarget.4858,PMID:40025578 | PMID:25026211 | PMID:26219339,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,,,
PUB40225167,10.1155/2023/9628049,PMID:40225167,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,Neurofibromatosis type 1 (NF1) and Legius syndrome (LS) are caused by inactivating variants in ,Human mutation,2023,Hannie Douben; Marianne Hoogeveen-Westerveld; Mark Nellist; Jesse Louwen; Marian Kroos-de Haan; Mattijs Punt; Babeth van Ommeren; Leontine van Unen; Peter Elfferich; Esmee Kasteleijn; Yolande van Bever; Margreethe van Vliet; Rianne Oostenbrink; Jasper J Saris; Anja Wagner; Yvette van Ierland; Tjakko van Ham; Rick van Minkelen
PUB40590220,10.1172/JCI188932,PMID:40590220,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,"Neurofibromatosis type 1 (NF1) is a genetic disorder caused by mutations of the NF1 tumor suppressor gene resulting in the loss of function of neurofibromin, a GTPase-activating protein (GAP) for Ras. While the malignant manifestations of NF1 are associated with loss of heterozygosity of the residual WT allele, the nonmalignant neurodevelopmental sequelae, including autism spectrum disorder (ASD) and/or attention deficit hyperactivity disorder (ADHD) are prevalent morbidities that occur in the setting of neurofibromin haploinsufficiency. We reasoned that augmenting endogenous levels of WT neurofibromin could serve as a potential therapeutic strategy to correct the neurodevelopmental manifestations of NF1. Here, we used a combination of genetic screening and genetically engineered murine models to identify a role for the F-box protein FBXW11 as a regulator of neurofibromin degradation. Disruption of Fbxw11, through germline mutation or targeted genetic manipulation in the nucleus accumbens, increased neurofibromin levels, suppressed Ras-dependent ERK phosphorylation, and corrected social learning deficits and impulsive behaviors in male Nf1+/- mice. Our results demonstrate that preventing the degradation of neurofibromin is a feasible and effective approach to ameliorate the neurodevelopmental phenotypes in a haploinsufficient disease model.",The Journal of clinical investigation,2025-07-01,Su Jung Park; Jodi L Lukkes; Ka-Kui Chan; Hayley P Drozd; Callie B Burgin; Shaomin Qian; Morgan McKenzie Sullivan; Cesar Gabriel Guevara; Nolen Cunningham; Stephanie Arenas; Makenna A Collins; Jacob Zucker; JinHee Won; Abbi Smith; Li Jiang; Dana K Mitchell; Steven D Rhodes; Steven P Angus; D Wade Clapp
PUB8eeda84c,10.1172/JCI188932 | 10.1158/2159-8290.CD-21-1671 | 10.1074/jbc.RA119.010934 | 10.1038/s41598-018-20894-0 | 10.1126/scisignal.aau8749 | 10.1155/2023/9628049 | 10.1002/glia.24075 | 10.1158/1078-0432.CCR-24-1750 | 10.1038/bjc.2012.518 | 10.1038/s41467-023-40408-5 | 10.1016/j.jneuroim.2010.05.002 | 10.1186/s12864-017-3519-7 | 10.1038/s41419-021-03716-6,PMID:40590220 | PMID:35789380 | PMID:31836666 | PMID:29402968 | PMID:31015291 | PMID:40225167 | PMID:34415582 | PMID:39269317 | PMID:23175151 | PMID:38216587 | PMID:20554030 | PMID:28166733 | PMID:33934112,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome. | Notch signaling via Hey1 and Id2b regulates Mller glia's regenerative response to retinal injury. | MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | HIF1-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,,,
PUB3f27522a,10.1172/JCI188932 | 10.1016/j.omtn.2022.10.026 | 10.15252/embr.201949117,PMID:40590220 | PMID:36420221 | PMID:32383545,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,,,
PUB40723243,10.3390/cancers17142359,PMID:40723243,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,Cancers,2025-07-16,Sajjad Khan; Oluwatosin Aina; Ximei Veneklasen; Hannah Edens; Donia Alson; Li Sun; Huda Zayed; Kimani Njoya; Daochun Sun
PUB40737523,10.2196/71728,PMID:40737523,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,"BACKGROUND: Accurate monitoring of tumor progression is crucial for optimizing outcomes in neurofibromatosis type 2-related schwannomatosis. Standard 2D linear analysis on magnetic resonance imaging is less accurate than 3D volumetric analysis, but since 3D volumetric analysis is time-consuming, it is not widely used. To shorten the time required for 3D volumetric analysis, our lab has been developing an automated artificial intelligence-driven 3D volumetric tool. OBJECTIVE: The objective of the study was to survey and interview clinicians treating neurofibromatosis type 2-related schwannomatosis to understand their views on current 2D analysis and to gather insights for the design of an artificial intelligence-driven 3D volumetric analysis tool. METHODS: Interviews examined for the following themes: (1) shortcomings of the currently used linear analysis, (2) utility of 3D visualizations, (3) features of an interactive 3D modeling software, and (4) lack of a gold standard to assess the accuracy of 3D volumetric analysis. A Likert scale questionnaire was used to survey clinicians' levels of agreement with 25 statements related to 2D and 3D tumor analyses. RESULTS: A total of 14 clinicians completed a survey, and 12 clinicians were interviewed. Specialties ranged across neurosurgery, neuroradiology, neurology, oncology, and pediatrics. Overall, clinicians expressed concerns with current linear techniques, with clinicians agreeing that linear measurements can be variable with the possibility of two different clinicians calculating 2 different tumor sizes (mean 4.64, SD 0.49) and that volumetric measurements would be more helpful for determining clearer thresholds of tumor growth (mean 4.50, SD 0.52). For statements discussing the capabilities of a 3D volumetric analysis and visualization software, clinicians expressed strong interest in being able to visualize tumors with respect to critical brain structures (mean 4.36, SD 0.74) and in forecasting tumor growth (mean 4.77, SD 0.44). CONCLUSIONS: Clinicians were overall in favor of the adoption of 3D volumetric analysis techniques for measuring vestibular schwannoma tumors but expressed concerns regarding the novelty and inexperience surrounding these techniques. However, clinicians felt that the ability to visualize tumors with reference to critical structures, to overlay structures, to interact with 3D models, and to visualize areas of slow versus rapid growth in 3D would be valuable contributions to clinical practice. Overall, clinicians provided valuable insights for designing a 3D volumetric analysis tool for vestibular schwannoma tumor growth. These findings may also apply to other central nervous system tumors, offering broader utility in tumor growth assessments.",JMIR human factors,2025-07-30,Shelby T Desroches; Alice Huang; Rithvik Ghankot; Steven M Tommasini; Daniel H Wiznia; Frank D Buono
PUB40862755,10.3390/cells14161276,PMID:40862755,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,"Plexiform neurofibromas (hereafter called pNF1) are often diagnosed in early childhood and occur in about 30% of neurofibromatosis type 1 (NF1) patients. pNF1 exhibits aggressive growth along a nerve in the body and has substantial potential for progression to malignant peripheral nerve sheath tumors that are rarely curable. There are two recently FDA-approved drugs, selumetinib and mirdametinib, for pNF1 patients who have symptomatic and inoperable plexiform neurofibromas; however, these treatments achieve only approximately 30% tumor shrinkage. Fibroblasts, the most abundant cell types within the pNF1 tumor microenvironment, are implicated in pNF1 growth and invasion; however, how fibroblasts affect a drug response of pNF1 remains poorly understood. In the present study, we focused on contributions of fibroblasts to the drug resistance in pNF1 via their secretome. We employed our established three-dimensional (3D) culture system incorporating human pNF1 tumor cells (",Cells,2025-08-18,Kyungmin Ji; George J Schwenkel
PUB40887659,10.1186/s40246-025-00803-z,PMID:40887659,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,"Identification of a pathogenic variant in NF1 is diagnostic for neurofibromatosis, but is often impossible at the moment of variant detection due to many factors including allelic heterogeneity, sequence homology, and the lack of functional assays. Computational tools may aid in interpretation but are not established for NF1. Here, we optimized our random forest-based predictor RENOVO for NF1 variant interpretation. RENOVO was developed using an approach of ""database archaeology"": by comparing versions of ClinVar over the years, we defined ""stable"" variants that maintained the same pathogenic/likely pathogenic/benign/likely benign (P/LP/B/LB) classification over time (n=3579, the training set), and ""unstable"" variants that were initially classified as Variants of Unknown Significance (VUS) but were subsequently reclassified as P/LP/B/LB (n=57, the test set). This approach allows to retrospectively measure accuracy on prediction with insufficient information, reproducing the scenario of maximal clinical utility. We further validated performance on: (i) validation set 1: 100 NF1 variants classified as VUS at the time of RENOVO development and subsequently reclassified as P/LP/B/LB in ClinVar; (ii) validation set 2: 15 de novo variants discovered in a prospective clinical cohort and subsequently reclassified per ACMG criteria. RENOVO obtained consistently high accuracy on all datasets: 98.6% on the training test, 96.5% in the test set, 82% in validation set 1 (but 96.2% for missense variants) and 93.7% on validation set 2. In conclusion, RENOVO-NF1 accurately interprets NF1 variants for which information at the time of detection is insufficient for ACMG classification and may overcome diagnostic challenges in neurofibromatosis.",Human genomics,2025-08-31,Emanuele Bonetti; Serena Pellegatta; Nayma Rosati; Marica Eoli; Luca Mazzarella
PUB41001593,10.1080/23723556.2025.2561292,PMID:41001593,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,Neurofibromatosis type 1 (NF1) is an autosomal dominant tumor syndrome caused by pathogenic variants in the ,Molecular & cellular oncology,2025,Sandra Leisz; Antonio Pelligrino; Saskia Fritzsche; Merle Wiegers; Markus Wsle; Christian Linke; Swanhild Lohse; Daniel Tippner; Christian Scheller; Christian Strauss; Eva Ehrentreich-Frster; Faramarz Dehghani; Stanislav Sys; Erik Maronde; Anja Harder
PUB05aef37d,10.1080/23723556.2025.2561292 | 10.1186/s12885-020-07397-w,PMID:41001593 | PMID:32948135,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,,,
PUB41022755,10.1038/s41467-025-63619-4,PMID:41022755,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,"Neurofibromatosis type 1 (NF1) is a tumor predisposition syndrome caused by alterations in NF1 gene that lead to tumor growth throughout the nervous system, which can cause morbidity and mortality, and transform to malignancy. NF1 gene replacement therapy, though promising, is hindered by NF1 gene's large size and delivery challenges. We introduced a membrane-targeted, truncated neurofibromin comprising the GAP-related domain (GRD) fused to the KRAS4B C-terminal domain, which effectively inhibits the RAS signaling pathway and restores Schwann cell differentiation in an NF1 iPSC-derived model. For systemic application, we engineered an adeno-associated virus (AAV) vector using in vivo capsid evolution through sequential DNA shuffling and peptide library screening in a NF1 xenograft mouse model. This tailored vector, AAV-NF, exhibits greatly reduced liver uptake, enhanced tumor targeting across various NF1-related MPNST, neurofibromas and glioma models, and therapeutic efficacy in xenografts of MPNST. This study not only advances a viable AAV vector for NF1 treatment but also outlines a replicable strategy for vector and payload development in other monogenic and tumor-associated disease manifestations.",Nature communications,2025-09-29,Ren-Yuan Bai; Jingyi Shi; Jianan Liu; Nihao Sun; Yuqing Lu; Xiaojun Chen; Manzhu Xu; Hotae Lim; Yang Li; Huazhen Xu; Karis Weisgerber; Zhihong Ren; Christine A Pratilas; Jaishri O Blakeley; Melissa L Fishel; Meritxell Carri; Eduard Serra; Verena Staedtke
PUB34bef85d,10.1038/s41467-025-63619-4 | 10.1186/s12864-017-3519-7 | 10.1158/1535-7163.MCT-23-0510 | 10.1186/s40478-024-01875-z | 10.1371/journal.pone.0340183 | 10.1038/s41467-018-07452-y | 10.1002/1878-0261.13704 | 10.1038/s41467-021-24505-x | 10.1038/s41419-021-03802-9 | 10.7554/eLife.05151,PMID:41022755 | PMID:28166733 | PMID:38714355 | PMID:39472976 | PMID:41564118 | PMID:30479396 | PMID:39129390 | PMID:34257279 | PMID:34011935 | PMID:25535838,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,,,
PUBece01cc9,10.1038/s41467-025-63619-4 | 10.15252/embr.201949117 | 10.1038/s41416-021-01270-8 | 10.1172/JCI176748 | 10.18632/oncotarget.793 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1186/s13104-018-3630-0 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.1158/1078-0432.CCR-23-2548 | 10.1080/23723556.2025.2561292 | 10.1186/s12885-020-07397-w | 10.1158/1078-0432.CCR-23-0749 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-21-0947,PMID:41022755 | PMID:32383545 | PMID:33658640 | PMID:38502231 | PMID:23328114 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:30055648 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38127282 | PMID:41001593 | PMID:32948135 | PMID:37410426 | PMID:23535903 | PMID:35511749,"Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression. | Canonical Wnt/-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.",,,,
PUB7f382a9c,10.1038/s41467-025-63619-4 | 10.1126/sciadv.adg8876 | 10.1158/0008-5472.CAN-20-1365,PMID:41022755 | PMID:38000020 | PMID:33032988,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,,,
PUB058134e4,10.1038/s41467-025-63619-4 | 10.1158/1535-7163.MCT-23-0510,PMID:41022755 | PMID:38714355,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,,,
PUB41036607,10.1158/1535-7163.MCT-24-1053,PMID:41036607,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,"Neurofibromatosis type I (NF1) is a common cancer predisposition syndrome caused by heterozygous loss-of-function mutations in the tumor-suppressor gene NF1. Individuals with NF1 develop benign tumors of the peripheral nervous system (neurofibromas), originating from the Schwann cell (SC) lineage after somatic loss of the wild-type NF1 allele, some of which progress further to malignant peripheral nerve sheath tumors (MPNST). There is only one FDA-approved targeted therapy for symptomatic plexiform neurofibromas and none approved for MPNSTs. The genetic basis of NF1 syndrome makes associated tumors ideal for using synthetic drug sensitivity approaches to uncover therapeutic vulnerabilities. We developed a drug discovery pipeline to identify therapeutics for NF1-related tumors using isogeneic pairs of NF1-proficient and NF1-deficient immortalized human SCs. We utilized these in a large-scale high-throughput screen for drugs that preferentially kill NF1-deficient cells, through which we identified 23 compounds capable of killing NF1-deficient SCs with selectivity. Multiple hits from this screen clustered into classes defined by the method of action. Four clinically interesting drugs from these classes were tested in vivo using both a genetically engineered mouse model of high-grade PNSTs and human MPNST xenografts. All drugs tested showed single-agent efficacy in these models as well as significant synergy when used in combination with the MEK inhibitor selumetinib. This high-throughput screen platform yielded novel therapeutically relevant compounds for the treatment of NF1-associated tumors and can serve as a tool to rapidly evaluate new compounds and combinations in the future.",Molecular cancer therapeutics,2026-02-04,Kyle B Williams; Alex T Larsson; Bryant J Keller; Katherine E Chaney; Rory L Williams; Minu M Bhunia; Garrett M Draper; Tyler A Jubenville; Wendy A Hudson; Gunda I Georg; Christopher L Moertel; Nancy Ratner; David A Largaespada
PUB41444363,10.1038/s41598-025-32031-9,PMID:41444363,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,"UNLABELLED: Neurofibromatosis type 2 (NF2)-related schwannomatosis is an autosomal dominant genetic disorder characterized by the development of cranial and peripheral nerve schwannomas, including bilateral vestibular schwannomas which are associated with substantial morbidity. Current therapeutic strategies comprise surgical resection, radiotherapy, and systemic administration of bevacizumab; however, these approaches are frequently limited by high recurrence rates and morbidity. In this study, a transgenic murine model ( SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1038/s41598-025-32031-9.",Scientific reports,2025-12-24,Jennifer L Spiegel; Alessandro De Maio; Manita V Patel; Omer J Ungar; Carolyn Lai; Tra Truong; Yumai Situ; D Wade Clapp; Simon J Conway; Joseph M Chen; Vincent Y W Lin; Kullervo Hynynen; Meaghan A O'Reilly; Trung N Le
PUBd78d35d1,10.1038/s41598-025-32031-9 | 10.1371/journal.pone.0097320 | 10.1111/j.1750-3639.2007.00105.x | 10.1016/j.redox.2024.103249,PMID:41444363 | PMID:24817309 | PMID:17924978 | PMID:38945076,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model. | Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner. | Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,,,
PUB41564118,10.1371/journal.pone.0340183,PMID:41564118,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,"Neurofibromatosis type 1 (NF1) is an autosomal dominant condition in which patients are heterozygous for a disruptive pathogenic variant in the NF1 gene. The most characteristic feature of the condition NF1 is the neurofibroma, a benign, multi-cellular tumor which initiates when a cell of the Schwann cell lineage gains a somatic pathogenic variant of the other NF1 allele. Neurofibromas developing at nerve termini in the skin are termed ""cutaneous"" neurofibromas (cNFs), while those developing within larger nerves are termed ""plexiform."" Most patients develop cNFs beginning in late childhood or early adulthood, continuing throughout life at variable rates. Some patients may develop only a few cNFs, while others suffer from thousands. There are no reliably effective physical or pharmaceutical therapies besides surgical removal. Although these are not life-threatening, they are disfiguring and can interfere with normal life functions. To provide a resource for research, we developed short-term cNF Schwann cell cultures from NF1 patients, from which we subsequently established the first semi-immortalized cNF cell lines through transduction with wild-type human telomerase reverse transcriptase (hTERT) and murine cyclin-dependent kinase 4 (mCdk4) genes. Here we present molecular, cellular, and functional characterization of these cell lines, which will be of utility for investigating and developing NF1 cNF therapies.",PloS one,2026,Hua Li; Alexander Pemov; Robert Allaway; David F Muir; Lung-Ji Chang; Jineta Banerjee; Alexandra J Scott; Jaime M W Nagy; Jian Liu; Meritxell Carri; Helena Mazuelas; Anthony Yachnis; Sang Y Lee; Xiaochun Zhang; Yang Lyu; Douglas R Stewart; Angela Hirbe; Jaishri O Blakeley; Eduard Serra; Deeann Wallis; Margaret R Wallace
PUBe5a5ea03,10.1371/journal.pone.0340183 | 10.1186/s40478-024-01821-z,PMID:41564118 | PMID:38907342,"Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,,,
